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This report is based on research conducted by the Kaiser Permanente Evidence-based Practice 
Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), 
Rockville, MD (Contract No. HHSA-290-2015-00007-I-EPC5, Task Order No. 5). The findings 
and conclusions in this document are those of the authors, who are responsible for its contents; 
the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no 
statement in this report should be construed as an official position of AHRQ or of the U.S. 
Department of Health and Human Services. 
 
The information in this report is intended to help health care decisionmakers—patients and 
clinicians, health system leaders, and policymakers, among others—make well-informed 
decisions and thereby improve the quality of healthcare services. This report is not intended to be 
a substitute for the application of clinical judgment. Anyone who makes decisions concerning the 
provision of clinical care should consider this report in the same way as any medical reference 
and in conjunction with all other pertinent information (i.e., in the context of available resources 
and circumstances presented by individual patients). 
 
This report may be used, in whole or in part, as the basis for development of clinical practice 
guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage 
policies. AHRQ or U.S. Department of Health and Human Services endorsement of such 
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Structured Abstract 
 
Objective: We undertook this systematic review to support the U.S. Preventive Services Task 
Force in updating its 2015 recommendation on tobacco cessation interventions for adults, 
including pregnant women. Our review addressed the effectiveness and safety of 
pharmacotherapy, behavioral interventions, and electronic cigarettes for tobacco cessation. 
 
Data Sources: We conducted an overview of reviews for evidence related to pharmacotherapy 
and behavioral interventions among the general adult population and for behavioral interventions 
among pregnant women. We searched the following databases and organizations’ websites to 
identify existing reviews through April 2019: PubMed, PsycInfo, the Database of Abstracts of 
Reviews of Effects, the Cochrane Database of Systematic Reviews, the Centre for Reviews and 
Dissemination Health Technology Assessment, the Agency of Healthcare Research and Quality, 
the Canadian Agency for Drugs and Technologies in Health, Center for Disease Control and 
Prevention’s Guide to Community Preventive Services, the Health and Medicine Division of the 
National Academies of Sciences, Engineering, and Medicine (formerly the Institute of 
Medicine), the National Health Service Health Technology Assessment Programme, and the 
Surgeon General. We conducted a search for primary evidence related to the effectiveness and 
safety of electronic cigarettes (through May 2020) and pharmacotherapy among pregnant women 
(through May 2020) and did not rely on existing systematic reviews for this evidence. We 
conducted ongoing surveillance for relevant literature through September 25, 2020.  
 
Study Selection: For the overview of reviews, we included reviews with or without meta-
analysis that were published in the English language that systematically reported the effects of 
tobacco cessation interventions on health, cessation, or adverse outcomes. We excluded 
nonsystematic meta-analyses and narrative reviews. For primary evidence related to the 
effectiveness and safety of electronic cigarettes among adults and pharmacotherapy among 
pregnant women, we included randomized controlled trials and large observational studies that 
reported health or cessation outcomes at 6 months or more followup or adverse events at any 
time point. For all evidence, we conducted critical appraisal of all provisionally included reviews 
and excluded reviews rated as having “critically low” credibility according to AMSTAR-2 
criteria and individual studies rated as “poor” quality according to study design-specific risk-of-
bias criteria. Data were abstracted by one reviewer and confirmed by another. 
 
Data Analysis: We grouped reviews based on population and intervention and identified one or 
more reviews within each population and intervention subgroup that represented the most current 
and applicable evidence to serve as the basis for the main findings (“primary” reviews) and 
discussed complementary and discordant findings from other included reviews as necessary. We 
did not reanalyze any of the individual study evidence but presented pooled analyses and existing 
point estimates from included reviews. We narratively synthesized the primary evidence for 
electronic cigarettes among adults and pregnant women and medications for smoking cessation 
among pregnant women and where appropriate, conducted random-effects meta-analyses to pool 
study results.  
 
Results: We included 67 systematic reviews, 33 of which served as the basis for the primary 
findings. While this review was broadly scoped to include abstinence of all tobacco products, the 
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primary outcome in all cases was abstinence from combustible cigarette smoking. Among adults, 
combined pharmacotherapy and behavioral interventions significantly increased smoking 
abstinence by 83 percent versus usual care or minimal support control groups not using 
medication (risk ratio [RR] 1.83 [95% confidence interval [CI], 1.68 to 1.98]). Furthermore, all 
seven FDA-approved medications for smoking cessation were found to be effective in increasing 
smoking quit rates compared with placebo or nondrug arms at 6 or more months followup. The 
pooled RR for abstinence for nicotine replacement therapy (NRT, all forms) was 1.55 (95% CI, 
1.49 to 1.61), for bupropion, 1.64 (95% CI, 1.52 to 1.77), and for varenicline, 2.24 (95% CI, 2.06 
to 2.43). Combined NRT versus a single form of NRT showed a statistically significantly greater 
cessation effect (RR 1.25 [95% CI, 1.15 to 1.36]). Pooled analysis of trials directly comparing 
NRT and bupropion did not suggest a difference between the two types of pharmacotherapy; 
however, varenicline has been shown to be superior to both NRT and bupropion in achieving 
abstinence at 6 months or greater, although there are fewer trials testing these differences. 
Although less evidence is available, certain medications such as nortriptyline and cytisine used 
for tobacco cessation have shown potential benefits. None of the drugs were associated with 
serious adverse events, including major cardiovascular adverse events or serious 
neuropsychiatric events.  
 
Compared with various controls, behavioral interventions such as in-person advice and support 
from clinicians including physician advice, nurse advice, individual counseling with a cessation 
specialist, group behavioral interventions, telephone counseling, mobile phone-based 
interventions, interactive and tailored internet-based interventions, and the use of incentives had 
modest but significantly increased relative smoking cessation at 6 or more months (15% to 88% 
range in relative effects). For example, the pooled RR of physician advice versus no advice was 
1.76 (95% CI, 1.58 to 1.96) for smoking cessation at 6 or more months’ followup. There was a 
lack of clear benefit of motivational interviewing, decision aids, print-based, nontailored self-
help materials, real-time video counseling, biofeedback (feedback on smoking exposure, 
smoking-related disease, or smoking-related harms), exercise, acupuncture, hypnotherapy, and 
system change interventions compared with controls; however, there was substantially less 
evidence related to each of these interventions. While some reviews found evidence of potential 
effect modification by specific intervention, population, or study design characteristics, there was 
no one factor that consistently predicted greater treatment effects, and nearly every subgroup 
analysis was found to be statistically significant. Few reviews on behavioral interventions 
captured information on potential harms, and none suggested serious adverse events that arose.  
 
We identified five trials that addressed the effectiveness and harms of the use of electronic 
cigarettes among adults. No trials testing the effects of electronic cigarettes for smoking 
cessation among pregnant women were identified. Results were mixed on smoking cessation 
effectiveness at 6 to 12 months among smokers intending to quit when compared with placebo 
devices or NRT. Four additional trials also reported on potential short-term harms of electronic 
cigarette use for cessation; none suggested relatively higher rates of serious adverse events.  
 
Among pregnant women, smoking cessation during late pregnancy was greater among women 
receiving any type of behavioral intervention, with evidence most clear for counseling versus 
controls (RR 1.31 [95% CI, 1.16 to 1.47]). Behavioral interventions were also associated with an 
increase in mean birthweight of babies as well as a decreased risk of low birth weight. We 
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identified one new trial of NRT among pregnant women, but no new trials testing the effects of 
bupropion or varenicline in this population. For NRT, rates of validated cessation among women 
allocated to NRT (5.4% to 28.2%) compared with placebo (5.0% to 25.4%) were not statistically 
different (pooled RR 1.11 [95% CI, 0.79 to 1.56]). Benefits of NRT on infant health outcomes 
were seen in a few trials, but that evidence was limited. There was no clear evidence of harms 
from behavioral interventions or associated with NRT use during pregnancy, but harms also 
could not be ruled out given sparse reporting, low statistical power for evaluating rare harms, and 
limitations of observational study comparisons.  
 
Limitations: The comprehensiveness of our overview of reviews is limited by the recency and 
quality of the source reviews; with exceptions, we did not describe or cite individual trials 
because of the large volume of trials represented in the reviews. Furthermore, there are a limited 
number of trials testing the benefits and harms of electronic cigarettes among adults as well as 
the use of medications to assist pregnant women stop smoking. Such sparsity in research 
hampers our ability to make any robust conclusions about their effectiveness and potential 
harms.  
 
Conclusions: There is strong evidence that a range or pharmacological and behavioral 
interventions, both individually and in combination, are effective in increasing smoking 
cessation in adults. Moreover, behavioral interventions can help pregnant women stop smoking. 
Data on the effectiveness and safety of electronic cigarettes for smoking cessation among adults 
are limited as are data on the use of tobacco cessation pharmacotherapies among pregnant 
women. Future research should focus on direct comparisons between different combinations and 
classes of drugs, adaptations of interventions for diverse populations, and the efficacy and safety 
of electronic cigarettes.  
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The Agency for Healthcare Research and Quality (AHRQ) has requested an updated evidence 
report on tobacco cessation interventions for adults and pregnant women. This report will be 
used by the United States Preventive Services Task Force (USPSTF) to update its 2015 
recommendation on behavioral and pharmacotherapy interventions for tobacco smoking 




Tobacco is a plant grown for its leaves, which are dried before being put in tobacco products. 
Tobacco contains nicotine, an ingredient that causes addiction, as well as many other harmful 
chemicals within the tobacco itself or created by burning it. Tobacco can be consumed in many 
combustible configurations including cigarettes, pipes, cigars, cigarillos, little cigars, bidis 
(tobacco wrapped in tendu or temburni leaves), kreteks (clove cigarettes), roll-your-own tobacco 
products, and through a hookah or waterpipe and noncombustible formats including chew, snuff 
including snus, nicotine pouches, nicotine gels, and dissolvable tobacco as strips, sticks, or 
lozenges.. Effective August 2016, the United States Food and Drug Administration (FDA) 
extended its regulatory authority to all other products made from or containing nicotine derived 
from tobacco, including electronic nicotine delivery systems (ENDS) (e.g., electronic cigarettes 
[e-cigarettes], e-hookah, e-cigars, vape pens, advanced refillable personal vaporizers, and 
electronic pipes) as well as components or parts intended or reasonably expected to be used with 
tobacco products or tobacco-derived nicotine. E-cigarettes intended for medical therapeutic 
purposes are subject to FDA regulations related to pharmaceuticals and medical devices rather 
than FDA regulations related to tobacco products. Companies that wish to make such claims 
must apply to the FDA’s Center for Drug Evaluation and Research.2, 3 Currently, no e-cigarettes 
are approved for therapeutic use as smoking cessation devices. In this review, given the 
regulatory environment in the U.S. regarding e-cigarettes, the use of e-cigarettes is included as 
both a tobacco product (for which we sought evidence related to quitting e-cigarette use) and as a 
potential smoking cessation aid (for which we sought evidence related to using e-cigarettes to 
quit combustible smoking). 
 
Electronic nicotine delivery systems are a diverse group of products that produce a heated 
aerosol that users inhale from a mouthpiece. Electronic cigarettes (i.e., e-cigarettes or e-cigs) 
range in design but share certain components: a battery, heating coil, atomizer (transforms e-
liquid to an aerosol), cartridge containing the e-liquid, and a mouthpiece. Users draw on the 
mouthpiece, activate the heating element, and inhale the aerosol. The liquid solution (i.e., e-
liquid, juice) contains propylene glycol and/or glycerol (glycerin), with various levels of nicotine 
(including no nicotine).4 Other components of the solution can include water and various 
additives including flavorings that vary among brands in presence and amount.4 Early generation 
devices closely resembled cigarettes and were disposable or partly disposable; second-generation 
devices (i.e., vape pens) are rechargeable (most have a USB charger) and have customizable 
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looks and tip.5 Later designs reflect a diverse set of products that may be square or rectangular 
and bear little resemblance to cigarettes. Many can be customized by the user and are referred to 
as modified vape devices (mods).5 Box-style mods allow greater customization (e.g., wattage, 
temperature control) and are generally larger and more powerful than the previous two e-
cigarette types. The more recent generation of e-cigarettes, including JUUL, Suorin and NJOY 
Ace, retail brands of e-cigarettes shaped like USB drives, are smaller and simpler than mods and 
are not refillable but use a pod that clicks onto the device to deliver the e-fluid (often referred to 
as pod mods). These devices typically have higher nicotine concentrations and utilize nicotine 
salts, which allows for higher levels of nicotine to be more palatably inhaled than free-base 
nicotine and can increase the rate of nicotine delivery as compared with earlier generations of e-
cigarettes.6, 7 Sales of JUULs increased markedly from 2015 to 2017, and JUUL is now the 
largest retail brand of e-cigarettes in the United States, accounting for more than half of the 
market share in tracked retail channels.8, 9 Because e-cigarettes are developed by a variety of 
manufacturers, the contents vary widely and in some cases are not consistent with product 
labeling.4, 10-12  
 
Tobacco dependence refers to a psychologic state typified by tolerance and withdrawal where the 
body is dependent on nicotine for normal function. According to the Diagnostic and Statistical 
Manual of Mental Disorders (fifth edition, DSM-5), a tobacco use disorder is diagnosed when an 
individual uses tobacco for more than a year and a minimum of two features that relate to 
nicotine tolerance, withdrawal symptoms, and social and behavioral factors related to use (e.g., 
failure to attend to responsibilities and obligations due to tobacco use, continue use despite 
adverse social or interpersonal consequences).13 In light of the significant harm that can result 
from even low-level exposure to cigarette smoke, both chronic tobacco use and dependence 
warrant clinical intervention.14 
 
Prevalence and Burden 
 
Tobacco smoking is the leading preventable cause of disease, disability, and death in the United 
States. According to a 2014 Surgeon General’s Report, cigarette smoking and exposure to 
tobacco smoke resulted in more than 480,000 premature deaths annually in the United States.15 
Combustible cigarette smoking causes various forms of cancer, cardiovascular disease, 
respiratory disease, reproductive disorders, and other adverse consequences. Fifty years after the 
1964 Surgeon General’s report was published, research continues to identify diseases caused by 
cigarette smoking, including diabetes mellitus, rheumatoid arthritis, colorectal cancer, erectile 
dysfunction, tuberculosis, and congenital defects.15 In addition to causing multiple diseases, 
cigarette smoking can cause inflammation and impair immune function.15 Smoking during 
pregnancy is known to be causally related to higher risks of miscarriage, stillbirth, preterm birth, 
fetal growth restriction, placental abruption, certain congenital anomalies, and impaired lung 
function in childhood and beyond.15-18 
 
There has been progress over the past several decades in reducing the use of tobacco products by 
U.S. adults. In 2019, an estimated 20.8 percent (50.6 million) of adults in the United States 
currently used any tobacco product.19 Combustible tobacco products were used by 80.5 of 
current tobacco product users and 18.6 percent of the same population reported use of two or 
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more tobacco products. The most commonly used tobacco product was combustible cigarettes 
(34.1 million; 14.0%).19 Estimates regarding current use of other tobacco products among adults 
in 2019 were: e-cigarettes, 4.5 percent (10.9 million); cigars, 3.6 percent (8.7 million); smokeless 
tobacco, 2.4 percent (5.9 million); and pipes, 1.0 percent (2.4 million).19  
 
According to findings from the nationally representative Behavioral Risk Factor Surveillance 
System, the overall current e-cigarette use prevalence rose from 4.5 percent (approximately 11.2 
million adults) to 5.4 percent (approximately 13.7 million adults) in 2016 and 2018 
respectively.20 The largest increase in prevalence occurred within the younger age group (18-24 
years of age), which rose from 9.2 percent to 15.0 percent in 2016 to 2018 respectively. 
According to the same survey data, in 2018, e-cigarette use was highest among males (6.9%), 
young adults ages 18 to 24 (15.0%), respondents identifying their race as “other” (6.4%) and 
white (5.8%), those identifying as bisexual (12.5%) or lesbian/gay (10.7%), respondents with 
high school and some college education (6.6%), respondents below the poverty line (6.9%) and 
respondents reporting current combustible cigarette us (14.7%).20  
 
Despite a reduction in tobacco product use in U.S. adults, during 2017-2018, the prevalence of 
current us of any tobacco product increased by 38 percent among high school students (from 
19.6% to 27.1%) and by 29 percent among middle school students (from 5.6% to 7.2%).21 The 
increase in tobacco use seen in this time period was driven by the considerable rise in e-cigarette 
use. Data from the 2011–2018 National Youth Tobacco Survey (NYTS), found that among high 
school students, current e-cigarette use increased from 1.5 percent in 2011 to 20.8 percent in 
2018; with a 78 percent increase just between 2017 (11.7%) to 2018 (20.8%).21 Similarly, for 
young adults ages 18 to 24 years, a significant increase in self-reported e-cigarette use was seen 
between 2017 (5.2%) and 2018 (7.6%) (difference, 2.4% [95% CI, 0.4% to 4.4%]) whereas there 
was no change among adults aged 25 to 44 years and a nonsignificant decrease in those aged 45 
to 64 and 65 and older.22 
 
Among adults, persistent disparities in tobacco use exist by age, sex, race/ethnicity, sexual 
orientation, education, income level, insurance and disability status, psychological status, and 
region.19 In 2019, prevalence of current tobacco product use was higher among those ages 25 to 
44 years (25.3%), 45 to 64 years (23.0%), and 18 to 24 years (18.2%) than among those age ≥65 
years (11.4%), and higher among males (26.2%) than females (15.7%). By race and ethnicity, 
current tobacco use prevalence was highest among American Indian/Alaska Natives (29.3%), 
followed by non-Hispanic adults of other races (28.1%), whites (23.3%), and blacks (20.7%), 
Hispanic or Latino adults (13.2%), and Asians (11.0%). Prevalence of tobacco use was also 
higher among adults who were lesbian, gay, or bisexual (29.9%) than among heterosexual adults 
(20.5%). Prevalence also varied by education and income levels: It was higher among adults who 
had a GED (43.7%) than among those who had completed any other levels of education (ranging 
from 26.4% in those with 0-12 year of education (with or without a high school diploma) to 
8.7% in those with a graduate degree), and higher among those who had an annual household 
income of <$35,000 (27.0%) than among those with higher incomes (ranging from 15.1% in 
those with annual household incomes ≥$100,000 to 22.0% in those with annual household 
incomes between $35,000 and $74,000). In 2019, there was higher prevalence of tobacco product 
use among those who were uninsured (30.2%), those insured by Medicaid (30.0%), or had other 
public insurance (25.6%) than among people covered by private health insurance (18.0%) or 
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Medicare only (11.4%). Prevalence was also higher among those who had a disability/limitation 
(26.9%) than among those who did not (20.1%), as well as among those who had Generalized 
Anxiety Scores (GAD-7) indicating mild (30.4%), moderate (34.2%), or severe (45.3%) anxiety 
than among those indicating no or minimal anxiety (18.4%). Additionally, by U.S. region, the 
Midwest (23.7%) and South (22.9%) had higher prevalence of tobacco product use than the West 
(16.4%) or Northeast (18.5%).19  
 
Among pregnant U.S. women who gave birth in 2016, 7.2 percent reported smoking cigarettes 
while pregnant.23 The prevalence of smoking during pregnancy was highest among women ages 
20 to 24 years (10.7%), followed by women ages 15 to 19 (8.5%) and 25 to 29 years (8.2%). 
Additionally, prevalence of smoking during pregnancy was highest for women with a high 
school diploma or GED (12.2%), followed by women with less than a high school diploma 
(11.7%) and women with some college or an Associate degree (7.9%) while prevalence was 
lowest among women with a master’s degree of higher (0.4%). Similar to trends in the general 
adult population, Non-Hispanic American Indian or Alaska Native women had the highest 
prevalence of smoking during pregnancy (16.7%), followed by white women (10.5%), black 
(6.0%), Native Hawaiian or other Pacific Islander (4.5%), Hispanic women (1.8%) and Asian 
women (0.6%).23 Additionally, from 2014 to 2017, 3.6 percent of pregnant women ages 18 to 44 
years reported current use of e-cigarettes, a proportion that was not statistically significantly 
different among non-pregnant women in the same age group (3.3%).24 
 
According to 2016-2018 Behavioral Risk Factor Surveillance System Survey data, 
approximately 2.2 percent of adult pregnant women (ages 18 to 49) reported current e-cigarette 
use.25 The prevalence of current e-cigarette use among pregnant women was highest among the 
younger age group, aged 18 to 24 years (3.2%), followed by pregnant women ages 25 to 29 years 
(2.3%). In addition, the prevalence of current e-cigarette use among pregnant women was highest 
in those reporting white race (63.3%), single marital status (57.6%), high school and some 
college education (66.6%), and employed (61.7%). The prevalence of current e-cigarette use 
among this population almost doubled from 2016 to 2018 (1.9% and 3.8% respectively).25 
 
Etiology and Natural History 
 
Initiation of cigarette smoking typically begins in early adolescence at an average age of 15 
years.17 Data suggest that smoking prevalence in adolescents increases over time, peaks during 
young adulthood, and then declines as individuals age. This trajectory may vary, however, given 
differences in age at initiation of smoking, time to progress to daily smoking, and dependence 
symptoms. About one-third of individuals who have ever tried cigarette smoking become daily 
smokers.17 Among adolescents, symptoms of dependence have been reported at even low levels 
of cigarette consumption (e.g., two cigarettes once a week).26, 27  
 
Tobacco dependence is a chronic condition and the majority of users make multiple quit attempts 
before achieving lasting success.28 According to the NHIS, approximately two-thirds of all 
people who smoked cigarettes in 2015 (68%) reported they were interested in quitting smoking, 
and 55.4 percent of these smokers had made a quit attempt during the previous year, although 
less than one-third had used evidence-based cessation treatments and less than one in 10 were 
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successful in quitting in the previous year.29 One study estimated that 22 percent of smokers 
relapsed within 3 months;30 however, long-term follow-up is recommended because successful 
quitters remain at risk of relapse for several years after smoking cessation.  
 
Research shows that the appearance of withdrawal symptoms early in the quit-attempt period is 
negatively associated with the ability to remain abstinent and avoid relapse.17 On average, a 
second lapse (i.e., one instance of smoking, even a puff) occurs with 24 hours of the first lapse, 
and lapse to relapse (i.e., return to one’s baseline level of smoking) occurs 3 to 5 weeks after the 
cessation attempt.17 Factors associated with relapse include higher severity of nicotine 
dependence, daily smoking onset at younger age, higher number of prior quit attempts, being 
female, presence of psychiatric symptoms (mainly anxiety and depression symptoms), and 
higher body mass index.17 The rate of relapse is inversely related to the duration of continuous 
abstinence (i.e., the risk of relapse decreases with longer abstinence). For example, one study 
found the relapse rate among those who achieved up to 11 months of abstinence was consistently 
above 50 percent, dropping to 36 percent after 2 years of abstinence and 25 percent after 5 years 
of abstinence, then stabilizing at around 10 percent after 30 years of abstinence.31 
 
Tobacco Cessation Interventions 
 
Various pharmacological and behavioral methods are available to assist adults quit tobacco use. 
Behavioral interventions and pharmacotherapy are believed to have complementary modes of 
action and independently increase the chances of maintaining long-term abstinence.14 
Pharmacotherapy Tobacco Cessation Interventions 
Seven FDA-approved over-the-counter (OTC) and prescription medications for treating tobacco 
dependence are available.32 These include three OTC nicotine replacement therapy (NRT) 
products (transdermal nicotine patches, nicotine lozenges, and nicotine gum), two prescription-
only nicotine replacement therapy products (nicotine inhaler and nasal spray [Nicotrol®]), and 
prescription-only bupropion hydrochloride sustained release (Zyban® and generic form; referred 
to as bupropion hereafter) and varenicline tartrate (Chantix®), neither of which contains 
nicotine. Although Wellbutrin SR® is not indicated for smoking cessation treatment, it contains 
the same active ingredient as Zyban®. Other medications are used clinically to treat tobacco 
dependence, including clonidine (antihypertensive) and nortriptyline (antidepressant), but these 
are not FDA-approved for smoking cessation.32, 33 Cytisine, a partial agonist of nicotine 
acetylcholine receptors, is available both with and without a prescription in eastern and central 
Europe34 and is widely available internationally (including in the United States) through online 
vendors although not FDA-approved.35   
Behavioral Tobacco Cessation Interventions 
Specific behavioral interventions include self-help materials (e.g., written materials, videos, 
audiotapes, computer), phone-based interventions, quitlines, brief provider-delivered 
interventions (e.g., advice from a physician or nurse), intensive counseling delivered on an 
individual basis or in a group setting, mobile phone and text-messaging interventions, biomedical 
risk assessment, and combinations of these approaches. Behavioral interventions generally aim 
to teach individuals to recognize high-risk situations and develop coping strategies to deal with 
them. Complementary and alternative therapies, such as acupuncture, acupressure, laser therapy, 
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electrostimulation, hypnotherapy, and the consumption of herbals (e.g., St. John’s wort), have 




There is a debate in the tobacco control community about the public health impact of e-
cigarettes, how best to regulate them, and their role in tobacco cessation.5, 36 Because e-cigarettes 
may offer both nicotine replacement and behavioral and sensory aspects similar to conventional 
cigarettes without the inhalation of tobacco smoke, they have the potential to serve as a tobacco 
cessation or harm reduction tool when used by smokers who transition completely to e-
cigarettes.37-39 Conversely, when taken up by nonsmokers (generally adolescents and young 
adults), e-cigarettes may serve as a pathway to nicotine addiction and tobacco smoking.15 In 
addition, questions remain regarding the effectiveness of e-cigarettes for tobacco cessation as 
well as their impact on individual and population health, including the potential for progression 
to conventional tobacco use among adult nontobacco users, long-term dual use among current 
smokers, relapse among former smokers, and exposure to harmful or potentially harmful 
constituents in specific products.14, 15, 40-43  
 
Current Clinical Practice in the United States 
 
In 2015, 68.0 percent of adult smokers wanted to stop smoking, 55.4 percent made a past-year 
quit attempt, 7.4 percent recently quit smoking, 57.2 percent had been advised by a health 
professional to quit, and 31.2 percent used cessation counseling and/or medication when trying 
to quit.29 Among smokers who made quit attempts, 6.8 percent reported using counseling, 29.0 
percent reported using medication, and 4.7 percent reported using both. Among those who used 
counseling, 4.1 percent used a telephone quitline, 2.8 percent used one-on-one counseling, and 
2.4 percent used a stop-smoking clinic, class, or support group. Among smokers who used a 
medication to quit, 16.6 percent reported using a nicotine patch, 12.5 percent used nicotine gum 
or lozenges, 7.9 percent used varenicline, 2.7 percent used bupropion, and 2.4 percent used a 
nicotine spray or inhaler.29  
 
The rates of counseling and treatment vary modestly depending on patients’ age, race/ethnicity, 
gender, insurance status, health status, physician status, and physician specialty.44, 45 Smokers 
aged 45–64 years (65.7%) and ≥65 years (65.7%) reported a higher prevalence of receiving 
advice to quit than did smokers aged 18–24 years (44.4%) and 25–44 years (49.8%).45 Lower 
prevalence of receiving advice to quit were reported by Asian (34.2%), American Indian/Alaska 
Native (38.1%), and Hispanic (42.2%) smokers than by white smokers (60.2%); and by 
uninsured smokers (44.1%) than by smokers with any type of insurance (range = 56.8%–69.2%). 
Smokers reporting a disability/limitation or serious psychological distress reported a higher 
prevalence of receiving advice to quit than did smokers without these conditions (71.8% and 
70.2%, respectively, vs 53.6% and 55.7%).29, 45, 46 One survey found that patients were more 
likely to receive counseling from their primary care physician (26.9%) than from other health 
care providers (15.5%), and internal medicine and cardiovascular disease physicians were more 
likely to provide tobacco cessation counseling (32.5% and 35.4%, respectively) than family or 
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obstetrics/gynecology physicians (23.5% and 19.7%). Psychiatrists ordered tobacco cessation 
prescriptions more than any other specialty (17.7%).45 
 
A few physician surveys and qualitative studies suggests that physician screening for e-cigarette 
use is limited, but report that some physicians recommend the use of e-cigarettes as cessation 
devices. When surveyed in 2013, two-thirds of a sample of 787 North Carolina physicians 
indicated that e-cigarettes were a helpful aid for smoking cessation, 13 percent incorrectly 
believed that e-cigarettes were approved by the FDA for smoking cessation, and 35 percent 
recommended them to their patients.47 Conversely, a survey of Kansas family physicians 
published in 2017 found that 82 percent would not recommend e-cigarettes for smoking 
cessation.48 A national survey of primary care physicians, pulmonologists, surgeons, and 
anesthesiologists conducted in 2015 found that approximately 54.5 percent agreed with a 
statement that e-cigarettes could help patients quit smoking, and 37.9 percent have at some point 
recommended electronic cigarettes to their patients that smoke.49  
 
Screening for e-cigarette use varies by practice and risk demographics. A 2012 survey of 
members of the American College of Obstetricians and Gynecologists (ACOG) found that 53 
percent of respondents reported screening pregnant women for chewing tobacco, snuff/snus, e-
cigarettes, and dissolvables all or some of the time.50, 51 One study of patient-reported screening 
prevalence from the 2013–2014 National Survey on Drug Use and Health showed that patients 
with anxiety, depression, and substance abuse disorders were more likely to be screened for 
noncigarette tobacco product use (88.6%, 79.6%, and 79.4%, respectively) than respondents with 
no reported mental health conditions (77.8%).52  
 
Recommendations of Others 
 
The 2015 USPSTF recommendation and 2008 Public Health Service (PHS) Guideline53 (the 
basis of the 2008 USPSTF recommendation) are endorsed by or are generally consistent with the 
recommendations of other national and international organizations, including those from the 
American College of Physicians and American Medical Association,54, 55 American Family 
Physicians,56 and the American Dental Association.57 The 2020 Surgeon General’s report on 
Smoking Cessation similarly concluded that smoking cessation medications approved by the 
FDA and behavioral counseling are cost-effective cessation strategies and increase the likelihood 
of successfully quitting smoking, particularly when used in combination.14 In addition, the 
Community Preventive Services Task Force recommends worksite-based incentives and 
competitions when these efforts are combined with other individual support interventions, 
increasing the unit price of tobacco products, mass-reach health communication interventions, 
quitline interventions, and smoke-free policies to encourage tobacco cessation among adults.58  
 
The World Health Organization released recommendations for the prevention of tobacco use 
during pregnancy in 201318 that were based on an overview of reviews and a panel of experts’ 
ratings of the quality of the evidence. The panel made a strong recommendation for advice and 
psychosocial interventions for pregnant women who were smokers. It recommended against the 
use of bupropion or varenicline for smoking cessation, based on very low-quality evidence, but 
could not make a recommendation for or against NRT use during pregnancy. Accordingly, a 
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strong recommendation for further research on pharmacotherapy for smoking cessation during 
pregnancy was made. ACOG recommendations for smoking cessation during pregnancy59 are 
also consistent with the 2015 USPSTF recommendations1 and the 2008 PHS Guideline.53  
 
Several national and professional organizations have issued recent recommendations regarding 
screening for and use of e-cigarettes among adults.14, 43, 59-64 Many recommend that e-cigarette 
use should be part of tobacco screening questions and that those who smoke or vape should be 
advised to quit all nicotine products and be provided with tobacco cessation interventions. 
Recommendations regarding the use of e-cigarettes as an aid for quitting use of other tobacco 
products (namely combustible cigarettes) are mixed: the 2020 Surgeon General’s report on 
Smoking Cessation concluded that that there is presently inadequate evidence to conclude that 
e-cigarettes, in general, increase smoking cessation.14 A recent 2019 American College of 
Preventive Medicine guideline states that clinicians should advise patients that e-cigarettes are 
not considered evidence-based smoking cessation therapy; but that a shared-decision making 
approach may be necessary if patients have failed or refused other therapies and are more willing 
to try e-cigarettes to cut down or quit smoking.63 ACOG recommends against the use of e-
cigarette products by pregnant and postpartum individuals, children and adolescents, and adults 
who currently do not use tobacco products.61 The American Cancer Society (2019) does not 
recommend the use of e-cigarettes as a cessation method62 and the American Heart Association 
concluded in its 2014 position paper that there was not enough evidence for clinicians to counsel 
their patients to use e-cigarettes as a primary cessation aid.43 Key policy recommendations by 
organizations including the AMA,65 Surgeon General,66, 67 and the American Association for 
Cancer Research and the American Society of Clinical Oncology65 have also been published in 
support of Federal, State, and local regulation of e-cigarettes, most specifically policies aimed at 
restricting the sale, distributions, marketing, and advertising of e-cigarettes to youth as well as 
smoke-free policies that include e-cigarettes. 
 
Previous USPSTF Recommendation 
 
In 2015, the USPSTF issued four recommendation statements (Table 1).1 Two “A” grade 
recommendations were given for behavioral and pharmacotherapy interventions for adults and 
for behavioral interventions for pregnant women, whereas two “I” statements were issued for 
pharmacotherapy interventions for pregnant women and the use of e-cigarettes for tobacco 
cessation among adults and pregnant women. The 2015 recommendation updated and was 
consistent with the 2009 and 2003 recommendations.68 In both years, the USPSTF recommended 
that clinicians ask all adults about tobacco use and provide interventions for smoking cessation 
for those who use tobacco products (A recommendation). It also recommended that clinicians 
ask all pregnant women about tobacco use and provide augmented, pregnancy-tailored 
counseling for those who smoke (A recommendation). The original USPSTF recommendation 
(2003) and reaffirmation (2009) were based on the 2000 and 2008 updates of the Public Health 
Service (PHS) Clinical Practice Guideline “Treating Tobacco Use and Dependence”.28, 69 
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Chapter 2. Methods 
Scope and Purpose 
 
This is an update of our 2015 review.70, 71 Consistent with that review, we relied primarily on an 
overview of reviews method for this update. In general, an overview of reviews focuses on a 
broad condition or problem for which there are two or more potential interventions. The 
overview of reviews approach was the most appropriate approach for our update because of the 
large number of tobacco cessation trials and the availability of multiple systematic reviews on 
the subject. To conduct this overview of reviews, we: 1) searched for reviews; 2) selected 
reviews; 3) assessed the credibility of the reviews; 4) determined the use of reviews; 5) 
abstracted review details and findings; and 6) synthesized findings across reviews. A typical 
Analytic Framework, Key Questions (KQs), and inclusion/exclusion criteria are outlined as they 
relate to the objectives of the overview of reviews. We did not search for original research (with 
the exceptions noted below), replicate quality rating or data abstraction of original studies, or 
replicate review-specific meta-analyses.  
 
Evidence for pregnant women was synthesized separately from evidence for the general adult 
population given the unique health risks of tobacco smoking for both women and children, 
physiological differences during pregnancy that can affect nicotine withdrawal symptoms, 
generally higher motivation to quit among pregnant than nonpregnant adults, and the potential 
different benefits and harms of various cessation treatments. 
 
Given the 2015 USPSTF conclusions of insufficient evidence for 1) the benefits and harms of e-
cigarettes for tobacco cessation and 2) the benefits and harms of pharmacologic tobacco 
cessation interventions among pregnant women, we decided a priori to conduct a de novo 
systematic review (i.e., an original search and synthesis of primary evidence) related to these 
specific areas. In addition, before initiating our review, we established that we would consider a 
search for primary research for specific interventions and/or questions if no recent (2014-present) 
reviews were identified for the topic. 
 
Key Questions and Analytic Framework 
 
With input from the USPSTF, we developed an Analytic Framework (Figure 1) and three KQs, 
using the USPSTF’s methods to guide the literature search, data abstraction, and data synthesis.  
 
1. Do tobacco cessation interventions improve mortality, morbidity, and other health 
outcomes in adults who currently use tobacco, including pregnant women? 
2. Do tobacco cessation interventions increase tobacco abstinence in adults who currently 
use tobacco, including pregnant women? 
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Data Sources and Searches 
 
We searched the following databases for relevant systematic reviews through April 2019 (with 
active surveillance through September 2020): PubMed, PsycINFO, the Database of Abstracts of 
Reviews of Effects, the Cochrane Database of Systematic Reviews (CDSR), and the Centre for 
Reviews and Dissemination Health Technology Assessment (Appendix A). In addition to these 
database searches, we searched the websites of the following organizations: AHRQ, the 
Canadian Agency for Drugs and Technologies in Health, CDC’s Guide to Community 
Preventive Services, Health and Medicine Division of the National Academies (formerly the 
Institute of Medicine), the NHS Health Technology Assessment Programme, and the U.S. 
Surgeon General. We restricted our searches to articles in the English language published since 
January 2014. We also examined the reference lists of all our included reviews to identify other 
reviews for inclusion. We supplemented our searches with suggestions from experts and reviews 
identified through news and table-of-contents alerts from sources such as ScienceDirect 
(Elsevier, Maryland Heights, MO) and Tobacco Control. We also searched for potentially 
relevant in-process or planned reviews as indicated by review protocols through AHRQ, CDSR, 
and the Centre for Reviews and Dissemination PROSPERO register.  
 
In addition to the search for reviews, we conducted two separate searches for primary evidence.  
 
The first search focused on studies addressing the use of e-cigarettes for tobacco cessation. We 
conducted searches in the following databases: CDSR, Cochrane Central Register of Controlled 
Clinical Trials (CENTRAL), PsycInfo, PubMed, and Scopus, from January 2014 through May 
2020 (Appendix A).  
 
The second search centered on pharmacotherapy tobacco cessation interventions among pregnant 
women; we conducted searches in Medline, CENTRAL, PubMed, PsycInfo from January 2014 
through May 2020 (Appendix A).  
 
We conducted ongoing surveillance for relevant primary literature through January 23, 2020 and 
for Cochrane systematic reviews through September 25, 2020 and have updated the review with 
new evidence as it is published.  
 
We also reviewed the reference lists of related systematic or narrative reviews to identify studies 
for potential inclusion and searched ClinicalTrials.gov for relevant ongoing trials that were listed 
as “recruiting,” “active, not recruiting,” “not yet recruiting,” “completed,” or “terminated” to 
identify any studies underway that might be of relevance for ongoing evaluation.  
 




We developed criteria for inclusion and exclusion of systematic reviews based on our previous 
review (Appendix A Table 1). Generally, we included studies if they were systematic reviews, 
with or without meta-analysis, that: 1) examined the effectiveness of tobacco cessation 
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interventions for adults and 2) were published in English from January 2014 to present. We 
included reviews focused on specific interventions (e.g., NRT, group counseling) and specific 
subpopulations (e.g., persons with serious mental illness). We considered reviews published by 
Cochrane as well as other non-Cochrane reviews. We excluded nonsystematic narrative reviews 
and other reviews of reviews. We excluded reviews that only or primarily evaluated 
interventions among children and adolescents and broader public health strategies. We included 
only the most recent version of updated reviews.  
 
We outlined separate inclusion and exclusion criteria when considering primary evidence related 
to e-cigarettes and pharmacotherapy interventions among pregnant women. For primary 
evidence related to the benefits (KQ 1-KQ 2) and safety (KQ 3) of e-cigarettes, we included 
randomized controlled trials (RCTs) in which smokers were randomized to  e-cigarettes or a 
control condition, such as a placebo/placebo device, a no-intervention condition, or another 
active tobacco cessation intervention (e.g., NRT, counseling). We included cohort studies with 
sample sizes of 1,000 participants or more. We included studies only if they reported a health 
outcome (KQ 1) or a measure of tobacco abstinence (KQ 2) at least 6 months after baseline 
assessment or adverse events (AEs) (KQ 3) at any point after treatment started. We excluded 
studies that only reported intermediate smoking outcomes (e.g., desire to smoke, withdrawal 
symptoms, quantity of cigarettes smoked). We required that studies take place in developed 
countries defined as “very high” on the 2015 Human Development Index (HDI) of the United 
Nations (http://hdr.undp.org/en/statistics). 
 
For pharmacotherapy interventions among pregnant women, we used the criteria outlined in the 
review by Coleman and colleagues.72 Accordingly, we included RCTs that permitted assessment 
of the independent effects of any type of first-line pharmacotherapy on smoking cessation. 
Included trials also had to provide very similar (or identical) levels of behavioral support to 
participants in the treatment and control groups. In addition, and unique from the Coleman 
review, we included large cohort studies (n>1000) that compared pregnant women who were 
exposed versus not exposed to medications for smoking cessation. We excluded quasi-
randomized, crossover, and within-participant designs, and required that studies take place in 
countries deemed “very high” on the Human Development Index. 
 
Two reviewers independently screened the abstracts and titles of all records identified in the 
searches, using the inclusion and exclusion criteria as a guide for identifying eligible studies. 
Subsequently, two reviewers assessed the full text of potentially relevant systematic reviews and 
primary studies using a standard form outlining the eligibility criteria. We resolved 
disagreements through discussion, although disagreements were minimal and easily resolved. All 
reviews were conducted in DistillerSR (Evidence Partners, Ottawa, Canada). We kept detailed 
records of all included and excluded studies (and reasons for exclusion) during full-text review. 
 
Quality Assessment and Data Abstraction 
 
We used the AMSTAR 2 (Assessment of Multiple Systematic Reviews) tool to rate the 
credibility of the systematic reviews under consideration for inclusion.73 The AMSTAR 2 tool 
contains 16 items that relate to the planning and conduct of the review (Appendix A Table 2). 
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We rated our overall confidence in the results of each review according to published guidance: a 
rating of “high” reflects that the review had zero or one noncritical weakness; “moderate” 
indicates the review was judged to have more than one noncritical weakness; “low” means the 
review was judged to have one critical flaw with or without noncritical weaknesses or multiple 
noncritical weaknesses; and “critically low” signifies that more than one critical flaw was 
present. In line with USPSTF criteria for primary evidence, we excluded reviews rated as 
critically low because they would not provide an accurate and comprehensive summary of the 
available evidence. We included low credibility reviews but rarely relied on them for the main 
results. One reviewer completed the AMSTAR 2 tool for all provisionally included reviews, and 
for all reviews that were rated critically low a second reviewer provided an independent 
assessment with the same tool.  
 
For individual studies, we used criteria developed by the USPSTF to assess the quality of 
included evidence (Appendix A Table 2).74 We examined potential risks of bias, including 
randomization and measurement procedures (including blinding and consistency between 
groups); comparability of the groups at baseline; overall and group-specific attrition; intervention 
fidelity; and the appropriateness of the statistical procedures, including methods for handling 
missing data. At least two independent reviewers assessed the quality of the primary evidence, 
and we resolved discrepancies through consultation with a third reviewer and discussion. We 
applied the typical USPSTF quality scores (i.e., good quality, fair quality, or poor quality) after 
reviewing the number and seriousness of the threats to validity. Those rated as poor quality 
contained a serious flaw or flaws that we felt likely biased or invalidated the results and were 
excluded from this review.  
 
We abstracted data from each included review and primary study into detailed abstraction forms 
using DistillerSR. For all included evidence, one reviewer completed primary data abstraction, 
and a second reviewer checked all data for accuracy and completeness.  
 
Data Synthesis and Analysis 
 
Given the large number of reviews that met our eligibility criteria and the overlapping scope and 
evidence between many of them, we developed a method to identify one or more reviews within 
each population and intervention subgroup that represented the most current and applicable 
evidence. These reviews serve as the basis for the main findings (called primary reviews 
hereafter). Box 1 describes the full set of criteria we applied to identify the primary reviews for 
each population and intervention. First, we categorized all included reviews according to the type 
of tobacco cessation intervention (i.e., distinct types of pharmacotherapy, behavioral, and/or 
combination interventions) and population (e.g., adults, pregnant women). Within each group, 
we listed the reviews in chronological order by the last search date (some reviews were listed 
more than once in the table if they addressed multiple populations or intervention types). Next, 
we compared the included studies within each review to evaluate comprehensiveness and noted 
concordance and discordance in the included primary literature. When we encountered highly 
discordant bodies of evidence, we sought an explanation for the difference by examining the 
inclusion and exclusion criteria. For example, if the most recent review for a given category did 
not appear to be the most comprehensive review in terms of the number of included studies, we 
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examined to what extent the inclusion criteria (e.g., allowable study designs, outcomes of 
interest) may have influenced the discrepancy in included studies. We also looked at individual 
included studies as necessary to ensure that the potential primary reviews did not omit important 
studies. Finally, we reviewed the inclusion and exclusion criteria and data analysis procedures of 
each review to determine the most applicable evidence. We reviewed the remaining reviews for 
complementary or discordant findings. In general, the results across reviews within each 
population and intervention grouping were consistent with one another and thus, we do not 
elaborate on these consistencies within the results.  
 
Box 1. Criteria for Choosing Primary Systematic Reviews Compared With Other Reviews 
for the Same Population and Intervention Group 
1. The search strategy is more up to date. 
2. The included studies apply inclusion/exclusion criteria that offer the most relevant and 
credible evidence (i.e., based on included study designs, populations, comparators, setting, 
followup >6 months, and outcomes). 
3. There are more (or an equal number of) included studies of the ideal study design 
4. Appropriately conducted pooled results are presented, with or without meta regression or 
subgroup analysis. 
5. The quality of the review is better. 
 
We summarized the characteristics of the primary evidence reviews in evidence tables but did 
not reanalyze individual study data. Instead, we reported the pooled analyses and existing point 
estimates presented in the included reviews. For reviews that included meta-analyses, we 
conducted comparisons of the pooled estimates of efficacy for each intervention versus 
comparator and took the definition of abstinence (continuous, point prevalence) and the length of 
followup into consideration. When extracting pooled estimates from the reviews, we considered 
the statistical validity of the available meta-analytic results. We also presented subgroup results 
related to the intensity or type of intervention, when available. We evaluated the appropriateness 
of meta-analytic procedures and used our technical judgment to interpret pooled analyses 
accounting for limitations or concerns from heterogeneity, statistical approaches, or other factors.  
 
In anticipation of sparse reporting of health outcomes (KQ 1), we decided a priori to synthesize 
any data related to health outcomes qualitatively. The primary outcome for KQ 2 was smoking 
cessation at 6 months’ or longer followup using the strictest definition of abstinence available in 
each review. We abstracted results at both 6 and 12 months’ followup if the reviews presented 
both. In most cases, the reviews reported the “longest followup” result and required at least 6 
months’ followup. The preferred outcome in most reviews was continuous abstinence (i.e., 
completely abstinent from quit date to followup allowing for up to five cigarettes) or prolonged 
abstinence (i.e., typically allows a “grace period” following the quit date to allow for lapses) over 
point prevalence abstinence (i.e., abstinent at a particular point in time such as 7 or 30 days 
before followup and thus includes a mix of recent and continuous quitters).75 Biochemical 
verification of self-reported abstinence was not required in most reviews, but validated outcomes 
were used when reported. All included reviews used analyses based on intention-to-treat 
principles in which participants lost to followup who could not be classified definitively as 
nonsmokers were counted as smokers.75  
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To evaluate health outcomes in pregnant women and neonates, we analyzed outcomes for all 
RCTs regardless of the control condition. Due to high statistical heterogeneity, we do not provide 
pooled effect estimates. Instead, we present descriptive forest plots comparing the NRT and 
control conditions for key reported perinatal health outcomes (preterm birth, low birthweight, 
stillbirth, birthweight) and narratively describe the results of the individual studies. The 
calculated relative risks are presented for most outcomes, but for low birthweight, the odds ratios 
were calculated for some trials and combined with study reported odds ratios to allow for 
comparisons of this outcome across all studies reporting the outcome. For some studies, data 
necessary for comparing health outcomes were not available in the primary studies. In such 
instances, we used data reported in a recent Cochrane review that directly contacted study 
authors for relevant data.72, 76 
 
For computing a pooled estimate across the included trials for pharmacotherapy smoking 
cessation among pregnant women, we used the DerSimonian and Laird model for pooling 
relative risks (RR) and used a restricted maximum likelihood model with the Knapp-Hartung 
correction for small samples to estimate the 95% CI interval.77 We used Stata version 15.1 
(StataCorp LP, College Station, TX) for all analyses. All significance testing was 2-sided, and 
results were considered statistically significant if the p-value was 0.05 or less. 
 
Grading the Strength of the Body of Evidence 
 
We graded the strength of the overall body of evidence for each KQ as follows. “High” indicates 
high confidence that the evidence reflects the true effect and that further research is very unlikely 
to change our confidence in the estimate of effects. “Moderate” indicates moderate confidence 
that the evidence reflects the true effect and that further research may change our confidence in 
the estimate of effect and may change the estimate. “Low” indicates low confidence that the 
evidence reflects the true effect and that further research is likely to change our confidence in the 
estimate of effect and is likely to change the estimate. A grade of “insufficient” indicates that 
evidence is either unavailable or does not permit estimate of an effect.  
 
For our overview of reviews method, we adopted the strength of the overall body of evidence 
assigned within the primary systematic review. In most cases, these grades were based on the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) working 
group definitions, which consider study limitations, consistency of effect, imprecision, 
indirectness and publication bias. Where strength of evidence grades were not available, 
including for our own primary evidence syntheses, we adapted the EPC approach – which 
generally aligns with GRADE methodology – to  assign an overall strength of evidence grade 
based on consensus discussions involving at least two reviewers.78  
 
Expert Review and Public Comment 
 
A draft Research Plan was posted on the USPSTF Web site for public comment from March 14 
through April 11, 2018. In response to public comment, the USPSTF made the following 
changes to the research plan. First, reviews focused on relapse prevention interventions are 
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included. Second, the USPSTF clarified that the target condition includes use of any tobacco 
product, as regulated by the FDA, including cigarettes, roll-your-own tobacco, smokeless 
tobacco, cigars, pipe tobacco, dissolvables, smoking tobacco through a hookah or waterpipe, and 
e-cigarettes. Reviews limited to or including cessation of any of these tobacco products are 
included. Third, reviews limited to specific subpopulations of adults with high prevalence of 
tobacco use or at risk of tobacco use-related morbidity are included, as are results from credible 
subgroup analyses. Last, reviews of medications that are not approved as first-line tobacco 
cessation medications but are used off-label and are available in the United States are included. 
The USPSTF made other minor modifications and clarifications as appropriate, including 
clarifying that any intervention that takes place in primary care or that can feasibly be referred to 
from primary care are included. A final research plan was posted on the USPSTF Web site on 
July 26, 2018. We made no deviations from the final research plan in the conduct of this review. 
 
A draft version of this report was reviewed by content experts, representatives of Federal 
partners, USPSTF members, and an AHRQ Medical Officer. Reviewer comments were 
presented to the USPSTF during its deliberations and subsequently addressed in revisions of this 
report. Additionally, a draft of the full report was posted on the USPSTF Web site from June 2, 
2020 to June 29, 2020. A few comments were received during this public comment period. All 
comments were read and considered; minor editorial changes were made to the report based on 




We worked with four USPSTF members at key points throughout this review, particularly when 
determining the scope and methods and developing the Analytic Framework and KQs. The 
USPSTF members approved the final Analytic Framework, KQs, and inclusion and exclusion 
criteria after revisions reflecting the public comment period. AHRQ funded this review under a 
contract to support the work of the USPSTF. An AHRQ Medical Officer provided project 
oversight, reviewed the draft report, and assisted in the external review of the report. 
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Chapter 3. Results 
 
This report addresses two populations of interest: the general adult population and pregnant 
women. Within each population, results are organized first by KQ and then by intervention-
specific categories.  
 




We identified 64 reviews that synthesized the benefits and/or harms of tobacco cessation 
interventions among adults, including those among an unselected population of adults and those 
limited to a specific subgroup of adults (Table 2).79-142 Fifty-eight of these reviews were newly 
identified (published from 2014 to 2020) and six reviews were carried forward from our previous 
systematic review. The remaining reviews included in our previous report were excluded 
because more recent and comprehensive reviews on each population or intervention have been 
published. Of the 210 full-text articles that were reviewed, the most common reasons for 
exclusion were study design (i.e., not a systematic review; k=42), absence of prespecified 
outcomes or cessation outcomes at 6 months or more (k=27), and critically low-quality rating 
(k=23) (Appendix B Figure 1).  
 
We designated 32 of the 64 reviews as primary reviews on smoking cessation interventions for 
general adult populations (Table 2). As described in the methods section, we chose these 
primary reviews based on their comprehensiveness, appropriateness (in scope and applicability), 
and critical appraisal ratings. Table 3 lists the inclusion and exclusion criteria for each primary 
review. Table 4 lists the characteristics of the included evidence for each primary review and 
Table 5 presents the pooled results for tobacco cessation outcomes for all included interventions.  
 
Eleven “ancillary” reviews had overlapping evidence with that synthesized in the primary 
reviews; results were consistent with the primary reviews in terms of statistical significance and 
effect magnitude and are not discussed further. An additional 21 reviews focused on specific 
subpopulations of adults (e.g., people with severe mental illness, smokeless tobacco users). 
Results of these subpopulation reviews were compared with results from general adult reviews; 
we only discussed findings of these subgroup reviews if they suggested substantive differences 
than that of the broader reviews. Seven of these reviews among specific subgroups presented 
results related to harms of medication use and are also included as main results. Characteristics 
of these additional reviews (ancillary and those limited to subpopulations) are provided in 
Appendix C. 
 
Our review of the primary evidence on the use of e-cigarettes for tobacco cessation resulted in 
nine included trials (reported in 16 publications), five of which addressed tobacco cessation and 
all of which address potential harms (Appendix B, Figure 2).143-158 Two of these trials were 
included in our previous review, and seven trials are new to this update.  
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We rated 29 of the reviews in adults as having high credibility, 26 as having moderate 
credibility, and the remaining 9 as having low credibility according to AMSTAR 2 criteria. Most 
of the main results (primary reviews) were based on reviews we rated as high or moderate 
credibility; only three reviews rated as low credibility were presented as main results given their 
unique foci (harms of varenicline, sex differences in the effectiveness of medications, and harms 
of varenicline use among smokeless tobacco users). Though they were rated as low credibility, 
the flaws noted in these reviews (e.g., lack of dual study selection, unclear ascertainment of 
funding of included studies, not accounting for risk-of-bias of studies in interpretation of the 
findings) are unlikely to invalidate the results we present from these reviews. We excluded 26 
reviews as having very low credibility; these reviews had more than one critical flaw and thus, 
we felt could not be relied on to provide an accurate and comprehensive summary of the 
available evidence. Many of these critical flaws related to the search and selection of included 
studies (e.g., a partial search strategy, no dual selection of studies), a lack of a risk-of-bias 
assessment, very little information about the included studies, or an inappropriate data synthesis 
or analysis method. Of the 64 included reviews, 32 were Cochrane Collaboration reviews. These 
reviews are generally well-conducted, well-reported, and use similar robust methods for study 
selection and synthesis, strengthening our confidence in these findings.  
 
We rated all eight trials of e-cigarettes as fair quality (Table 6). Major quality limitations of 
these trials included uncertain validity of randomization and allocation concealment procedures, 
differences in reasons for missing data across treatment groups, unclear blinding of outcome 
assessors, substantial crossover and relatively high loss to follow-up with unclear treatment of 
missing data.  
 
Key Question 1. Do Tobacco Cessation Interventions Improve 
Mortality, Morbidity, and Other Health Outcomes in Adults Who 
Currently Use Tobacco? 
 
Combined Pharmacotherapy and Behavioral Interventions 
  
None of the included systematic reviews reported the effectiveness of combined 
pharmacotherapy and behavioral interventions on health outcomes, including mortality and 




None of the included systematic reviews that assessed pharmacotherapy interventions among a 
general adult population reported the effects of interventions on mortality, morbidity, or other 
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One systematic review125 reported the results from a single RCT159 that evaluated the effect of a 
behavioral tobacco cessation intervention on health outcomes. In this trial, males considered to 
be at high risk of cardiorespiratory disease (n=1,445) were randomized to an intensive stop-
smoking intervention that included advice, written materials, and one followup visit on health 
outcomes or a no intervention control group. At 20-year followup, in the intervention compared 
with the control group, total mortality was 7 percent lower, fatal coronary disease was 13 percent 
lower and lung cancer (death plus registrations) was 11 percent lower.160 These differences were 
not statistically significant, reflecting low power and the diluting effects of incomplete 
compliance with the cessation advice in the intervention group, and a progressive reduction in 




We did not identify any primary evidence on the use of e-cigarettes as tobacco cessation 
interventions that reported results related to health outcomes.  
 
Key Question 2. Do Tobacco Cessation Interventions Increase 
Tobacco Abstinence in Adults Who Currently Use Tobacco? 
 




Only one review, the moderate-credibility review by Stead (2016), assessed the effect of 
combining pharmacotherapy and behavioral support for smoking cessation among adults.127 The 
review included 53 trials (12 of which were new to this update) that enrolled 15 to 5887 
participants. In a meta-analysis that combined 52 of the 53 trials, there was a statistically 
significant benefit of combined pharmacotherapy and behavioral interventions versus control on 
smoking cessation at 6 months’ followup or longer (risk ratio [RR] 1.83 [95% confidence 
interval [CI], 1.68 to 1.98]; I2=36%; k=52; n=19,488) (Table 5).127 Average quit rates in these 
trials ranged from 2 to 50 percent (mean: 15.2%) among participants receiving pharmacotherapy 
and behavioral support versus 0 to 36 percent (mean: 8.6%) among participants randomized to a 
control group. The review found some evidence of asymmetry in a funnel plot, with an excess of 
smaller trials detecting larger effects, suggesting the possibility of publication or other bias; 
however, a sensitivity analysis removing the smaller trials did not have a marked effect on the 
pooled estimate.127 
 
Control participants were offered usual care, self-help materials or brief advice on quitting that 
was of lower intensity than that given to intervention participants.127 Studies limited to 
adolescents or pregnant women were excluded. About half of the studies were conducted in the 
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United States. A high proportion of trials were conducted in health care settings (e.g., primary 
care clinics, dental clinics, Veterans Administration medical centers) and/or recruited people 
with specific health needs (e.g., general and psychiatric hospital inpatients, patients awaiting 
admission for surgery, mental health patients, those with mild airway obstruction or COPD). In 
more than half of the trials (32/53, 60%), participants were required to be motivated to quit 
smoking for inclusion or were classified as likely to be interested in quitting; the remaining trials 
(21/53, 40%) did not select participants based on motivation to quit. The average age of 
participants typically ranged from low 40s to mid-50s.127 
 
The included interventions typically offered or prescribed NRT; only seven trials offered 
bupropion or nortriptyline, and no trials offered varenicline.127 There was a great deal of 
variation in the intensity (number of sessions) and format of behavioral support. The typical 
intervention involved multiple contacts with a trained specialist cessation adviser or counselor, 
including face-to-face contact with additional sessions often provided by phone. Most trials 
(28/53, 53%) offered between four and eight sessions and a quarter (13/53, 25%) offered more 
than eight sessions. Total planned intervention contact time typically ranged from 90 to 300 
minutes. Specialized cessation counselors or trained trial staff delivered most of the 
interventions. A primary care provider was the main interventionist in only four included 
studies.127  
 
Evidence of Effect Modification  
 
The review by Stead conducted planned subgroup analyses by setting, participant motivation to 
quit, provider, intensity, and compliance with medication and behavioral support.127 They found 
that the pooled effect of combined interventions was higher among 43 studies that were 
conducted in or recruited participants from a health care setting, compared with eight trials that 
recruited community volunteers. The results in both settings, however, showed significant 
benefit (health care: RR 1.97 [95% CI, 1.79 to 2.18] vs. community: RR 1.53 [95% CI: 1.33 to 
1.76]) (Chi2 test for subgroup difference, p=0.00). There was no evidence that the relative effect 
of the intervention differed according to participant readiness-to-quit (meta regression, p=0.09). 
The subgroup of trials that included participants selected for motivation to change had a slightly 
larger effect estimate than the subgroup not selected for motivation, although the confidence 
intervals overlapped. Likewise, there was not an important difference in the effects of 
interventions delivered by cessation counseling specialists versus those provided by a 
nonspecialist health care provider, peer supporter, or lay health advisor (meta-regression, 
p=0.37). There was no clear evidence that increasing number of sessions or duration of personal 
contact had larger effects (bivariate meta regression, p=0.73). The subgroup of trials that offered 
eight or more sessions had the largest estimate (RR 2.10 [95% CI, 1.65 to 2.68])), but the 
confidence intervals overlapped for all four groups of interventions categorized by the number of 
sessions that included personal contact (i.e., 0 sessions, 1-3 sessions, 4-8 sessions, more than 8 
sessions). Finally, there was no evidence of effect modification according to treatment uptake 
when comparing those with high (over 70% starting pharmacotherapy and receiving at least one 
session of support), moderate (over 30% starting pharmacotherapy and over 50% receiving at 
least one session of support), or low (less than 30% starting pharmacotherapy or less than 50% 
receiving at least one session of support) compliance with the intervention (Chi2 test for 
subgroup difference, p=0.07).127 
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Pharmacotherapy Interventions 
 




The most recent high-credibility review, conducted by Hartmann-Boyce (2018), systematically 
searched for evidence through July 2017 that compared NRT with placebo or no NRT control 
groups among adult smokers.96 The review included 136 RCTs, 18 of which are new to this 
update, that ranged in size from fewer than 50 to over 8000 participants (median: 257). All six 
forms of NRT significantly increased the rate of cessation compared with placebo or no NRT, as 
did choice of NRT product (Table 5). Considering any form of NRT compared with placebo or 
no NRT, the pooled RR for abstinence was 1.55 (95% CI, 1.49 to 1.61; I2=39%; k=133; 
n=64,640) at the longest followup (6 months or more). Overall, 16.9 percent of participants who 
received some type of NRT achieved abstinence at 6 months or longer (range 1.7% to 60.0%), 
compared with 10.5 percent of control participants (range 0.5% to 46.0%).  
 
The review included trials among men or women, including six trials among pregnant women 
who smoked and were motivated to quit, irrespective of the setting from which they were 
recruited or their initial level of nicotine dependence. In most studies, participants were an 
average age of 40 to 50 years and the average number of cigarettes smoked was over 20 per day. 
Most studies took place in North America (k=62) and Europe (k=56) and included members of 
the community who volunteered in response to media advertisements and were treated in clinical 
settings. Twenty-six trials were conducted in a primary care or similar setting, with smokers 
typically recruited in response to a specific invitation from their doctor. The remaining trials 
were conducted in antenatal clinics, specialized smoking-cessation clinics, hospitals (in- or 
outpatient), drug abuse or psychiatric treatment centers, schools, or in settings designed to 
resemble over the counter (OTC) use of NRT.96 
 
The primary analysis (i.e., the effectiveness of one or more types of NRT compared with a 
placebo or a control group receiving no NRT) consisted of 131 trials reporting 133 comparisons 
among 64,640 participants.96 In this group of studies, 56 trials evaluated nicotine gum, 51 trials 
evaluated transdermal nicotine patches, 8 evaluated an oral nicotine tablet or lozenge, 7 
evaluated a choice of products being offered, 4 evaluated intranasal nicotine spray, 4 evaluated 
nicotine inhaler, 2 evaluated the provision of patch and inhaler, 1 evaluated oral spray, and 1 
each evaluated the provision of a patch and lozenge, patch and inhaler, and patch, gum, and 
lozenge. Most of the 56 trials that compared nicotine gum to a control provided the 2 milligram 
(mg) dose, while the remaining trials provided 4 mg. The treatment periods were usually 2 to 3 
months but ranged from 3 weeks to 12 months. Many of the trials included a variable period of 
dose tapering, but most encouraged participants to be gum-free by 6 to 12 months. Among the 
nicotine patch trials (k=51), the typical maximum daily dose was 15 mg for a 16-hour patch or 
21 mg for a 24-hour patch. Eight trials directly compared a higher-dose patch to a standard-dose 
patch. The minimum duration of therapy ranged from 3 weeks to 3 months. In the nicotine tablet 
or lozenge studies (k=8), three trials used 2 mg sublingual tablets, one trial used a 1 mg lozenge, 
and two trials used 2 mg or 4 mg lozenges. All trials provided the same behavioral support in 
terms of advice, counseling, and number of followup visits to the active pharmacotherapy and 
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control groups, but different trials provided different amounts of support (in terms of number and 
duration of support).96  
 
Evidence of Effect Modification  
 
Indirect comparisons of trials within the Hartmann-Boyce review based on various study-, 
population-, intervention-, and outcome-related characteristics showed that the relative rates of 
abstinence were similar across groups.96 For instance, there was no evidence that timing (12- vs. 
6-months) or choice of outcome (continuous vs. point prevalence abstinence) produced different 
treatment effects among trials of nicotine gum or patch (there were too few trials to test these 
differences for other products). Likewise, there was no evidence of effect modification through 
indirect subgroup comparisons according to the intensity or type of behavioral support that was 
provided to the intervention and control groups. As expected, absolute quit rates among control 
groups varied according to the intensity of the behavioral support; for example, rates averaged 
3.5 percent with low-intensity support, 9 percent with high-intensity individual support, and 11.7 
percent with group-based support. In terms of setting, the pooled RRs according to subgroup 
were all similar, with overlap in the 95% confidence intervals. The pooled RR for trials of any 
form of NRT among community volunteers for whom care was provided in a medical setting 
was 1.62 (95% CI, 1.53 to 1.72; I2=25%; k=6; n=24,957), similar to that of trials conducted in 
smoking clinics (RR 1.70 [95% CI, 1.48 to 1.96; I2=0%; k=12; n=3300), in primary care settings 
(RR 1.50 [95% CI, 1.33 to 1.69]; I2=0%; k=24; n=11,974), in hospitals (RR 1.39 [95% CI, 1.24 
to 1.55]; I2=15%; k=13; n=7037), and in settings similar to OTC (RR 1.40 [95% CI, 1.26 to 1.55; 
I2=83%; k=9; n=13,163). Finally, there was no substantive change in the pooled effect estimate 
after a series of sensitivity analyses accounting for trial risk of bias (i.e., either excluding studies 
at high risk of bias or limiting the analysis to only those at low risk of bias) or study methods 
(i.e., removing studies with no biochemical verification or restricting to only placebo-controlled 
trials).96 
 
Comparative Effectiveness of Different Doses, Duration, and Modes of NRT  
 
A separate high-credibility review by Lindson (2019a) evaluated the effectiveness and safety of 
different forms, deliveries, doses, durations, and schedules of NRT for achieving smoking 
cessation.104 The review included trials among people of any age who smoked and were 
motivated to quit, irrespective of the setting from which they were recruited or of their initial 
level of nicotine dependence. Any form of NRT was included, with eligible comparisons being 
any other form, dose, duration, or schedule of NRT use. Studies were not eligible if one of the 
study arms received an additional intervention component that could not be separated from the 
NRT intervention, making it impossible to establish whether any effect found was as a result of 
the difference in NRT use or the additional component.104 
 
The review included 63 studies (n=41,509), 21 of which were new to this update.104 The median 
sample size was 400 participants but ranged from 45 to 3575 participants. Most trials were 
among adult cigarette smokers with an average age of approximately 45 years old; six trials 
targeted specific populations including adolescents (1 trial), older adults (1 trial), men only (1 
trial), those who were alcohol dependent or who had a history of alcohol dependence (2 trials), 
and adults with PTSD (1 trial). Trials typically recruited people who smoked at least 15 
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cigarettes per day; in most, the average number smoked was great than or equal to 20 cigarettes 
per day. Just about half of the studies (31/63, 49%) recruited participants directly from the 
community, typically in response to media advertisements, with the remaining trials mostly 
recruiting from referrals from clinicians or health care clinics including smoking cessation clinics 
or quitlines, substance abuse clinics, or primary care clinics.104  
 
Fourteen studies compared the use of combination NRT (a fast-acting form plus a patch) with a 
single form of NRT and found that combination NRT resulted in higher long-term (6 months or 
longer) quit rates (RR 1.25 [95% CI, 1.15 to 1.36]; I2=4%; k=14; n=11,356) (Table 5).104 There 
was no evidence of subgroup differences when comparing combination therapy versus patch 
alone or a fast-acting form of NRT alone (Chi2 test for subgroup difference, p=0.61). There was 
no evidence from direct comparisons that a higher dose patch of 42/44 mg or 21/25 mg patch 
was more effective than a lower dose patch of 21/22 mg patch or 14/15 mg. Five trials compared 
4 mg to 2 mg gum use; overall, there was a statistically significant greater effect of the higher 
dose of gum on cessation; however, sensitivity analyses revealed that was only true among trials 
that were among high dependency smokers, with no evidence of an effect in low dependency 
smokers. Evidence from eight trials suggested that using either a form of fast-acting NRT or a 
patch resulted in similar quit rates at 6 months or more (RR 0.90 [95% CI, 0.77 to 1.05]; I2=0%; 
k=8; n=3319). Nine trials compared the use of NRT or no NRT prior to the set quit date (i.e., 
“preloading” by using NRT while still smoking prior to an official quit date). The pooled effect 
found a positive statistically significant effect of NRT preloading on abstinence at 6 months or 
longer (RR, 1.25 [95% CI, 1.08 to 1.44]; I2=0%; k=9; n=4395). No comparisons based on 
duration of combination therapy or patch therapy showed a statistically significant difference on 
smoking abstinence. Except for the comparison of combination versus single form NRT, these 
comparisons and findings are based on a relatively small number of trials and should be 




Primary Results  
 
The high-credibility Howes (2020) review included the most comprehensive evidence synthesis 
on the effectiveness of bupropion versus placebo or no pharmacotherapy.98 The review included 
87 studies that evaluated the effects of bupropion on smoking cessation and provided an analysis 
of 46 trials that evaluated smoking cessation after 6 months or more in those taking bupropion 
versus those taking a placebo or no pharmacotherapy. The pooled RR was 1.64 (95% CI, 1.52 to 
1.77; k=46; n=17,866) with little evidence of heterogeneity (I2=15%) (Table 5).98 Within this 
analysis, most studies were based on continuous abstinence measures that were biochemically 
validated and were placebo controlled. Quit rates ranged from 3.7 to 43.5 percent (mean, 23.3%) 
among those receiving bupropion and from 0 to 32.8 percent (mean, 11.0%) among those in the 
control groups. Almost all included studies (45 of 46) randomized intervention participants to the 
recommended dose of bupropion at 300 mg daily (150 mg twice per day). Treatment duration 
ranged from 7 to 26 weeks.98  
 
The Howes review assessed the effects of antidepressant medications, including bupropion, on 
smoking cessation rates at followup at least 6 months following initiation of treatment.98 
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Evidence related to other antidepressant medications, such as nortriptyline or citalopram, from 
the Howes review is discussed below under “Other Medications.” For smoking cessation 
outcomes, the review required RCTs to compare bupropion with placebo or another 
nonbupropion control or compare different dosages of bupropion. The authors excluded trials in 
which all participants received the same bupropion treatment but different behavioral support. 
Most trials (75%) were conducted in North America. Forty-five (52%) of the trials recruited 
special populations, such as individuals with comorbid health conditions (e.g., chronic 
obstructive pulmonary disease, schizophrenia, cardiovascular disease), adolescents, specific 
racial and ethnic groups (African American, Maori), or those who had previously failed to quit 
smoking using bupropion or NRT.98  
 
Evidence of Effect Modification  
 
In the review by Howes, the effects of bupropion were found to be similar regardless of the level 
of behavioral support offered.98 None of the three studies that used factorial designs to compare 
the effects of bupropion with varying levels of behavioral support found evidence that the 
efficacy of bupropion varied between lower and higher levels of behavioral support or by type of 
counseling approach provided (i.e., individual-based cognitive behavioral therapy vs. group 
therapy). There was also no evidence of a differential effect of bupropion on cessation between 
subgroups depending on whether they participants were recruited specifically because they had a 
mental health disorder or they represented the general population. Additionally, four included 
studies – including the large EAGLES trial,161 directly assessed whether there was any 
interaction between depression and cessation rates; none of these studies found evidence of 






A 2016 moderate-credibility review by Cahill included 39 RCTs among adult smokers that 
evaluated the efficacy or safety of varenicline.85 The review found that varenicline at standard 
doses more than doubled the chances of quitting compared with placebo. The pooled RR for 
validated continuous abstinence at 6 or more months’ followup was 2.24 (95% CI, 2.06 to 2.43; 
I2=60%; k=27; n=12,625) (Table 5). Quit rates ranged from 5.3 to 46.8 percent (mean, 25.6%) 
among those receiving varenicline and from 0 to 28.2 percent (mean, 11.1%) among those in the 
control groups.85  
 
Just over half of the studies were conducted in the United States or were multisite and included 
settings in the United States or Canada.85 The trials were conducted in smoking cessation clinics, 
hospitals, and universities and other research centers. None of the included studies took place in 
or involved primary care staff. Participants in most trials were adult smokers who were willing to 
make a quit attempt. Several trials were conducted in clinical subgroups, including among 
hospital inpatients and disease-specific subgroups (i.e., people with CVD, asthma, substance use 
disorder, depression, and bipolar/schizoaffective disorder).85 
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Most of the trials used the standard 12-week regimen of varenicline, routinely titrating the first 
week up to the recommended daily dose of 1 mg twice a day.85 Three trials compared different 
dosage arms of varenicline against a placebo arm. Most trials compared varenicline with an 
identical placebo regimen; trials comparing varenicline with other pharmacotherapies are 
discussed below (“Comparative Effectiveness”). All trials provided brief counseling for quit 
support to both treatment and control groups. As a condition of inclusion, all the trials reported 
cessation at least 6 months from the start of the intervention. All the trials except one used 
biochemical verification of abstinence.85   
 
Evidence of Effect Modification 
 
There was no evidence of differences in the effects of varenicline according to different study, 
drug, and population characteristics in the review by Cahill.85 A separate review by McKee 
(2016) found that varenicline versus placebo had a larger statistically significant effect size for 
women than men for continuous abstinence at both 3 and 6 months’ followup (sex x medication 
interaction, p<0.05).112 For example, at 6 months, varenicline increased the odds of quitting in 
women by 3.49 times (95% CI, 2.64 to 4.57) and by 2.59 times (95% CI, 2.20 to 3.06) in men, 
with the interaction demonstrating that varenicline was 31 percent more efficacious in women 
(OR, interaction for treatment condition by sex 1.31 [95% CI, 0.97 to 1.84; p<0.05). Equal 
efficacy was seen between men and women for both point prevalence abstinence and continuous 




In addition to the seven FDA-approved medications for smoking cessation (i.e., five forms of 
NRT, bupropion, and varenicline), various other antidepressants and nicotine receptor partial 
agonists have been evaluated for their effectiveness and safety in helping people stop smoking.  
 
The review by Howes included a synthesis of the effectiveness of antidepressants including 
bupropion (discussed above), nortriptyline, selective serotonin reuptake inhibitors (SSRIs: 
fluoxetine, paroxetine, sertraline, citalopram and zimelidine), monoamine oxidase inhibitors 
(MAOIs: moclobemide, selegiline, lazabemide, EVT302), and other antidepressants 
(venlafaxine, St. John’s wort, S-Adenosly-L-Methionine, doxepin, imipramine, tryptophan).98 
There was limited evidence for all comparisons, which prevents drawing robust conclusions 
about these therapies. A pooled analysis of six trials showed evidence of a significant benefit of 
nortriptyline versus placebo at 6 or more months followup (RR 2.03 [95% CI, 1.48 to 2.78]; 
I2=16%; k=6; n=975). In contrast, none of the individual trials of SSRIs (k=7), MAOIs (k=6), or 
other antidepressants (k=4) showed a benefit on smoking cessation at 6 or more months followup 
nor did pooled estimates of these medications. Furthermore, comparing any of these other 
antidepressants as an adjunct to nicotine patch therapy versus nicotine patch alone did not show 
evidence of an additional benefit over NRT.98  
 
In addition to synthesizing the evidence on varenicline (discussed above), the review by Cahill 
on nicotine receptor partial agonists included five trials testing the effects of cytisine (k=4, 
n=3461) to increase smoking abstinence.85 The pooling two of the more recent trials of cytisine 
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found that more participants taking cytisine stopped smoking compared with placebo at 6 or 
more months’ followup, with a pooled RR of 3.98 (95% CI, 2.01 to 7.87).85  
 
Comparative Effectiveness of Different Pharmacotherapy Agents or Regimens 
 
Comparison of Different Types of NRT  
 
As noted above, no studies that compared fast-acting NRT with a nicotine patch found a 
differential effect on smoking cessation (RR 0.90 [95% CI, 0.77 to 1.05]; I2=0%; k=8; 
n=3319).104 One trial (n=1410) included in the Lindson review also compared participant- versus 
clinician-selected NRT and found no difference in quit rates at 6 months.104  
 
Combination NRT vs. Single NRT 
 
As stated above, combination NRT (i.e., the use of a fast-acting product and nicotine patch) was 
found to be superior to a single form of NRT in a pooled analysis of 14 direct comparisons (RR 
1.25 [95% CI, 1.15 to 1.36]; I2=4%; k=14; n=11,356) (Table 5).104 
 
NRT vs. Bupropion 
 
Howes included ten studies that directly compared bupropion with any form of NRT.98 Pooled 
results did not detect a significant difference between the bupropion versus NRT (RR 0.99 [95% 
CI, 0.91 to 1.09]; I2=18%, k=10; n=8230) (Table 5).98   
 
NRT vs. Varenicline 
 
Cahill and colleagues included eight trials that tested NRT against varenicline.85 A pooled 
analysis of all of the trials indicated a benefit for varenicline over NRT at 6 months (RR 1.25 
[95% CI, 1.14 to 1.37]; I2=39%; k=8; n=6264) (Table 5). Removing three open-label trials (all at 
high risk of bias for blinding) slightly strengthened the effect estimate (RR 1.34 [95% CI, 1.19 to 
1.50]) and increased the I2 to 47%. In a separate review examining sex differences in the relative 
effectiveness of pharmacotherapy, the benefits of varenicline over NRT were greater for women 
than with men (RR for interaction effect, 1.19 [95% CI, 1.01 to 1.40).124 In that review, women 
treated with varenicline were 41 percent more likely to achieve 6-month abstinence than women 
treated with NRT (RR 1.41 [95% CI, 1.12 to 1.76]). For men, the benefit of varenicline over 
NRT (16%) was smaller and not statistically significant (RR 1.16 [95% CI, 0.91 to 1.47]).124 
 
NRT vs. Cytisine 
 
One recent trial comparing cytisine with NRT in 1310 people found a benefit for cytisine at 6 
months (RR 1.43 [95% CI, 1.13 to 1.80]).85 
 
Bupropion vs. Varenicline 
 
Six trials included in the Howes review directly compared the effects of bupropion versus 
varenicline on smoking cessation.98 All six studies showed more favorable effects for varenicline 
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compared with bupropion, and all but one found these differences to be statistically significant. 
A pooled estimate of the six trials found that bupropion was less effective than varenicline (RR 
0.71 [95% CI, 0.64 to 0.79]; I2=0%; k=6; n=6286) (Table 5).98 A separate review and network 
meta-analysis found greater effectiveness of varenicline versus bupropion in achieving 6-month 
abstinence among women (RR 1.38 [95% CI, 1.08 to 1.77]) versus men (RR 1.11 [95% CI, 0.85 
to 1.45] (RR for interaction effect, 1.22 [95% CI, 1.02 to 1.47]).124 
 
Bupropion Plus NRT vs. NRT  
 
A pooled estimate of 12 studies that directly compared the addition of bupropion to NRT versus 
NRT alone did not suggest a significant benefit of this combination of drugs versus NRT alone 
(RR 1.19 [95% CI, 0.94 to 1.51]; I2=52%; k=12; n=3487), although studies were clinically and 
statistically heterogeneous.98 
 
NRT Plus Varenicline vs. Varenicline  
 
A review by Chang and colleagues (2015) included three RCTs with 904 participants that 
compared combined varenicline and NRT therapy with varenicline alone.87 Only two of the trials 
reported continuous smoking abstinence at 6 months. Both trials showed a favorable effect of 
combination therapy, although only one reached statistical significance.87  
 
Bupropion Plus Varenicline vs. Varenicline  
 
In the Howes review, there was no evidence that combination bupropion and varenicline resulted 
in higher smoking cessation rates than varenicline alone (RR 1.21 [95% CI, 0.95 to 1.55]; 
I2=15%; k=3; n=1057).98  
 
Support for Medication Adherence 
 
Finally, a 2019 review by Hollands assessed the effectiveness of interventions that aimed to 
increase adherence to medications for smoking cessation.97 The review included 10 studies, all of 
which reported the effects of the intervention on adherence outcomes. There was some evidence 
that interventions that devote special attention to improving adherence through the provision of 
information and facilitation of problem-solving can lead to modest increases in adherence, when 
added to behavioral support for smoking cessation. Five studies also reported on the effects of 
the adherence intervention on abstinence at 6 months or greater, with evidence of no effect on 








The high-credibility review by Hartmann-Boyce (2018) assessed the effect of increasing the 
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intensity or changing the content of behavioral support among smokers using smoking cessation 
medications.95 The review included RCTs in which adult smokers in both the intervention and 
control conditions received pharmacotherapy for smoking cessation, but they differed by the 
amount or content of behavioral support. Participants in the control condition received less-
intensive behavioral support than participants in the intervention condition, often limited to 
written information alone, or a different approach to behavioral support but matched for contact 
time.95  
 
Eighty-three studies were included, of which 36 are new for this update.95 Over 29,000 
participants are represented in the included study arms, with a range of 30 to 4614 participants in 
the individual trials. A meta-analysis of 65 trials suggested that increasing the intensity of 
behavioral support for smokers making a cessation attempt with the aid of pharmacotherapy 
typically leads to a relatively small increase in the proportion who have quit at 6 to 12 months. 
The estimated RR was 1.15 (95% CI, 1.08 to 1.22; I2=8%; k=65; n=23,331) (Table 5). The 
average absolute quit rate of both the intervention (20%) and control groups (17%) were quite 
high and were comparable to the intervention groups in the trials of pharmacotherapy versus 
placebo. While most studies reported point prevalence abstinence instead of continuous or 
prolonged abstinence, the review found no difference in the relative effect between studies that 
reported point prevalence rather than continuous abstinence at 12 months.95  
 
Twenty-nine studies (35%) recruited people in a health care setting (excluding smoking cessation 
clinics), including 10 studies that took place in primary care.95 Since the intervention included 
the provision of pharmacotherapy, most of the studies recruiting in a health care setting enlisted 
volunteers who were interested in making a quit attempt, although motivation to quit was not 
always an explicit eligibility criterion. The remaining studies recruited community volunteers 
interested in quitting.95 
 
Most studies offered NRT, specifically the nicotine patch.95 Seven studies provided bupropion 
alone, one provided nortriptyline alone, and four provided varenicline alone. The remaining 
studies offered participants a choice or combination of medications. The intensity of the 
behavioral support, in both the number of sessions and their duration, was very heterogeneous 
for both the intervention and control arms. In seven studies, the controls received no counseling. 
In 30 studies, the control arms had one to three contacts (either face-to-face or by telephone), and 
most of these had a total contact duration of 4 to 30 minutes. In 34 studies the control group was 
scheduled to receive four to eight contacts, with most involving a total contact duration of over 
90 minutes. The 12 remaining studies scheduled over eight contacts for the controls. Typically, 
the intervention involved only a little more contact than the control, so that the least intensive 
control conditions were in trials with only moderate-intensity interventions.95 
 
Evidence of Effect Modification  
 
The effect was similar and statistically significant for the subgroup of studies that examined 
behavioral support as an adjunct to NRT (k=50) and bupropion (k=5) specifically.95 Results of 
the remaining trials among smokers using other pharmacotherapies (e.g., varenicline) or a choice 
of pharmacotherapy were generally not statistically significant, although there were few trials in 
these subgroups and a test for difference between subgroups was not significant. There was little 
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evidence of any dose-response effect according to the number of contacts in the intervention and 
control groups (and the contrast between those groups), although the point estimate was highest 
for the subgroup in which controls did not have any personal contact (RR 1.20 [95% CI, 1.02 to 
1.43]). Seventeen studies, all new to this update, compared interventions matched for contact 
time but provided through different modalities, providing different content, or employing 
different behavior change techniques. All studies in this group employed different comparisons 
and were not pooled. Only one trial – comparing motivational interviewing with health education 
– found a statistically significant difference between the two interventions, with the finding in 






The high-credibility review by Stead (2013b) summarized evidence from 42 trials on the 
effectiveness of physician advice in promoting smoking cessation published through January 
2013.125 This review included RCTs that compared physician advice to stop smoking versus no 
advice (or usual care), or compared different levels of physician advice to stop smoking. Advice 
was defined as verbal instructions from the physician with a “stop smoking” message regardless 
of whether information was provided about the harmful effects of smoking. In a meta-analysis, 
smokers who were offered cessation advice by a physician had a statistically significant increase 
in the likelihood of quitting at 6 months or longer compared with smokers receiving no advice or 
usual care (RR 1.76 [95% CI, 1.58 to 1.96]; I2=40%; k=26; n=22,239) (Table 5). Absolute quit 
rates ranged from 1 to 23 percent among intervention participants (mean: 8.0%), and from 1 to 
14 percent among control participants (mean: 4.8%).125  
 
Evidence of Effect Modification  
 
The results of the main meta-analyses were not sensitive to exclusion of trials at high risk of bias 
for any item.125 When stratified by intervention intensity, both brief advice (single consultation 
lasting less than 20 minutes plus up to one followup visit) (RR 1.66 [95% CI, 1.42 to 1.94]) and 
intensive advice (greater time commitment at the initial consultation, use of additional materials 
beyond a brochure, or more than one followup visit) (RR 1.86 [95% CI, 1.60 to 2.15]) showed 
statistically significant increases in quit rates when compared with no advice controls. There was 
no evidence of an interaction effect between strata (p=0.31). However, direct comparisons 
between intensive and minimal advice in 15 trials suggested a statistically significant advantage 
of more intensive advice (RR 1.37 [95% CI, 1.20 to 1.56]; I2=32%; k=15; n=9,775). Subgroup 
analyses within this group of 15 trials suggested that this effect might be small or nonexistent 
among smokers without smoking-related disease (10 studies), but the effect might be larger when 
the intervention is provided to smokers in high-risk groups (e.g., those with heart disease, 
chronic obstructive pulmonary disease) (based on only 5 trials).125  
 
An indirect comparison between subgroups of studies within the main analysis suggested that 
interventions that included additional followup visits had a slightly larger effect estimate (RR 
2.27 [95% CI, 1.87 to 2.75]; I2=27%; k=6; n=4,510) compared with no advice than interventions 
delivered at a single visit versus no advice (RR 1.55 [95% CI: 1.35 to 1.79]; I2=35%; k=18; 
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n=14,675).125 Five additional included trials directly compared the addition of further followup 
to a minimal intervention but were not included in the main analysis of advice versus no advice. 
None of these five trials individually detected significant differences between groups.125 
 
Nurse Advice  
 
Primary Results  
 
A more recent high-credibility review by Rice (2017) synthesized the evidence on nursing 
interventions for smoking cessation.119 Similar to the review of physician advice, included 
nursing interventions consisted of the provision of advice, counseling, and/or other strategies to 
help people stop smoking provided by a nurse. This review used the same definition of what 
constituted “advice” but defined intervention intensity slightly differently. In the Rice review, 
low-intensity interventions were those that were conducted during a single consultation lasting 
10 minutes or less, with up to one followup visit (as opposed to 20 minutes in the physician 
advice review) and high-intensity interventions as those in which the initial contact lasted more 
than 10 minutes (again, as opposed to more than 20 minutes for physician advice). These high-
intensity interventions also distributed additional materials, used additional strategies, and 
typically included more than one followup visit.119  
 
The Rice review included 58 trials, nine of which are new to this update.119 Twenty-eight trials 
(48%) recruited from primary care or outpatient settings, and another 22 trials (38%) intervened 
with hospitalized patients. The remaining trials recruited from workplaces, communities, 
universities, and other sites. Just under half of the trials recruited individuals with chronic 
diseases (e.g., cardiovascular disease, respiratory disease, diabetes) or hospitalized patients. Most 
trials (k=44) compared a nursing intervention to a usual care or minimal intervention control and 
contributed to the primary meta-analysis. The remaining comparisons were made between two 
nursing interventions that involved different components or a different number of contacts 
(k=11) or were excluded from meta-analyses because of incomplete data (k=6). The estimated 
pooled RR comparing smoking cessation support provided by a nurse with usual care or minimal 
intervention was 1.29 (95% CI, 1.21 to 1.38; I2=50%; k=44; n=20,881) (Table 5).119  
 
Evidence of Effect Modification  
 
There was no evidence of different effects among interventions classified as low- versus high-
intensity (Chi2 test for subgroup difference, p=0.87).119 
 
Individual Behavioral Counseling 
 
Main Results  
 
We identified one recent high-credibility review by Lancaster (2017) that reviewed the evidence 
on individual counseling in promoting smoking cessation.103 The review included studies among 
nonpregnant smokers that tested the effect of an individual counseling intervention compared 
with no treatment, brief advice, self-help materials, or a less intense individual counseling 
intervention. Individual counseling was defined as a face-to-face encounter between a smoker 
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and a counselor trained in providing smoking cessation assistance. Studies of counseling 
delivered by physicians or nurses, those that combined counseling with pharmacotherapy, and 
those using motivational interviewing were excluded given their inclusion in other relevant 
reviews (which are all included in this overview of reviews). Forty-nine trials were included, 
with around 19,000 participants. Thirty-three studies contribute to the primary analysis 
comparing individual counseling with a minimal-contact behavioral intervention. Eleven studies 
compared different intensities of interventions, and five compared counseling approaches that 
were similar in intensity of contact. The recruitment settings and study populations were highly 
variable and included those recruited as medical or surgical inpatients or outpatients, at primary 
care clinics and worksites, and as community volunteers. The counseling intervention typically 
included a review of a participant’s smoking history and motivation to quit, help in identification 
of high-risk situations, and the generation of problem-solving strategies to deal with such 
situations. Some studies also provided additional components such as written materials or videos. 
The therapists who providing the counseling were generally described as smoking cessation 
counselors with professional backgrounds in social work, psychology, psychiatry, health 
education, and nursing.103  
 
The pooled effect size based on 33 studies demonstrated statistically significant benefit of 
individual counseling compared with a minimal contact control (RR 1.48 [95% CI, 1.34 to 1.64]; 
I2=46%; k=33; n=13,762) (Table 5).103 In these studies, a minimal contact control ranged from 
usual care to up to 15 minutes of advice, with or without the provision of self-help materials. 
Most of the interventions implemented multiple sessions of face-to-face support in addition to 
telephone contact. Within this group of studies, six trials included pharmacotherapy for both 
arms. The effect estimate was higher in the subgroup of studies when pharmacotherapy was not 
provided (RR 1.57 [95% CI, 1.40 to 1.77]; I2=50%; k=27; n=11,100) than in the studies testing 
the additional effect of counseling when participants had access to pharmacotherapy (RR 1.24 
[95% CI, 1.01 to 1.51]; I2=0%; k=6; n=2662) and the test for a subgroup difference was 
statistically significant (Chi2 test for subgroup difference, p=0.04). There was some evidence that 
more intensive versus less intensive counseling resulted in greater cessation (16.8% vs. 12.7% 
absolute quit rates, respectively) (RR 1.29 [95% CI, 1.09 to 1.53]; I2=48%; k=8; n=2920), and 
there was a difference in this effect according to whether pharmacotherapy was also provided 
(Chi2 test for subgroup difference, p=0.04). There was limited evidence from studies comparing 
different types of individual counseling.103 
 
Group Behavioral Therapy 
 
Primary Results  
 
The moderate-credibility review by Stead (2017) synthesized the evidence on the effect of 
group-delivered behavioral interventions in achieving long-term (6 months or more) smoking 
cessation among nonpregnant adult smokers.126 Included interventions were those in which 
smokers attended scheduled meetings and received some form of behavioral intervention, such 
as information, advice, and encouragement or cognitive behavioral therapy delivered over at 
least two sessions. The review included 66 trials, 44 of which compared a group program with a 
non-group-based cessation intervention or a no-intervention control. The remaining 22 did not 
have a non-group control and only contributed to comparisons between different group-based 
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programs. Most studies recruited community volunteers prepared to participate in group 
programs; only three recruited from primary care. The group programs varied in length, format, 
and content. Most programs offered six to eight sessions, with the first few sessions devoted to 
motivation for quitting, health benefits, and strategies for planning a quit attempt. Compared 
with non-group self-help programs, group-based therapy interventions resulted in a statistically 
significant increased risk of quitting tobacco at 6 or more months’ followup (RR 1.88 [95% CI, 
1.52 to 2.33]; I2=0; k=13; n=4395) (Table 5). A separate analysis of 14 trials found a small 
benefit of group support compared with brief support from a physician, nurse, or pharmacist with 
a conference interval just excluding no effect (RR 1.22 [95% CI, 1.03 to 1.43]; I2=59%; k=14; 
n=7286). When combining the results of five trials (n=1523) that examined group therapy as an 
adjunct to pharmacotherapy, the analysis did not detect a statistically significant increased quit 
rate for combined therapy over pharmacotherapy without group support. Similarly, there was no 
evidence, based on six trials (n=980), that group therapy was more effective than individual 
therapy when the number of sessions were matched.126  
 




A 2019 high-credibility review by Lindson (2019b) reviewed the evidence on the effectiveness 
of motivational interviewing (MI) to increase smoking cessation.106 In this review, RCTs 
conducted among nonpregnant smokers with an MI intervention were included. The intervention 
must have been based on the MI principles as defined by Miller and Rollnick,162 making explicit 
reference to at least some MI principles: exploration of ambivalence, decision balance, 
assessment of motivation and confidence to quit, elicitation of “change talk,” and support for 
self-efficacy and in the opinion of the review authors, complied with these principles and 
practices. The review identified 37 trials, involving over 15,000 participants. The included MI 
interventions were conducted in one to 12 sessions, with the total duration of MI ranging from 5 
to 315 minutes. Interventions were primarily delivered by primary care physicians, nurses, or 
counselors. Pooling studies that compared a smoking cessation intervention supplemented by MI 
with the same smoking cessation intervention without MI suggested a small potential benefit of 
MI; however, the 95% CI spanned one and there was moderate heterogeneity detected (RR 1.07 
[95% CI, 0.85 to 1.36]; k=12; n=4167; I2=47%) (Table 5). Nineteen trials compared an MI 
intervention to another type of smoking cessation intervention. The point estimate was in favor 
of MI; however, the confidence intervals were consistent with substantial benefit and with 
potential harm (RR 1.24 [95% CI, 0.91 to 1.69]; k=19; n=5192; I2=54%). Furthermore, there was 
no evidence of a benefit of a MI smoking cessation intervention when compared with no 
intervention within four trials.106 
 
Evidence of Effect Modification  
 
There was no clear evidence to suggest that the effect of MI was moderated by the intervention 
provider participants’ motivation to quit at baseline, whether MI was delivered face-to-face, or 
whether MI fidelity monitoring took place.106 Five trials directly compared the effectiveness of 
more intensive versus less intensive MI intervention. There was some suggestion that more 
intensive interventions were associated with greater smoking abstinence; however, this analysis 
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included several studies at high risk-of-bias and removing those studies produced a 






A 2018 moderate-credibility review by Moyo synthesized the evidence on the effectiveness of 
decision aids for smoking cessation in adults.115 Both experimental and quasi-experimental 
studies that evaluated the use of decision aids to promote shared decision making between a 
patient and healthcare provider were included. For the purpose of this review, a decision aid was 
defined as a tool any healthcare provider used to share with and inform people about treatment 
options, including the risks, and costs and benefits of potential choices. Any form of decision aid 
was included such as pamphlets, brochures, cards, DVDs, or web-based applications. The review 
identified seven studies that met eligibility criteria with decision aids including web- or 
computer-based aids (3 studies), a video decision aid (1 study), a print-based aid (2 studies), and 
a video plus print decision aid (1 study). The decision aids were delivered by a healthcare 
provider in only two cases. The other studies all evaluated a decision aid where provider 
followup was optional based on the participant’s decision after use of the aid. Of the six studies 
that measured abstinence, only two suggested a benefit of using a decision aid (versus usual care) 
on smoking abstinence and only one was statistically significant.115   
 
Print-Based Self-Help Materials 
 
Primary Results  
 
A recent updated moderate-credibility review by Livingstone-Banks (2019b) assessed the 
effectiveness of different forms of print-based self-help materials compared with no treatment or 
other minimal intervention strategies.109 The review included 75 studies, with only 3 of them 
new to this update. Self-help interventions were defined as any manual or program designed to 
be used by individuals to assist a quit attempt not aided by health professionals, counselors, or 
group support. For the most part, that included written materials such as booklets and 
leaflets/brochures, but information could also have been provided via audio, video, or a similar 
medium. Brief leaflets on the health effects of smoking were considered a control condition if 
they were compared with a more substantial print-based intervention. Interventions that included 
a single face-to-face session for the purpose of supplying the print-based materials were 
included, but interventions that provided repeated sessions of advice in addition to self-help 
materials were excluded. Additionally, interventions delivered via a computer or mobile phone 
as well as those that included telephone counseling as adjuncts to self-help materials were 
excluded because these interventions were covered in other published reviews (which are also 
included in this overview of reviews).109  
 
The content and format of the self-help programs varied.109 The most frequently used materials 
were the American Lung Association’s cessation manual: Freedom From Smoking in 20 Days, 
and the maintenance manual: A Lifetime of Freedom From Smoking.163 Most other programs 
were not named or fully described. Most of the recent studies used computerized expert systems 
 
Tobacco Cessation in Adults 33 Kaiser Permanente EPC 
to provide tailored materials judged to be relevant to the characteristics of each smoker, based on 
baseline data.109  
 
Overall, after pooling 32 studies of non-tailored self-help materials compared with no self-help, 
irrespective of the level of contact and support common between groups, the point estimate 
showed a small, but not statistically significant, benefit of the intervention (RR 1.06 [95% CI, 
0.95 to 1.19]; I2=25%; k=32; n=28,451) (Table 5).109 Trials varied considerably in ways that 
could potentially impact results, such as whether the materials were tailored, and the amount of 
face-to-face advice or counseling provided to both the intervention and control groups.109  
 
Evidence of Effect Modification 
 
When isolated to only studies that compared groups who received self-materials versus groups 
who received no intervention at all, results were statistically significant: a meta-analysis of 11 
trials that provided standard non-tailored self-help manuals or materials compared with no 
materials for the control group showed some benefit of self-help materials, although the 
confidence interval only narrowly excluded 1.0 (RR 1.19 [95% CI, 1.03 to 1.37]; I2=0%; k=11; 
n=13,241).109 Relative effects were also larger when comparing the subset of studies in which 
participants in the intervention group received tailored self-help materials versus controls 
receiving no intervention (RR 1.34 [95% CI, 1.19 to 1.51]; I2=0%; k=10; n=14,359). However, 
there was no evidence that tailored materials were superior to nontailored materials in indirect or 
direct comparisons.109  
 




A recent moderate-credibility review by Matkin (2019) evaluated the effects of telephone 
support to help smokers quit.110 Included trials evaluated the impact of proactive (i.e., recruiter-
initiated contact) and reactive (i.e., smoker-initiated contact) among smokers of any age, 
including pregnant individuals. The review identified 104 trials (30 of which are new to this 
update) including 111,653 participants that met inclusion criteria. All included trials were 
relatively large, with a median sample size of 735 and only 7 trials with a sample size of less 
than 100. Participants were mostly adult smokers from the general population, but some studies 
included adolescents, pregnant women, and people with long-term or mental health conditions. 
Most studies (100/104) assessed proactive telephone counseling programs as opposed to reactive 
forms. Proactive telephone counseling interventions included: 1) additional counseling calls that 
took place following smokers calls to helplines and 2) counseling calls from counselors or other 
health care providers that were among samples of smokers who had not originally contacted a 
help line (essentially a “cold call”). Some studies provided telephone counseling alone, but many 
others provided telephone counseling along with minimal support such as self-help materials, or 
more active support such as face-to-face counseling, or with medications. The number of calls 
ranged from a single call to 12 calls. The duration of the calls was typically 10 to 20 minutes, 
although the first calls were often longer. Counseling was most often provided by professional 
counselors or trained health care professionals.110  
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Among trials including smokers who contacted helplines, quit rates were higher for smokers 
receiving multiple additional telephone counseling sessions (mean quit rate, 10.8%) compared 
with a control condition that was provided self-help materials or brief counseling in a single call 
(mean quit rate, 7.8%) (RR 1.38 [95% CI, 1.19 to 1.61]; I2=72%; k=14; n=32,484) (Table 5).110 
Likewise, in studies that recruited smokers who did not call a helpline, telephone counseling 
increased quit rates (mean quit rate, 13.9%) modestly compared with other minimal or brief 
counseling control groups (mean quit rate, 11.0%) (RR 1.25 [95% CI, 1.15 to 1.35]; I2=52%; 
k=65; n=41,233) (Table 5). In both instances, however, statistical heterogeneity was moderate to 
substantial. Only three included studies assessed the impact of offering reactive counseling by 
providing access to a helpline/quitline, compared with not being provided access with only one 
finding a statistically significant increased rate of quitting among those with helpline access. 
Both proactive and reactive telephone counseling appeared to increase quit rates compared with 
health care provider counseling, but this finding is limited by the small number of trials testing 
this comparison (four trials).110  
 
Evidence of Effect Modification  
 
The exclusion of trials among pregnant women, adolescents, and those at high risk of bias did 
not have a large influence on the effect size or statistical heterogeneity in the review.110 
Likewise, subgroup analyses based on the baseline support provided to both intervention and 
control groups, counseling intensity, or motivation did not fully explain the heterogeneity in the 
results. However, there was some evidence through multivariate meta regression that the baseline 
support offered to both treatment arms as well as whether participants were selected for 
motivation to quit may have had some influence on the effect size related to proactive telephone 
counseling for smokers who did not call quitlines. The relative difference was greater for those 
receiving adjunctive self-help materials (35% greater) or brief face-to-face counseling (37% 
greater) than pharmacotherapy (referent). In the same model, studies that selected participants 
because of their motivation to quit were associated with a 26 percent increased relative risk 
compared with studies that did not select participants based on their motivation to quit. There 
was not enough evidence to suggest that a higher number of calls would result in a larger effect, 
although there was limited evidence that offering 3 to 6 calls may be more effective than offering 
just one single proactive call.110  
 
Mobile Phone-Based Support 
 
Primary Results  
 
The high-credibility review by Whittaker (2019) identified 26 RCTs 14 of which are new) 
(n=33,849) that included an evaluation of a mobile phone-based intervention.138 The review 
included interventions that were aimed at mobile phone users, were based on delivery via mobile 
phone, or used any functions or applications that could be used or sent via a mobile phone. The 
review excluded trials that used mobile phones as an adjunct to face-to-face or internet-based 
programs or that could not separate the effects of the mobile phone intervention components 
from the effects of a multicomponent intervention. All studies tested automated text messaging 
interventions (SMS) as a central component of the intervention. Several studies paired SMS with 
in-person visits, although the majority were purely test-messaging interventions. Five studies 
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tested the effectiveness of smoking cessation smartphone apps alone, although the apps varied 
considerably in intervention content and components. Trials represented both young adults 
(mean age 18–27 years) and middle-age adults (up to mean age of 45 years).138  
 
A meta-analysis of 13 studies that compared a text messaging intervention with minimal 
smoking cessation support showed a positive benefit of text messaging interventions on smoking 
cessation at 6 months’ followup (RR 1.54 [95% CI, 1.19 to 2.00]; I2=71%; k=13; n=14,133) 
(Table 5) with the average absolute quit rates of 9.5 percent versus 5.6 percent in the 
intervention versus control groups, respectively.138 A similar effect was found when comparing 
mobile phone-based interventions with no intervention (RR 1.59 [95% CI, 1.09 to 2.33]; I2=0%; 
k=4; n=997).138 
 
Evidence of Effect Modification  
 
The review found minimal differences in the overall result when pooled subgroups of studies 
were based on frequency of text messages (high-frequency vs. low-frequency), text message-
only interventions, or those with only minimal (versus active) controls.138  
 
Real-Time Video Counseling 
 
Primary Results  
 
A new high-quality review by Tzelepis (2019) assessed the effectiveness of real-time video 
counseling delivered individually or to a group (e.g., via video communication software such as 
Skype and FaceTime) in increased smoking cessation.134 Only two trials were identified (n=615). 
Both studies delivered real-time video counseling for smoking cessation individually, compared 
with telephone counseling. There was no statistically significant tretement effect for smoking 
cessation across the two included studies (RR 2.15 [95% CI, 0.38 to 12.04]; I2=66%; k=2; 




Primary Results  
 
An updated high-credibility review by Taylor (2017) was designed to determine the effectiveness 
of internet-based interventions for smoking cessation and to evaluate whether intervention 
effectiveness was altered by tailoring interactive features, and if there was a difference in 
effectiveness between adolescents, young adults, and adults.129 Any type of internet intervention 
was eligible, and the comparison could be a no-intervention control, a different internet 
intervention, or a non-internet intervention. The review identified 67 RCTs, including data from 
over 110,000 participants. Thirty-nine of the trials were new to this update. Most of the studies 
were among adults; three studies recruited adolescents only and seven studies recruited young 
adults or university or college students. Most studies were conducted in the United States and 
recruitment and all intervention components were Web-based, with participants finding the sites 
through search engines and browsing. As a result of the recruitment methods, participants in 
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these trials were motivated to quit smoking and chose the internet as a tool for smoking cessation 
support. Sample sizes ranged from fewer than 70 to nearly 12,000.129  
 
A range of internet interventions was tested in the included studies, from a very low-intensity 
intervention providing a list of websites for smoking cessation, to highly intensive interventions 
consisting of internet-, email- and mobile phone-delivered components.129 Many interventions 
provided tailored interventions but differed substantially in the amount of tailoring. Some trials 
also included counseling or support from nurses, peer coaches, or tobacco treatment specialists. 
Some of the more recent trials incorporated online social networks such as Facebook, Twitter, 
and online forums. In 15 trials, all participants were using, or were offered, pharmacotherapy and 
the internet component was thus evaluated as an adjunct to pharmacotherapy. Nine trials of 
lifestyle interventions provided content on a range of topics, including smoking cessation. These 
trials were not included in the main synthesis and meta-analysis given that results were not 
isolated for smokers only.129  
 
Given the heterogeneity of the included evidence in terms of the interventions (i.e., tailored vs. 
not, interactive vs. not) and control conditions (i.e., nonactive controls [printed self-help guides, 
usual care], active controls [telephone, face-to-face counseling], addition of an internet program 
plus behavioral support, or comparing one internet intervention with another), the results were 
synthesized into distinct subgroups.129 Compared with a nonactive control group, pooled results 
demonstrated an effect in favor of interactive and tailored internet-based interventions (RR 1.15 
[95% CI, 1.01 to 1.30]; I2=58%; k=8, n=6786) (Table 5). However, these results should be 
interpreted with caution, as statistical heterogeneity was high and was unexplained despite 
perceived clinical homogeneity. Furthermore, though the pooled effect was in the direction of 
potential benefit, this analysis was based on a fixed effect model which can result in substantially 
different results compared with a random effect model when there are big imbalances in sample 
sizes in the studies being pooled. In fact, in this analysis, average absolute quit rates were 
slightly lower for the intervention (12.8%) vs. control (12.9%) groups. Five studies evaluated an 
internet intervention plus behavioral therapy compared with a nonactive control and indicated a 
collective positive effect on the intervention (RR 1.69 [95% CI, 1.30 to 2.18]; k=5; n=2334), 
although again, the statistical heterogeneity was quite high (I2=60%).129  
 
Evidence of Effect Modification  
 
Given the heterogeneity in the included interventions and comparators, the review analyzed 
studies within distinct groups (interactive and tailored internet-based interventions, interactive 
but not tailored internet-based interventions, and neither interactive nor tailored internet-based 
interventions).129 When compared with a nonactive control group, in all cases, statistical 
heterogeneity was high and unexplained; although the review performed no further analyses to 
explain this heterogeneity (likely due to largely null effects). In direct comparisons, none of the 
studies comparing an Internet intervention or Internet intervention plus behavioral support with 
an active control detected statistically significant evidence for differences between the 
conditions. Seven studies compared an interactive and/or tailored internet program or website 
with an internet intervention that was neither tailored nor interactive. Pooled results favored the 
intervention group; however, they were not statistically significant (RR 1.10 [95% CI, 0.99 to 
1.22]; I2=0%; k=7; n=14,623).129 
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Incentives 
 
Primary Results  
 
We included one high-credibility review by Notley (2019) that examined whether incentives and 
contingency management programs led to higher long-term quit rates among smokers.116 Thirty-
three studies among adults met inclusion criteria, including over 21,600 participants. Nearly 
three-quarters of the trials (22/33) took place in the United States. The incentives included cash 
rewards or monetary incentives in the form of vouchers, prize drawings alongside a guaranteed 
reward, the recovery of money deposited by those taking part, or a combination of incentive 
types. Seven studies included complex payment schedules that specifically rewarded continuous 
abstinence. The total financial amount of incentives (where reported) varied considerably 
between trials, from zero (self-deposits) to a range between $45 and $1,185. All but one study 
included additional cessation support such as brief advice, pharmacotherapy, and in one case –  
e-cigarettes. Most of the studies took place in worksites or substance misuse clinics; six studies 
delivered support in a health clinic including mental health clinics, head and neck cancer clinics, 
or primary care clinics. The pooled RR for quitting with incentives at longest followup (6 months 
or more) compared with usual care or a non-incentive-based intervention was 1.49 ([95% CI, 
1.28 to 1.73]; I2=33%; k=30; n=20,097) (Table 5).116  
 
Evidence of Effect Modification  
 
There was no significant difference between studies that offered incentives up until the point of 
measuring abstinence (i.e., at 6 months) versus those where the longest followup occurred after 
the incentive schedule had ended.116 In the subgroup of studies in which followup was beyond 
the provision of incentives a statistically significant benefit was found, suggesting that the impact 
of incentives continues for a least some time after incentives are no longer provided. The results 
of an exploratory meta-regression suggested that there was no clear direction of effect between 
trials offering low or high total value of incentives. Two studies conducted a head-to-head 
comparison between a rewards-based and deposit-refund-based approach and found both to be 
effective with no significant differences or negligible differences between groups.116  
 
Biomedical Risk Assessment 
 
Primary Results  
 
We identified one moderate-credibility review, Clair (2019), that evaluated the efficacy of 
biomedical risk assessment (with or without other behavioral counseling) to aid in smoking 
cessation.88 Biomedical risk assessment interventions included a physical measurement to 
increase motivation to quit smoking, such as exhaled carbon monoxide (CO), spirometry, 
atherosclerotic plaque imaging, and genetic testing. The review identified 20 studies, 5 of which 
are new to this update, that met inclusion criteria. These trials represented over 9000 participants, 
with studies ranging from 64 to 2110 participants per study. In most studies, the biomedical 
testing component was added to intensive quit-smoking sessions (which both the intervention 
and control groups received), with counseling lasting up to 60 minutes and complemented by 
written material and reinforcement sessions or followup phone calls.88  
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Five studies tested feedback on smoking exposure, each measuring the effect of exhaled CO 
measurements; there was no evidence of a statistically significant benefit from these studies in 
pooled analysis (RR 1.00 [95% CI, 0.83 to 1.21]; I2=0%; k=5; n=2368) (Table 5).88 Likewise, 
there was no evidence of a significant benefit of interventions providing feedback on 
participants’ genetic susceptibility to smoking-related cancer or Crohn’s disease (RR 0.80 [95% 
CI 0.63 to 1.10]; I2=0%; k=5; n=2064). Eleven studies provided feedback on smoking-related 
harm: four tested the combination of exhaled CO measurement and spirometry, five tested the 
effect of spirometry alone or with the addition of feedback on lung age; and two tested the effect 
of undergoing an ultrasonography of carotid arteries and/or femoral arteries with photographic 
demonstration of atherosclerotic plaques when present. A pooled analysis of all 11 studies 
resulted in an unclear effect on smoking cessation (RR 1.26 [95% CI, 0.99 to 1.61]; I2=34%; 
k=11; n=3314).88  
 
Evidence of Effect Modification  
 
There was no evidence that the effectiveness of these interventions differed according to the type 







We included one high-credibility review by Ussher (2019)  that evaluated the effect of exercise 
on smoking cessation (n=7,279).135 The review included RCTs that compared an exercise 
program alone, or an exercise program as an adjunct to another smoker cessation program, with a 
cessation program alone or another non-exercise control group among adult smokers who were 
motivated to quit. Trials among adolescents as well as persons with psychological health 
conditions were excluded. The review included 24 trials that met inclusion criteria; six new 
studies were identified since the last review on this subject. Most of the trials used supervised, 
group-based aerobic exercise intervention supplemented by home-based exercise. In most cases, 
the exercise intervention started before the stated quit date. Twenty-two studies included 
smoking cessation support as the comparator, and two studies had relapse prevention support as 
the comparator, with all but one study offering this support for both exercise and control groups. 
The sample size in these trials was smaller than that seen in other smoking cessation trials, 
ranging from 20 to 2318, with more than half of the studies enrolling fewer than 100 
participants.135  
 
In pooled analyses, there was no statistically significant difference between smoking cessation 
interventions that included exercise versus those that did not (RR 1.08 [95% CI, 0.96 to 1.22]; 
I2=0%; k=21; n=6607) at 6 or more months’ followup (Table 5).135  
 
Evidence of Effect Modification  
 
There was no evidence in the review that the effects differed according to whether the exercise 
included aerobic exercise, resistance training combined modalities, or unknown types of physical 
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activity.135 None of the effects were statistically significant among these subgroups by exercise 
type, and the confidence intervals of pooled analyses and individual effects all overlapped. 
Excluding studies among special populations such as those with mental health issues, or pregnant 
populations did not affect the interpretation of the results.135  
 
Complementary and Alternative Therapies 
 
Primary Results  
 
We included two reviews that examined the effectiveness of complementary and alternative 
therapies on smoking cessation, one on acupuncture and acupressure137 and one on 
hypnotherapy.82 The high-credibility review on acupuncture, by White (2014), included 38 RCTs 
that compared the effects of acupuncture (23 studies), acupressure (5 studies), laser therapy (3 
studies), and electrostimulation (7 studies) versus no or sham intervention for smoking cessation 
at short-term (6 weeks or less) and long-term (6–12 months) followup.137 This review reported a 
positive effect for acupuncture compared with sham acupuncture on short-term cessation (RR 
1.22 [95% CI, 1.08 to 1.38]; I2=46%; k=16; n=2,588) but failed to find a pooled effect on longer 
term outcomes (RR 1.10 [95% CI, 0.86 to 1.40]; I2=23%; k=9; n=1,892) (Table 5). Similarly, 
there was no evidence of a benefit of acupressure, continuous auricular stimulation, or 
electrostimulation versus sham interventions on long-term cessation.137  
 
The high-credibility review on hypnotherapy, by Barnes (2019), included 14 trials.82 Given the 
clinical heterogeneity of intervention and control conditions in the body of evidence, this review 
grouped the studies into comparisons according to the control conditions (i.e., no intervention, 
attention-matched behavioral interventions, brief behavioral interventions, intensive behavioral 
interventions, rapid/focused smoking, drug, and placebo). The studies varied greatly in the 
method of hypnotic induction and the number and duration of hypnotherapy sessions. In general, 
this review found no evidence of a difference in smoking cessation at 6 months’ or greater 
followup among trials that compared hypnotherapy versus no intervention or other smoking 
cessation interventions (Table 5). In the group with the most trials, there was no overall 
difference in smoking cessation rates between groups at 6 months or greater followup between 
hypnotherapy versus attention-matched smoking cessation behavioral intervention (RR 1.21 




Primary Results  
 
We included two reviews that addressed the effectiveness of system-level interventions to 
support smoking cessation.84, 130 The reviews contained mutually exclusive bodies of evidence 
given differences in scope. The first high-credibility review, by Boyle (2014), focused on the 
effectiveness of electronic health record (EHR)-facilitated interventions on smoking cessation 
support actions by clinicians, clinics, and health care delivery systems.84 The most common 
enhancement of the EHR was connecting smoking patients with a telephone-based quitline. 
While the review included 16 studies (6 group RCTs, 1 individual RCT, and 9 nonrandomized 
observational studies), none of the studies included a direct assessment of patient quit rates 
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(Table 5). One group RCT (n=9589) reported a comparison of quit rates between intervention 
and control clinics that were measured indirectly based on EHR documentation of smoking 
status. In that study, significantly more smokers in the intervention clinics were subsequently 
documented as nonsmokers compared with smokers in the control clinics 6 months after changes 
were implemented (5.3% vs. 1.9%, p<0.001). The remaining studies focused on the impact of 
EHR changes on smoking support actions by clinicians, clinics, and health systems and 
specifically focused on the 5 A’s (Ask, Advise, Assess, Assist, Arrange). In general, most studies 
found an increase in the documentation of tobacco use and quit assistance following the 
introduction of an electronic reminder.84  
 
The other high-credibility review, by Thomas (2017), was more broadly scoped and focused on 
the effectiveness of practice and policy changes within organizations to integrate the 
identification of smokers and the subsequent offering of evidence-based nicotine dependence 
treatments into usual care, beyond just changes to the EHR.130 The review included seven group 
RCTs, of which all but one was conducted in the United States. The settings included primary 
care clinics (2 trials), dental clinics (2 trials), a community pharmacy (1 trial), VA medical center 
(1 trial), and a pediatric practice focused on parents (1 trial). Interventions were characterized 
based on the provision of six system change components: 1) identification/documentation of 
smoking status, 2) smoking cessation training/resources/feedback for providers, 3) dedicated 
staff to support cessation activities, 4) policies to improve access to cessation interventions, 5) 
free smoking cessation treatment from the organization, and 6) reimbursement of clinics for 
providing smoking cessation support. None of studies incorporated all six system change 
strategies. The identification of all smokers and training staff and provision of evidence-based 
treatment were components of all seven included studies. All included studies used the services 
of existing staff to provide the intervention. Four studies (n=7142) reported the effects of the 
intervention on smoking cessation. Of these, two studies found that the quit rate was higher in 
the intervention group than in the control group at 6 and 12 months’ followup whereas the other 
two showed no difference between groups. There was some evidence for the effectiveness of the 
interventions on secondary outcomes such as documentation of smoking status and provision of 
cessation counseling, but each outcome was not consistently reported and several showed mixed 




Most standard smoking cessation interventions, including most of the interventions synthesized 
above, encourage quitting smoking abruptly on a designated quit day. One recent high-credibility 
review by Lindson (2019c) assessed the effect of reduction-to-quit interventions versus no 
cessation intervention or abrupt quitting on long-term (6 months or more) cessation.105 Trials that 
included at least one arm where smokers were advised to reduce their smoking consumption 
before quitting smoking altogether were included. This advice could be delivered through self-
help materials or behavioral support or alongside smoking cessation medications. Fifty-one trials 
(n=22,509) were identified. Compared with no smoking cessation intervention, there was no 
evidence that reducing smoking consumption before quitting was more effective for abstinence 
at 6 months or greater (RR 1.74 [95% CI, 0.90 to 3.38]; I2=45%; k=6; n=1599) and no evidence 
that reducing consumption was superior (or inferior) to abrupt quitting (RR 1.01 [95% CI, 0.87 
to 1.17]; I2=29%; k=22; n=9219) (Table 5).105    
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Interventions for Relapse Prevention 
 
A separate moderate-credibility review by Livingstone-Banks (2019a) focused on relapse 
prevention interventions for tobacco cessation.108 While there is no clear definition of a relapse 
prevention intervention, in general, relapse prevention is considered to apply to interventions that 
explicitly seek to reduce relapse rates after an acute treatment phase is successfully completed, or 
at some time after the quit date. The duration of the acute treatment phase varies, leading to 
variability in the post at which measurement of a relapse prevention effect begins. Studies of 
interventions for relapse prevention may randomly assign people who have already quit, or they 
may randomly assign smokers before their quit attempt and provide a general smoking cessation 
intervention to all participants, in addition to an extra component provided for those randomly 
assigned to relapse prevention.108  
 
The 77 studies included in the review were highly variable and included both pharmacologic and 
behavioral interventions to help prevent relapse.108 They (a) focused on people who had already 
quit or (b) helped people to quit, then tested treatments to prevent relapse. Several studies 
centered on special populations that needed to stop smoking for a limited period of time because 
they were pregnant (18 studies), in a hospital (5 studies, or serving in the military (3 studies). 
Analyses of behavioral interventions among abstainers did not detect an effect in both studies of 
assisted abstainers (RR 0.99 [95% CI, 0.87 to 1.13]; I2=56%; k=10; n=5408) and unaided 
abstainers (RR 1.06 [95% CI, 0.96 to 1.16]; I2=1%; k=5; n=3561) from the general population. 
Twelve included studies focused on pharmacologic interventions for existing abstainers (either 
unaided or following cessation pharmacotherapy, 11 studies) or for those that were randomly 
assigned extended treatment (1 study). There was some evidence that extending varenicline 
could be beneficial in preventing relapse, but it was only reported by two studies. NRT was 
found to help in unassisted abstainers, but no difference was seen among those who achieved 
abstinence with NRT. None of the six studies that examined the use of bupropion to prevent 
relapse found a statistically significant effect.108 
 
Ancillary and Population Subgroup Effects 
 
Two reviews specifically explored the differences in the effectiveness of pharmacotherapy 
according to sex112, 124 and were discussed within the sections on pharmacotherapy results. 
Nineteen additional reviews synthesized the evidence on the benefits of pharmacotherapy or 
behavioral interventions among specific subpopulations of adults (Table 2). These included: 
eight reviews limited to persons with severe mental illness;80, 100, 101, 118, 120, 133, 136, 142 two limited 
to those with or in treatment for alcohol or drug dependence;81, 132 five focused on adapted 
interventions for ethnic minorities86, 99, 107 or otherwise disadvantaged persons;83, 139 two limited 
to smokeless tobacco users;92, 123 one among individuals categorized as not motivated to quit,141 
and one that explored the effectiveness of pharmacotherapy by subgroups defined by genetically 
informed biomarkers.122 Within these 19 reviews, most included trials were limited to these 
subpopulations and very few included trials (or reviews) addressed the relative effectiveness 
according to subgroup (e.g., the relative effects among those with or without depression). Results 
of these reviews were consistent with the broader evidence among general adult populations 
(reviews in which many of these subpopulation studies were included) and suggested 
effectiveness of both pharmacotherapy and behavioral interventions, alone and combined, to quit 
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smoking. Where pooled results were presented, the direction and magnitude of effects was 
almost identical to that seen with the broader evidence base, although the number of studies 




We identified five fair-quality RCTs (reported in 10 publications) that evaluated the 
effectiveness of using e-cigarettes to help current conventional smokers stop or reduce smoking 
compared with placebo or nicotine replacement therapy (Table 6).143-145, 151-157 The five trials all 
took place outside of the United States with one in the United Kingdom, one in Italy, one in 
Korea, and two in New Zealand. The mean age of enrolled smokers was 41 to 44 years in all five 
trials. Three trials enrolled mostly females (~60-70%) whereas one enrolled only males, and the 
other enrolled mostly males (36.7% female). Smokers within all five trials were heavy smokers 
with the median cigarettes smoked per day ranging from 15 to 20 and most had tried to quit in 
the past year. Further demographic details of the enrolled samples were sparsely reported 
(Appendix F Table 1). The types of e-cigarettes, nicotine content, delivery of the intervention, 
and additional intervention components differed across all five trials as did the comparisons 
(Appendix F Table 2). One trial compared 1) NRT patch plus a nicotine e-cig (18 mg/mL), 2) 
NRT patch plus a nicotine-free e-cig (0 mg/mL), and 3) NRT patch only. Another trial compared 
1) nicotine e-cig (18 mg/mL) to 2) any form of NRT. Another trial compared 1) nicotine e-cig 
(16 mg/mL), 2) nicotine patch (21 mg), and 3) nicotine-free e-cig. A small Korean trial in males 
compared nicotine e-cigarettes (0.01 mg/mL) with nicotine gum (2mg/tablet). And, the final trial 
compared 1) nicotine e-cig (7.2 mg/mL) for 12 weeks, 2) nicotine e-cig (7.2 mg/mL for 6 weeks 
followed by 5.4 mg for 6 weeks), or 3) nicotine-free e-cigs. Whereas one trial allowed 
participants to use any brand of e-cigarette with any concentration of nicotine after a 4-week run-
in period with a starter kit, four trials provided participants with e-cigarette cartridges for the 
whole study period. Of the five e-cigarettes evaluated for cessation, only the eVOD device 
(Walker trial), OneKit Aspire (TEC trial), and eGo-C (Lee trial) are currently available in US 
markets; the Elusion e-cigarette model used in the ASCEND trial has been discontinued and the 
Categoria e-cigarette (ECLAT trial) is not sold in US markets.  
 
The largest trial, conducted in New Zealand, randomized participants to a 12-week treatment 
phase of 1) a nicotine patch plus a nicotine e-cig (n=500); 2) a nicotine patch plus a nicotine-free 
e-cig (n=499), or 3) a nicotine patch only (n=125).155 All three groups also received behavioral 
counseling, although compliance data indicated that the patch plus nicotine e-cig group received 
more calls than the patch-only group. After 6 months following the agreed-upon quit date, 
verified continuous abstinence was statistically significantly higher in the patches plus nicotine 
e-cig group (7%) versus the patch plus nicotine-free e-cig group (4%) (RR 1.75 [95% CI, 1.02 to 
2.98; p=0.038) but not the patch-only group (2%) (RR 2.92 [95% CI, 0.91 to 9.33]; p=0.05) 
(Table 7). Complete case and per-protocol analyses produced similar results with differences 
found between the two e-cig groups but not the nicotine-containing e-cig versus patch only 
groups. Absolute rates of self-reported quitting at 6 months were considerably higher than 
verified abstinence in all three groups (patch plus nicotine e-cigs: 18%, patch plus nicotine-free 
e-cigs: 11%, and patches only: 8%) with statistically significant differences found when 
comparing the nicotine-containing e-cigs to the other two groups, respectively.155  
 
 
Tobacco Cessation in Adults 43 Kaiser Permanente EPC 
Median time to relapse (defined as smoking at least 5 cigarettes in the past 7 days) did not differ 
significantly between the patch plus nicotine e-cig group (193 days) versus the patch plus 
nicotine-free e-cig group (153 days) (hazards ratio [HR] 0.85 [95% CI, 0.70 to 1.03]; p=0.01) or 
patch only group (160 day (HR 0.90 [95% CI, 0.63 to 1.28; p=0.56).155 Thirty-nine percent of the 
participants in the patch plus nicotine e-cig group relapsed within 6 months versus 43 percent of 
participants in the patch plus nicotine-free e-cig group and 31 percent of participants in the patch 
only group. Furthermore, in those still smoking at 6 months, there was no significant difference 
in change from baseline in the average number of cigarettes smoked per day or the proportion 
who reduced the number of cigarettes smoked per day by at least 50 percent.155  
 
The results of this trial should be interpreted in light of some considerable limitations including 
high and differential loss to followup: at 6 months, only 50 percent of participants in the patch-
only group were retained as opposed to 68 percent in both the nicotine and nicotine-free e-cig 
groups.155 The majority of participants in the patch group who withdrew did so immediately 
post-randomization citing not wanting to be in that group. Furthermore, of those retained in the 
patch-only group, 15 percent crossed over and used an e-cigarette during the trial, with most 
crossing over within the first 6 weeks. Similarly, 11 percent of those randomized to the nicotine-
free e-cig group crossed over to using nicotine-containing e-cigarettes. Detection bias was also 
likely with 70 percent of the nicotine e-cig group correctly identifying the presence of nicotine in 
their e-liquid. At 6 months, 22 to 40 percent of participants in all three groups were still using the 
patch whereas 49 to 56 percent of participants were still using an e-cig only or both a patch and 
e-cig.155 
 
In another large trial (the TEC trial) in the United Kingdom, Hajek and colleagues randomized 
886 smokers participating in National Health Services stop-smoking services to tobacco flavored 
e-cigarettes with 18 mg nicotine/ml (intervention group) or any form of NRT (comparison 
group).154, 156 Both groups received 4 weeks of behavioral counseling. The primary outcome was 
abstinence at 1 year, defined as self-report of not more than five cigarettes from the target quit 
date, validated by expired CO<8 parts per million (ppm). At 1 year, 18 percent in the e-cigarette 
group were abstinent from smoking, compared with 9.9 percent in the comparison group (RR 
1.83 [95 % CI, 1.30 to 2.58]) (Table 7). However, 80 percent of abstinent subjects assigned to 
the intervention group were still using e-cigarettes, compared with 9 percent in the comparison 
group continuing to use nicotine replacement therapy at 1 year. Overall loss to followup was 21 
percent (19% in the e-cigarette group and 23% in the NRT group).154 
 
In the ASCEND trial, Bullen and colleagues randomized 657 smokers in New Zealand who 
wanted to stop smoking to one of three interventions: 16 mg nicotine e-cigarette (n=285), 21 mg 
nicotine patch (n=295), or placebo e-cigarette (n=73).144 Those randomized to one of the e-
cigarette arms were directly mailed the e-cigarette, a spare battery and charger, cartridges, and 
simple instructions on how to use the e-cigarette, whereas those randomized to receive a patch 
were mailed cards and vouchers to redeem a patch from community pharmacies. All participants 
were also offered telephone-based support via a quitline that called them directly; participants 
who declined or did not call back were still able to access other quitline support such as text 
messages. The primary outcome, abstinence at 6 months, was verified by exhaled CO<10ppm. 
Tobacco smoking cessation was generally low in all three groups: 7.3 percent with e-cigarettes, 
5.8 percent with nicotine patches (RR for nicotine e-cigarettes vs. patches 1.26 [95% CI, 0.68 to 
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2.34]), and 4.1 percent with placebo e-cigarettes (RR for nicotine e-cigarettes vs. placebo 1.77 
[95% CI, 0.54 to 5.77]) (Table 7). Thirty-eight percent of those who were abstinent and assigned 
to e-cigarettes still used e-cigarettes at 6 months, although it was unknown whether they were 
using nicotine or non-nicotine cartridges. There was differential loss-to-followup between groups 
at 6 months: 27 percent of those assigned to the patch versus 17 percent and 22 percent of those 
randomized to the nicotine and placebo e-cigarette groups, respectively.144  
 
In a secondary analysis of cessation data from the ASCEND trial, O’Brien and colleagues 
examined the effectiveness of e-cigarettes among patients with (n=86) and without (n=571) a 
mental illness (defined as taking prescription medication for a diagnosed mental illness) at the 
time of randomization.151 At the 6-month followup among participants randomized to e-
cigarettes, there were no significant differences in smoking cessation between people with (5%, 
n=2/39) and without mental illness (n=7%, 19/250) (p=0.75). Among those with a mental illness 
(n=86), there were no significant differences in quit rates among those randomized to e-cigarettes 
(5%, 2/39) had biochemically verified smoking abstinence) as compared with those who used 
nicotine patches (14%, 5/35) (p=0.245). Among participants with mental illness randomized to 
placebo e-cigarettes, none had achieved cessation at 6 months (Table 7).151  
 
Caponnetto and colleagues conducted an RCT in Italy, the ECLAT trial, in which 300 
conventional smokers who were not intending to quit were randomized to receive one of three e-
cigarette nicotine cartridge doses for the Categoria brand model 401 e-cigarette: 7.2 mg nicotine 
for 12 weeks; 7.2 mg nicotine for 6 weeks followed by 5.4 mg nicotine for 6 weeks; or cartridges 
with no nicotine.145 The appearance of the cartridges was identical to maximize blinding, 
although it is unclear whether allocation was concealed. After the 12-week intervention phase, 
participants were free to purchase e-cigarettes on their own. At 1 year, abstinence rates (verified 
by <7.5 ppm exhaled CO) were 11 percent for participants in the combined nicotine groups 
compared with 4 percent in the group receiving no-nicotine cartridges (p=0.04) (Table 7). At the 
1-year assessment, 26.9 percent of all study participants were still using e-cigarettes. There was 
substantial loss to followup in the study: no followup data was available for 36 percent of those 
randomized to one of the nicotine-containing cartridges and 45 percent of those receiving no-
nicotine cartridges.145 
 
Lee and colleagues conducted a small RCT in male workers from a Korean motor company, 
randomizing 150 participants to receive a 12 week supply of either e-cigarettes or nicotine 
gum.157 Eligible participants smoked at least 10 cigarettes per day for the past year, had smoked 
for at least three years, and were motivated to stop or reduce their cigarette smoking. All 
participants received a fifty-minute education session on smoking cessation and use of smoking-
cessation aids and they were instructed to visit the medical office every four weeks for 
evaluation and counseling from an independent health practitioner. Continued abstinence was 
verified using self-report questionnaires and both end-expiratory carbon monoxide (<10 ppm) 
and urine cotinine (negative result). Biochemically validated continued abstinence rates from 
weeks 9 to 24 did not differ significantly between the groups (21.3% vs. 28% (p=0.344) in the e-
cigarette group and nicotine group respectively) (Table 7). The seven-day point prevalence 
abstinence at 24-weeks was similar, with 22.7 percent in the e-cigarette group and 29.3 percent 
in the nicotine gum group reporting no smoking (p=0.352).157 
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Key Question 3. What Harms Are Associated With Tobacco 
Cessation Interventions in Adults? 
 
Combined Pharmacotherapy and Behavioral Interventions 
 
None of the included reviews synthesized the evidence on harms related to combined 
pharmacotherapy and behavioral support versus no or minimal interventions. Any harms of 




We included nine primary reviews85, 87, 96, 98, 104, 113, 114, 128, 131 that reported AEs related to 
pharmacotherapy interventions for smoking cessation in general adult populations. In addition, 
six reviews80, 101, 118, 120, 133, 142 addressed the harms of pharmacotherapy among persons with 
severe mental illness.  
 
Nicotine Replacement Therapy 
 
Harms related to NRT use were reported in four reviews among the general adult population96, 
104, 113, 114 and one review among persons with severe mental illness.120 All five of these reviews 
were rated as moderate or high credibility. AEs from the use of NRT are typically related to the 
type of product and include skin irritation from patches and irritation to the inside of the mouth 
from gum and lozenges.96, 104, 114 Pooled results from multiple reviews indicate a higher risk of 
heart palpitations and chest pains, or any CV event (any clinical diagnoses of a CV event 
including minor events such as palpitations, bradycardia, and arrhythmia) from NRT versus non-
NRT control groups (Table 8).96, 113, 114 For instance, among non-high-risk adults, one review 
found an approximate 80 percent increase risk of any CV event among those randomized to NRT 
compared with placebo (RR 1.81 [95% CI, 1.35 to 2.43]; I2=0%; k=21; 11,647).113 A sensitivity 
analysis found that these treatment effects were driven predominantly by more minor CV events, 
however, including bradycardia and arrhythmia, and occurred primarily in studies with longer 
followup periods. When restricted to major adverse CV events (defined by the FDA as a 
combined outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke), 
pooled results did not clearly establish harm (RR 1.38 [95% CI, 0.58 to 3.26]; I2=0%), but the 
confidence interval was quite wide and incorporated potential benefit as well as significant harm 
and the overall number of SAEs was very low.113 Pooled results also found an increased risk of 
NRT versus non-NRT control for nausea and vomiting (although patch users had a decreased 
risk), gastrointestinal complaints, and insomnia.114 There was no statistically significant 
increased risk of headache, dizziness, anxiety or depression, or mortality.114 Eight studies 
reported on mortality and did not find a significant association between NRT and controls (OR 
0.74 [95% CI, 0.33 to 1.67]; I2=0%; k=8; n=2765).96 
 
There was no evidence of an effect on cardiac AEs, SAEs, or withdrawals when looking at 
different forms, deliveries, doses, durations, and schedules of NRT (Table 8).104 Furthermore, 
there was no evidence of a difference in harms, including a worsening of psychiatric symptoms, 
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Harms related to bupropion use were reported in two moderate-to-high credibility reviews 
among unselected adults98, 113 and one moderate credibility review among persons with severe 
mental illness.120 The Howes review (2020) examined SAEs reported in 21 trials of bupropion 
versus placebo or no pharmacotherapy control, including trials that were excluded from their 
efficacy analysis because of short followup (i.e., less than 6 months).98 SAEs were defined per 
the FDA as any event that was life-threatening, resulted in hospitalization, death, disability, or 
permanent damage, or required intervention to prevent one of the above outcomes reported 
during or within 30 days of drug treatment. Meta-analysis of 21 trials did not provide clear 
evidence that the use of bupropion increased the risk of SAEs control (RR 1.16 [95% CI, 0.90 to 
1.48], I2=0%; k=21; n=10,625), with very low SAE rates of 2.3 percent for bupropion users and 
2.4 percent for placebo users or non-bupropion participants (Table 8).98  
 
A separate older review (Mills 2014) suggested no significant increased risk of any CV event for 
bupropion versus placebo (RR 1.03 [95% CI, 0.71 to 1.50], I2=0%; k=27; n=10,402) (Table 
8).113 The confidence interval of the pooled estimate was wide and consistent with a mildly 
beneficial or mildly harmful effect. While the results for major CV events were imprecise due to 
small numbers of events, they were consistent with a possible protective effect or very minor 
harms (RR 0.57 [95% CI, 0.31 to 1.04]; I2=0%; k=27; n=10,402) (Table 8). When restricted to 
the eight trials of high-risk patients, the results were in the same direction as non-high-risk adults 
but were not statistically significant. In the recent EAGLES trial, there was no significant 
difference in the incidence of cardiovascular events during treatment between those on 
bupropion versus placebo, nor a significant difference in time to onset of major cardiovascular 
AEs (hazard ratio [HR] 0.50 [95% CI, 0.10 to 2.50]).164  
 
In the review by Howes there was evidence to suggest that participants randomized to bupropion 
were more likely to report psychiatric AEs compared with those randomized to placebo.98 A 
pooled analysis of six placebo-controlled trials found a 25 percent increased risk of any 
neuropsychiatric AEs among those taking bupropion (RR 1.25 [1.15 to 1.36]; k=6; n=4439).98 In 
the Howes review, all neuropsychiatric events and symptoms were included regardless of 
severity.98 Conversely, when limited to moderate or severe neuropsychiatric events, the 
EAGLES trial found was no evidence of a significant increase in neuropsychiatric AEs 
attributable to bupropion relative to nicotine patch or placebo.161, 165 The primary endpoint in this 
trial was a composite measure based on post marketing reports of neuropsychiatric AEs in 
smokers taking bupropion and varenicline and included 16 neuropsychiatric symptom categories. 
The overall incidence of neuropsychiatric AEs was similar across the bupropion (4.5%, 90 of 
2006 participants), nicotine patch (3.9%, 78 of 2022 participants), and placebo (3.7%, 74 of 2014 
participants) groups. For both the nonpsychiatric and psychiatric cohort, there was no significant 
difference in neuropsychiatric AEs in those assigned to bupropion versus placebo (risk difference 
[RD] -0.08 [95% CI, -1.37 to 1.21], n=1988 and RD 1.78 [95% CI, -0.24 to 3.81], n=2032), 
respectively. Likewise, there was no difference between the bupropion and placebo groups in 
rates of suicidal behavior and ideation.161, 165  
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A separate moderate-credibility review by Roberts (2016) synthesized the direct and indirect 
evidence on pharmacologic tobacco cessation treatment among adult smokers with any form of 
severe mental illness, defined as any nonorganic disorder with psychotic features that results in a 
substantial disability including schizophrenia, schizoaffective disorder, bipolar disorder, 
delusional disorder or depressive psychoses.120 Harms were measured using a tolerability 
outcome which equaled the number of patients discontinuing the trial due to any adverse event. 
Across six trials that compared bupropion with placebo, three trials reported that no participants 
in either group discontinued the trials because of AEs. In the remaining three trials, two found 
greater rates of dropout among those in the placebo group versus bupropion group, whereas the 
remaining found five versus two dropouts due to AEs among the bupropion versus placebo 
groups, respectively. Pooling all six trials showed no statistically significant difference between 




Harms related to varenicline use were reported in three reviews among unselected smokers, 85, 
128, 131 four reviews among persons with severe mental illness,80, 101, 120, 142 and one review limited 
to smokeless tobacco users.123 The most commonly reported adverse effect of varenicline was 
nausea, which was mostly at mild to moderate levels and usually subsided over time. Other 
common side effects of varenicline versus placebo with a statistically significant increase were 
insomnia, abnormal dreams, headache, and fatigue.85, 131 A meta-analysis of SAEs occurring 
during or after active treatment suggested there may be a 25 percent increase in the chance of 
SAEs among people using varenicline compared with placebo (RR 1.25 [95% CI, 1.04 to 1.49]; 
k=29; 15,370) (Table 8); however, many of these events included comorbidities that were 
mostly considered by the trialists to be unrelated to the treatments. Across all reviews, very few 
deaths were reported in the included trials and no review found a difference in all-cause 
mortality between varenicline and placebo.128, 131 
 
Pooled analyses representing over 12,000 participants do not indicate a statistically significant 
increased risk of cardiovascular events (Table 8).85, 113, 128 For instance, within the Mills (2014) 
review, among 18 trials comparing varenicline with placebo, there was no evidence of an 
increased risk of cardiovascular AEs (RR 1.24 [95% CI, 0.85 to 1.81]; I2=0%; k=18; n=9072) of 
major cardiovascular AEs among adults (RR 1.44 [95% CI, 0.73 to 2.83]; I2=0%; k=18; 
n=9072).113 Similarly, in a more recent low-credibility review, when pooling data across 38 
studies, the review by Sterling (2016) found no significant difference for cardiovascular SAEs 
when comparing varenicline (57 events within 7213 participants) with placebo (43 events within 
5493 participants) (RR 1.03 [95% CI, 0.72 to 1.49]).128 Furthermore, similar results were found 
among patients with and without a history of cardiovascular disease.128  
 
There was also no evidence of a statistically significantly higher risk of neuropsychiatric AEs for 
those on varenicline versus placebo (Table 8).85, 131 In the most recent review by Cahill (2016), 
23 trials representing nearly 9000 smokers found no difference in the number of people 
experiencing a neuropsychiatric event between those randomized to varenicline versus placebo 
(RR 0.82 [95% CI, 0.57 to 1.19]).85 Likewise, in the review by Thomas (2015), there was no 
evidence of an increased risk of suicide or attempted suicide (Peto OR 1.67 [95% CI 0.33 to 
8.57]), suicidal ideation (Peto OR 0.58 [95% CI, 0.28 to 1.20]), or depression (Peto OR 0.96 
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[95% CI, 0.75 to 1.22]) associated with varenicline.131 There was no evidence that the risk of 
depression and suicidal ideation differed by age, sex, ethnicity, smoking status, the presence or 
absence of psychiatric illness, or study sponsorship. The effect estimates (Peto OR) for the trials 
in which all participants had psychiatric illnesses compared with those where none of the 
participants had psychiatric illness were 0.79 (95% CI, 0.32 to 1.93) versus 0.34 (95% CI, 0.09 
to 1.29) for suicidal ideation and 1.49 (95% CI, 0.84 to 2.65) versus 0.91 (95% CI, 0.69 to 1.21) 
for depression.131 Four other reviews similarly found no differences in neuropsychiatric AEs or 
discontinuation due to AEs between smokers with severe mental illness taking or not taking 
varenicline (Table 8).80, 101, 120, 142 Finally, no differences in the rates of nausea, sleep 
disturbances, or mood disorders were seen within three trials testing the effectiveness of 




There was insufficient evidence to indicate whether other antidepressants such as nortriptyline, 
SSRIs, or MAOIs increased the risk of AEs relative to placebo given too few trials for each 
comparison.98 
 
In general, four trials of cytisine that all reported on harms did not identify more AEs or SAEs in 
the intervention versus control arm, but this data is limited by the few numbers of trials and lack 




Only three of the reviews on behavioral interventions included any discussion of potential harms 
from behavioral-based tobacco cessation interventions, including the review on internet-based 
interventions,129 the review on incentives,116 and the review on hypnotherapy.82 There was no 
clear harm related to any of these interventions. In the review on internet-based interventions, 
few trials reported AEs (6 of 67 included trials) and in those that did, AEs were rare and minor 
(i.e., weight gain, perceived stress, sleep disorder, fatigue).129 In the review on incentives for 
smoking cessation, one trial found no evidence of worsened psychiatric symptoms among 
smokers with serious mental illness. None of the other included studies reported on any harms, 
unintended consequences or AEs associated with the offering incentives.116, 166 The Barnes 
review looked for reported AEs among participants taking part in hypnotherapy interventions 




The review by Lindson (2019c) reported no clear evidence that the number of people reporting 
SAEs, or changes in withdrawal symptoms, differed between those advised to reduce their 
smoking versus those receiving no advice or advice for abrupt quitting; although pre-quit AEs, 
SAEs, and withdrawal symptoms were measured and reported variably and infrequently across 
studies.105  
 
Tobacco Cessation in Adults 49 Kaiser Permanente EPC 
E-Cigarettes 
 
The five RCTs that evaluated the effectiveness of e-cigarettes to aid in efforts to quit smoking 
conventional cigarettes at 6 months or longer,144, 145, 154, 155, 157 as well as four RCTs of e-
cigarettes with shorter followup periods,146-148, 150 were included in the evaluation of e-cigarettes’ 
harms. No cohort studies met criteria for inclusion. Characteristics of studies included for harms 
are described in Table 6 and Appendix F Tables 1 and 2.  
 
None of the studies reported statistically significant differences in SAEs between intervention 
and control groups (Table 9).144-148, 150, 154, 155, 157 Four of the five trials that evaluated e-cigarette  
effectiveness reported nonsignificant distributions of AEs between the intervention and control 
groups at ≥6 months of followup (Table 9).144, 145, 154, 155  The ASCEND trial, conducted by 
Bullen and colleagues, found no statistically significant difference in the incidence rate ratio 
(IRR) for AEs between these groups at 6 months’ followup (IRR 1.05 [95% CI, 0.82 to 1.34], 
p=0.7), despite a higher number and proportion of SAEs occurring in the nicotine e-cigarette 
group (27 serious events, 19.7%) than in the nicotine patch group (14 events, 11.8%).144 The 
authors deemed none of the AEs to be related to product use in any of the treatment groups.144 
Similarly, the ECLAT study by Caponnetto and colleagues found no difference in the frequency 
of AEs among study groups at 12 and 52 weeks.145 No serious events occurred during the 
study.145 In the TEC trial, Hajek and colleagues reported that, as compared with participants 
assigned to NRT, those assigned to e-cigarettes had higher rates of throat and mouth irritation (e-
cigarettes: 65.3% vs. NRT: 51.1%; RR 1.27 [95% CI, 1.13 to 1.43]) and lower rates of cough (e-
cigarettes: 30.8%  vs. NRT: 39.8%; RR 0.8 [95% CI, 0.6 to 0.9]) at 12 months of followup.154 
SAEs occurred in both groups, but the trial clinicians determined that none of these events were 
attributable to study product use (Table 9).154 In a recent trial, SAEs occurred in 16 participants 
in the patch plus nicotine e-cig group, 22 people in the patch plus nicotine-free e-cig group, and 
3 people in the patch only group; although the incidence rate ratios between group were not 
statistically significant and the authors deemed that none of the SAEs were considered treatment 
related.155 Another recent trial reported no SAEs among participants in either group but reported 
that the percentage of participants who experienced any adverse event was significantly lower in 
the e-cigarette group than in the nicotine gum group (6.7% vs 17.3% in e-cigarette group and 
nicotine gum group respectively)157 (Table 9). 
 
Among the four trials newly identified by this review with followup periods <6 months, no 
significant differences in the incidence of AEs overall or SAEs between intervention and control 
groups were reported (Table 9).146-148, 150 At four months of followup, Carpenter and colleagues 
found that participants in a U.S. trial who were randomized to e-cigarettes (either 16 mg/mL or 
24 mg/mL nicotine concentration), as compared with participants with ongoing conventional 
cigarette (CC) use, reported higher rates of cough (e-cigarettes: 32% vs. CCs: 21%), but 
exhibited similar rates of throat irritation (e-cigarettes: 16% vs. CCs: 17%).147 Although 
differences in the incidence of AEs between the intervention and control groups were observed, 
statistical comparisons were not made, and no AEs resulted in study withdrawal.147 Similarly, 
Cravo and colleagues, comparing e-cigarettes with ongoing CC use in the United Kingdom at 4 
months, found higher rates of cough (e-cigarettes: 17.0% vs. CCs: 7.8%), sore throat (e-
cigarettes: 27.8% vs. CCs: 8.8%), and headache (e-cigarettes: 47.4% vs. CCs: 33.3%), but no 
statistical comparisons were made.148 Compared with a nonnicotine-containing e-cigarette 
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(placebo), Masiero and colleagues found the subjects who used nicotine-containing e-cigarettes 
reported higher rates of burning throat (e-cigarette: 5.7% vs. placebo: 2.9%) and cough (e-
cigarette: 10.0% vs. placebo: 2.9%) at 3 months of followup, but statistical comparisons were not 
made.146 In a study by Tseng and colleagues, young adult smokers in the United States who were 
randomized to low-nicotine (4.5%) e-cigarettes reported almost twice the proportion of AEs 
(22.5%) over a 3-week followup period as participants randomized to no-nicotine placebo e-
cigarettes (10.3%); however, this difference was not statistically significant (p=0.14).150 
 




Based on a primary literature review of 64 full-text articles, we identified seven RCTs (reported 
in 12 publications)167-178 evaluating the use of NRT among pregnant women and five large 
observational studies (reported in six publications)179-184 that reported on the harms of NRT, 
bupropion, or varenicline use (Appendix B Figure 3).  
 
Using the overview of reviews approach, we identified five reviews that addressed the benefits 
and harms of behavioral interventions for supporting women to stop smoking pregnancy (Table 
2).108, 116, 185-187 The review by Chamberlain (2017) included any behavioral support intervention 
including counseling, health education, feedback, incentives, social support, exercise, and 
dissemination of cessation interventions.185 The included bodies of evidence within the three 
other reviews focused on digital interventions,186 incentives,116, 187 and psychotherapy187 were 
mostly duplicative and the results were entirely consistent with those of Chamberlain. 
Additionally, one review on relapse prevention provided a detailed synthesis of interventions 
among pregnant women and is reported below.108  
 
We identified no studies that met eligibility criteria that addressed the benefits or harms of the 




Of the seven RCTs included that examined the benefits and harms of NRT among pregnant 
women, we rated two as good quality and the remaining five as fair quality (Table 10). Increased 
risk of bias in the fair quality studies was primarily owing to lack of allocation concealment, 
attrition, and study arm imbalances in baseline characteristics. Of the five observational studies 
included for harms, we rated four of them as good quality and one as fair quality. The fair quality 
study was assessed to have elevated risk of bias due to limitations in the data source for 
assigning individuals to the exposed and unexposed groups and insufficient adjustment for 
possible confounding factors.  
 
The review by Chamberlain (2017) was rated as having high credibility according to AMSTAR-
2 criteria and had no critical weaknesses. The other reviews that included evidence for pregnant 
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women were all rated as moderate or high credibility with only minor weaknesses in the 
methodology noted. 
 
Key Question 1. Do Tobacco Cessation Interventions Improve 
Mortality, Morbidity, and Other Health Outcomes in Adults Who 




Nicotine Replacement Therapy 
 
All seven included RCTs were designed to test the effectiveness of NRT on smoking cessation 
and reported infant, child, and maternal health outcomes (Table 10).167, 168, 171, 174-176, 178 Most 
evaluated NRT patch interventions, but one gave participants a choice of patch, gum, or 
lozenge,176 one trial offered NRT gum,174 and one used a nicotine inhaler175 (Appendix G Table 
2). In all cases, women were offered behavioral support in addition to NRT. Five of the seven 
RCTs were placebo controlled. The largest study (n=1050) was the Smoking, Nicotine, and 
Pregnancy trial (SNAP), which was a multisite RCT of NRT patches conducted in the United 
Kingdom.168-170 The second largest and most recent NRT trial was conducted in France at 
multiple sites, randomizing 402 women to nicotine patches or placebo nicotine patches.167 
Women enrolled in the seven trials were mainly ages 18 years and older (mean ages ranged from 
25.1 to 29.3 years).167 One trial exclusively enrolled African-American women.171 Study 
recruitment tended to be at the first antenatal visit or before the end of the second trimester of 
pregnancy; one small trial allowed women to enroll any time before 30 weeks gestation but the 
average gestation at baseline was in the early second trimester (Appendix G Table 1).171 In one 
trial174 women were invited to participate if they smoked one or more cigarettes per day during 
pregnancy and in the other trials five or more cigarettes per day. Five trials, including the two 
largest, reported the percentage of participants with a history of preterm birth (range 9% to 
15%).167, 168, 174-176 Low adherence to NRT therapy was noted in the trials. For example, in the 
SNAP trial;168-170 only 7.2 percent of women in the NRT condition and 2.8 percent with placebo 
used the patch for more than one month, and in the trial offering a choice of gum, patch, or 
lozenge,176 the average use of NRT was lower than the prescribed and dispensed medications.  
 
Five placebo-controlled trials reported on preterm birth (delivery at <37 weeks gestation). 167, 168, 
174, 175, 178 The most recent study reported a statistically significant lower incidence of preterm 
delivery among those in the NRT inhaler group (3/67, 4%) compared with the placebo group 
(10/67, 15%) (p=0.030 after controlling for history of preterm birth).175 Within the other trials, 
one reported similar numbers of women with preterm birth in the NRT and placebo arms (14.0% 
vs. 13.5%, respectively),167 two reported only slightly fewer women with preterm birth in the 
NRT arm,168, 178 and the smallest study reported reduced incidence of preterm birth with NRT 
compared with placebo (RR 0.39 [95% CI, 0.17 to 0.91]) (Appendix G Figure 1).174 The three 
placebo-controlled trials that did not report statistically significant differences had larger samples 
and estimated effects closer to null, ranging from a RR 0.85 to 1.04.167, 168, 178 Two trials without 
placebo controls were imprecise and estimated effects in opposite directions.171, 176 
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All seven trials reported the association between the intervention and mean birthweight.167, 168, 171, 
174-176, 178 Two placebo-controlled trials found significantly higher birthweights among women 
allocated to the NRT arm174, 178 (Appendix G Figure 2), while only one of the trials174 reported 
similar effect for the proportion of infants categorized as having low birthweight (Appendix G 
Figure 3). The two largest, good-quality, placebo-controlled trials of NRT patch interventions, 
did not find evidence of increased infant birthweight with NRT treatment.167, 168 Further, 
Coleman and colleagues found more low birthweight infants were reported for the NRT 
condition, although the result was not statistically different from null (RR 1.38 [ 95% CI, 0.90, 
2.09).168 Four trials also reported stillbirths, but low event rates and imprecision limit inference 
(Appendix G Figure 4).167, 168, 174, 176   
 
The trial by Coleman and colleagues, reported 2-year followup data on child health outcomes.168-
170, 173 In this trial, just under one-third of participants in each arm completed the 2-year 
questionnaire. Nonrespondents’ family physicians were also surveyed. Both study trial arms 
reported that 88 percent of participants or clinicians completed followup at 2 years, with similar 
rates of withdrawal and nonresponse between arms over the time period (NRT n=445 and 
placebo n=446). Comparison group characteristics were similar in the original and followup 
cohort. This study’s authors reported composite variables based on an a priori statistical analysis 
plan. The main outcomes were survival with no impairment (i.e., developmental, neuromotor, 
and sensory) and respiratory problems (i.e., respiratory symptoms, asthma diagnosis, and 
admissions to hospital for respiratory problem). Group comparisons using intention-to-treat 
analyses with multiple imputation indicated that survival with no impairment was significantly 
higher among those allocated to the NRT group compared to placebo (73% versus 65%; OR 1.40 
[95% CI, 1.05 to 1.86]). There was no significant difference in rates of definite developmental 
impairment (11% NRT, 14% placebo; OR 0.71 [95% CI, 0.47 to 1.09]) between the groups. For 
respiratory problems, a 5 percent observed difference between the arms (30% NRT vs. 25% 
placebo) was not statistically significant (OR 1.30 [95% CI 0.97 to 1.74]).169, 170 Results from a 




We identified no trials that addressed the effectiveness of bupropion among pregnant women that 




We identified no trials that addressed the effectiveness of varenicline among pregnant women 




The review by Chamberlain (2017) identified 102 trials that addressed the effects of smoking 
cessation interventions during pregnancy on smoking behavior and perinatal health outcomes 
(Tables 2 and 3).185 Most of the trials in this review included generally healthy women over 16 
years of age, while two trials targeted women younger than 20 years of age, eight trials 
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specifically targeted women with psychosocial risk factors, and two trials were limited to women 
under methadone treatment for opioid addiction (Table 4). About half the trials (k=52, 66 study 
arms) explicitly recruited women categorized as having low socioeconomic status, and 10 trials 
included mainly women belonging to an ethnic minority population. Most of the included trials 
recruited women during their first antenatal visit or second trimester of pregnancy and excluded 
women in their last trimester of pregnancy due to the limited time available to receive an 
intervention. There were, however, four trials that targeted women who smoked into late 
pregnancy.185  
 
Within the trials that were included for any meta-analysis, 94 were aimed exclusively at 
supporting smoking cessation and 12 trials aimed to improve maternal health, which included 
smoking cessation.185 The latter studies were only included for KQ 2 (cessation outcomes) given 
that there is a potential for other aspects of these interventions to have impacted birth outcomes. 
All interventions differed substantially in their intensity, duration, and interventionists. Included 
trials presented many comparisons. Interventions included counseling, health education, 
feedback, incentives, social support, exercise, and dissemination (active dissemination of a 
smoking cessation intervention) and comparators included usual care, less intensive 
interventions, and alternative interventions (e.g., cognitive behavioral counseling versus 
traditional health education). The review excluded trials comparing efficacy of pharmacotherapy 
with equal levels of behavioral support. Of interventions categorized as counselling interventions 
(54 intervention arms), most involved face-to-face contact, using a variety of strategies either 
alone or in combination (such as motivational interviewing, cognitive behavioral therapy, stages 
of change). The duration and frequency of counseling varied considerably but has generally 
increased over time. Health education (12 intervention arms) were those interventions that 
provided information about the risk of smoking and advice to quit but did not give further 
support or advice on how to make this change. Most were provided through automated support 
such as self-help materials or automated text messaging. Feedback interventions (6 intervention 
arms) were those where the mother was provided feedback with information about the fetal 
health status or measurement of by-products of tobacco smoking to the mother. Incentive-based 
interventions (13 arms) included interventions were women received a financial incentive, 
contingent on their smoking cessation, including gift vouchers. Social support interventions (7 
arms) were those that explicitly included the provision of support from a peer or partners.185  
 
Of the 102 included trials, 26 study arms reported mean birthweight, 17 arms reported rates of 
low-birthweight babies (less than 2500 g) and three reported rates of very low birthweight babies 
(less than 1500 g), and 19 study arms reported rates of preterm births (less than 37 weeks’ 
gestation).185 Other, less commonly reported data included stillbirths (k=8), perinatal deaths 
(k=4), and neonatal deaths (k=5).185   
 
When all 26 studies that reported mean birthweight were combined, there was evidence that 
infants born to women receiving behavioral smoking cessation interventions had an increase in 
mean birthweight of 55.60 g, compared with women in the usual care control groups (MD 55.60 
g [95% CI, 29.82 to 81.38]; I2=31%; k=26; n=11,338) (Table 11).185 The magnitude and 
significance of the effect was similar when limited to counseling interventions (42.17 g [95% CI, 
11.79 to 72.55], I2=0%; k=14; n=5471), and a test for subgroup differences showed no evidence 
of effect modification by type of intervention (p=0.11). The magnitude of the mean difference 
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between groups for all types of interventions was modest, yet there was general consistency in 
the direction of effects across studies, with only six reporting effects (none statistically 
significant) favoring the control condition. Evidence of beneficial effects was also observed in 
the pooled analyses across all interventions and comparators for low birthweight (under 2500 g). 
The pooled effect estimate suggested a 17 percent risk reduction for delivery of a low 
birthweight baby (RR 0.83 [95% CI, 072 to 0.94]; I2=0%; k=18; n=9402) (Table 11). When 
restricted to specific types of interventions, while results suggested similar benefits, none of the 
pooled results were statistically significant. None of the three trials reporting on rates of birth to 
very low birthweight babies (less than 1500 g) found a beneficial effect of the behavioral 
intervention versus control.185  
 
Of the 19 trials reporting the effects of the intervention on preterm birth (less than 37 weeks), 
results were mixed, although the majority reported a reduced risk of preterm birth among women 
within the behavioral interventions versus control groups.185 Meta-analysis of these trials resulted 
in uncertainty in the potential benefit of behavioral interventions compared with controls on rates 
of preterm birth (RR 0.93 [95% CI 0.77 to 1.11]; I2=18%; k=19; n=9222) (Table 11). In separate 
comparisons of studies, the effect was also unclear across comparisons by type of specific 
intervention and control groups.185  
 
Among the eight trials reporting stillbirth, none of the trials found significant differences 
between study groups, and the pooled result was consistent with either potential benefit or harm 
(RR 1.20 [95% CI, 0.76 to 1.90]; I2=0%; k=8; n=6170) (Table 11).185 There were very low event 
rates within each group across trials, however, overall, there were slightly more stillbirths 
recorded in the intervention groups (40/3053) compared with the control groups (33/3117). 
Three trials of counseling, one trial of a feedback intervention, and one exercise trial reported on 
neonatal deaths, but events were too rare to inform valid conclusions. Similarly, there was no 




We identified no trials that addressed the effectiveness of e-cigarettes among pregnant women 
that met our eligibility criteria.  
 
Key Question 2. Do Tobacco Cessation Interventions Increase 
Tobacco Abstinence in Adults Who Currently Use Tobacco, 




Nicotine Replacement Therapy 
 
There was no evidence of differences in smoking cessation with NRT intervention across the 
included RCTs. Meta-analysis of five placebo-controlled trials generated a pooled effect of NRT 
on validated smoking cessation at followup (RR 1.11 [95% CI, 0.79 to 1.56]; I2 = 0%, n=2033) 
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and low statistical heterogeneity (Appendix G Figure 5).167, 168, 174, 175, 178 Quit rates in these 
trials ranged from 5 to 28 percent in the intervention groups and 5 to 25 percent in the control 
groups (mean,11.8% vs. 10.6%). The results across trials for the efficacy of NRT were relatively 
consistent, with effect estimates ranging from 1.08 to 1.24 in the placebo-controlled trials (with 
the exception of one new trial that found a higher quit rate among those in the placebo group 
[17.9%] compared with the NRT group [10%] (RR 0.56 [95% CI, 0.23 to 1.33]).175 The results 
of the two smaller trials with no treatment controls171, 176 were not statistically significant, and 
estimates of efficacy were greater than for the placebo-controlled trials. Including these studies 
in meta-analysis did not change the overall findings (data not shown). Low rates of adherence to 
the intervention were described (mean adherence rates of less than 25 percent were often 
observed); particularly in the trials with good reporting.167, 168, 174, 175, 178  
 
The 2-year SNAP followup study found continuous smoking abstinence rates to be very low in 
both groups: 3 percent of mothers in the NRT group and 2 percent of mothers in the placebo 
group self-reported prolonged (or continuous) abstinence at two years since the quit date set in 
pregnancy, with no statistical difference between groups.170 Cessation was ascertained by 
clinician survey for over half of the trial participants at 2 years. Nonrespondents were assumed to 
be smokers and included in the denominator. While there were no significant differences 
between groups earlier in the postpartum period (6 months), a significant effect was observed at 
one year (4% NRT vs. 2% placebo) with further adjustment (site, baseline salivary cotinine, 




We identified no trials that addressed the effectiveness of bupropion among pregnant women that 




We identified no trials that addressed the effectiveness of varenicline among pregnant women 




Primary Results  
 
The review by Chamberlain (2017) identified 102 trials with 120 study arms testing the effects of 
a behavioral interventions for smoking cessation among pregnant women.185 Of the 120 study 
arms included in the review, 97 arms reported the primary outcome measure of smoking 
abstinence in late pregnancy, up to and including the period of hospitalization for birth. In 71 of 
these study arms (73%), this abstinence was biochemically validated. In most trials, women were 
classified as “current smokers”; some other studies included women who had spontaneously quit 
in early pregnancy but are included here. The remaining trials did not report a measure of 
smoking abstinence in late pregnancy but focused on abstinence in the postpartum period only, 
smoking reduction, or perinatal outcome measures.185  
 
Tobacco Cessation in Adults 56 Kaiser Permanente EPC 
Pooled analyses of all behavioral interventions (k=97), regardless of type and including self-
reported outcomes, indicated a statistically significant effect on smoking cessation in late 
pregnancy when compared with usual care or a minimal intervention (RR 1.35 [95% CI, 1.23 to 
1.48]; k=97; n=26,637), with moderate heterogeneity of estimated effects (I2=44%) (Table 
12).185 While an overall Chi2 test for subgroup differences found no difference by the type of 
intervention (p=0.39), the number of studies varied considerably by intervention type 
(counseling [51 trials], health education [11 trials], feedback [6 trials], incentives [13 trials], 
social support [14 trials], exercise [1 trial], and other [1 trial]. The results were similarly 
beneficial when restricted to trials comparing counseling with any type of control (RR 1.31 [95% 
CI, 1.16 to 1.47]; I2=40%; k=51; n=18,2786) as well as when comparing counseling with usual 
care (RR 1.44 [95% CI 1.19 to 1.73]; I2=49%; k=30; n=12,432). Results of trials of feedback and 
incentives were also suggestive of a benefit; but there was no evidence of a statistically 
significant effect of social support interventions from analysis of 10 trials that were included in 
the review (RR 1.29 [95% CI, 0.97 to 1.73]). The effects of other types of interventions versus 
any comparator or usual care generally favored the intervention conditions, but pooled results did 
not rule out the possibility of no benefit. Direct comparisons between interventions of greater 
versus less intensity were found to be statistically significant for trials testing counseling, but not 
for the fewer studies of health education (4 trials), feedback (3 trials), or social support (7 trials) 
interventions (Table 12). There was some evidence that the positive effects of behavioral 
interventions on smoking cessation in late pregnancy continued into the postpartum period, up 
until approximately 18 months postpartum. For instance, in an examination of counseling 
interventions compared with usual care, the average RR was 1.59 (95% CI, 1.26 to 2.01; k=11) 
at 0 to 5 months postpartum, 1.33 (95% CI, 1.00 to 1.77; k=6) at 6 to 11 months postpartum, and 
2.20 (95% CI, 1.23 to 3.96; k=2) at 12 to 17 months.185 
 
Evidence of Effect Modification  
 
Regarding the whole set of trials, meta regression analyses found no differences in the effects of 
behavioral interventions according to the specific intervention strategies, comparator, intensity 
(categorized according to frequency of contact), intervention duration, the provision of self-help 
manuals, including telephone support, the SES of the sample, newly added studies, or study 
design (cluster versus individually randomized trials).185 In general, interventions of higher 
intensity typically also had control groups of higher intensity, potentially explaining why no 
clear differences were seen with increasing intervention intensity. There was some evidence that 
studies with a high risk of bias related to allocation concealment had a larger pooled-effect size 
estimate compared with lower risk or unclear risk of bias studies. Studies with unclear and low 
risk of bias for equal baseline characteristics in study arms showed larger effect sizes than those 
at high risk of bias for this item. No other measures of risk of bias (random sequence generation, 
attrition bias, selective reporting bias, detection bias, blinding, contamination, or intervention 
fidelity) predicted larger effect estimates.185 
 
Several of the individual trials provided findings of subgroup analyses based on participant 
characteristics.185 Of 13 studies that reported a sensitivity analysis by a measure of 
socioeconomic status with studies (such as education levels and employment), eight reported 
lower abstinence rates among women with lower SES, three reported no difference, and two 
reported higher rates of intervention success among women with low SES. Among the eleven 
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trials that reported outcomes by ethnic status results were inconsistent: one study reported the 
intervention was less effective among Hispanic and African American women compared with 
white women, one study reported the intervention was less effective among Hispanic compared 
with African American women, four studies reported no difference in outcomes by race or 
ethnicity, and five study arms reported higher quit rates among African American and/or 
Hispanic women compared with women of other races and ethnicities. Four studies reported a 
negative association between treatment effectiveness and higher rates of depression, and of six 
studies that reported measures of social support, four reported a negative association with low 
social support and quitting.185  
 
Interventions for Relapse Prevention 
 
The moderate-credibility review by Livingstone-Banks (2019a) included 18 trials focused on 
relapse prevention among pregnant and/or postpartum ex-smokers.108 Pooled results from eight 
studies of interventions in pregnancy did not demonstrate a clear benefit on relapse prevention at 
the end of pregnancy (RR 1.05 [95% CI, 0.99 to 1.11]; k=8; n=1523; I2=0%). There was also no 
significant benefit seen among 15 studies that included followup into the postpartum period 
overall or when subgrouped according to timing of the intervention (overall RR 1.02 [95% CI, 




We identified no trials that addressed the use of e-cigarettes to quit smoking among pregnant 
women that met our eligibility criteria.  
 
Key Question 3. What Harms Are Associated With Tobacco 




Nicotine Replacement Therapy – Trial Evidence 
 
Given the low number of trials and high statistical heterogeneity, we did not report pooled 
analyses for health outcomes that could also be evaluated as potential harms of NRT treatment 
(e.g., stillbirth). The available trials (Table 10) were underpowered for assessing rare harms with 
statistical confidence.167, 168, 171, 174-176, 178 As reported above, significant effects of NRT on health 
outcomes included beneficial effects for some individual studies, including higher birthweight in 
two trials174, 178 and reduced risk of preterm birth in one.174 Three trials reported miscarriage by 
study arm, but there were too few events in the study arms to draw valid inference and no 
difference was evident.167, 168, 175   
 
The two large, good-quality NRT patch trials reported detailed maternal adverse events.167, 168 In 
the Berlin trial, there was insufficient statistical power to assess the statistical significance of the 
observed 4 percent difference in having one or more serious maternal adverse event (NRT 12%, 
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placebo 8%).167 The trial did, however, report a statistically significant 0.02 mm Hg per day rise 
in diastolic blood pressure over time in the trial among NRT compared with placebo allocated 
participants (p=0.01). Reported cases of preeclampsia were few, but consistent with the 
differences in blood pressure, preeclampsia was diagnosed among more women in the NRT 
condition than the placebo control (3/203 vs. 1/199).167 The Coleman trial, however, did not find 
differences in high blood pressure readings on at least two occasions between study groups and 
reported slightly fewer cases of preeclampsia/eclampsia in the intervention group (3/521 versus 
5/529), although again, event rates were too low to establish a valid association.168 The two 
largest trials reported that the most common adverse event was skin reaction at the patch site, 
with higher rates in the active NRT patches—nearly 9 percent of NRT users in the one RCT 
discontinued treatment due to the reaction.167, 168  
 
Fetal and infant harms were reported as individual outcomes and composite measures with 
variable definitions. In the Coleman study, a composite measure of any serious adverse event, 
defined as any miscarriage, stillbirth, neonatal or post neonatal death, was higher in the NRT 
intervention group (9/521) vs. placebo (6/529), but precision was too low to assess statistical 
differences.168 A composite outcome of any serious adverse event was also reported in the 2008 
Oncken trial and included birth outcomes, miscarriage, stillbirth, and neonatal death as well as 
neonatal or maternal hospitalization.174 More serious adverse events were observed in the 
placebo condition than in the intervention group, and the difference approached statistical 
significance (NRT 24/97, placebo 33/87, p=0.06), with much of the difference attributed to lower 
rates of preterm birth and low birthweight in the intervention group.174 A similar composite 
outcome was reported in the Pollak trial (preterm birth, NICU admissions, small-for gestational 
age, placenta abruption, fetal demise), with more events found in the intervention group  (NRT 
30.1%, 34/113 versus placebo 17.2%, 10/58, risk difference 0.13 [95% CI, 0.00 to 0.26]).176 
Adjustment for previous preterm birth narrowed the risk difference (RD=0.09 [95% CI, 0.05 to 
0.21]).176 
 
In the two larger studies reporting counts of stillbirths, nine occurred in the NRT arms and seven 
occurred in the placebo control groups (1.3% versus 1.0% respectively).167, 168 Three trials 
reported neonatal deaths;167, 168, 174 there were a total of three cases in the intervention arms and 
four cases in the control arms in the trials. Congenital malformations were reported in the Berlin 
and Coleman trials, with fewer cases occurring in the NRT group for both studies (Berlin, NRT 
4/203 versus placebo 6/203; Coleman, NRT 9/507 versus placebo 13/517).167, 168 Between group 
differences were lower than 1 percent, however, and the confidence intervals crossed null.167, 168  
 
The 2-year followup data from the Coleman SNAP trial described for KQ1 did not find evidence 
of longer-term developmental or respiratory harms associated with NRT use during pregnancy 
compared with a placebo.170  
 
Bupropion – Trial Evidence 
  
We identified no trials that addressed the benefits or harms of bupropion among pregnant women 
that met our eligibility criteria. 
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Varenicline – Trial Evidence 
 
We identified no trials that addressed the benefits or harms of varenicline among pregnant 
women that met our eligibility criteria. 
 
NRT, Bupropion, and Varenicline – Observational Evidence 
  
We included five cohort studies (4 good quality, 1 fair quality), reported in 6 publications, that 
evaluated the association between gestational use of a smoking cessation medication and risk of 
adverse fetal and maternal outcomes (Table 10).179-184 Two studies examined exposure to NRT 
only, one study examined exposure to NRT or bupropion, one study focused on varenicline, and 
the final study examined exposure to NRT, bupropion, or varenicline. Most studies included two 
compactors: women who smoked but did not use the cessation medication and non-smoking 
women or ex-smokers. Here we focus on those who used or were prescribed a smoking cessation 
medication compared with those who were current smokers. Collectively, there was no evidence 
of increased risk of premature delivery, small-for-gestational age, stillbirth, congenital 
anomalies, associated with the use of NRT, bupropion, and varenicline versus smoking.179-184  
 
A good quality cohort study using the Quebec Pregnancy cohort data found a lower risk of 
premature delivery (<37 weeks’ gestation) with NRT (adjusted OR, 0.21 [95% CI, 0.13 to 0.34], 
n=316) and bupropion (adjusted OR, 0.12 [95% CI, 0.03 to 0.50], n=72) compared with women 
who smoked during pregnancy but did not take either medication (n=900).179 NRT patch use was 
associated with a significant reduction in the risk of small for gestational age (<10th percentile for 
gestational age birthweight) when compared with smoking (adjusted OR, 0.61 [0.41 to 0.90]). 
Gestational exposure to bupropion was not statistically significantly associated with small for 
gestational age when compared with smoking (adjusted OR, 0.97 [95% CI, 0.50 to 1.89]).179   
 
A fair-quality cohort study conducted in the United Kingdom using the Health Improvement 
Network database analyzed data from 220,630 singleton pregnancies to assess whether NRT 
exposure during pregnancy could be associated with stillbirth.181 A related article reported on 
congenital anomalies for live-born infants (n=192,498) using the same data source and similar 
comparisons.180 Absolute risk of stillbirth was the same (5/1000 births) in women prescribed 
NRT (n=5221) and those continuing smoking (18,407) and there was no statistically significant 
difference in the relative risk of stillbirth (adjusted OR, 0.95 [95% CI 0.62 to 1.48]).181 Similarly, 
there was no difference in the risk of major congenital anomalies between women prescribed 
NRT during pregnancy (n=2677) and those who smoked during pregnancy (n=9980) (odds ratio, 
1.07 [99% CI, 0.78 to 1.47], p=0.58).180 There was, however, evidence of an increased risk of 
respiratory anomalies in the NRT group compared with smokers (OR, 3.49 [99% CI, 1.05 to 
11.62], p=0.007), however, this finding was based on only 10 NRT-exposed cases.180 
 
Longer-term child health outcomes were also assessed in an included good-quality cohort study 
using Danish National Birth Cohort data (n=84,803).184 The study analyzed outcomes for 
children up to age 14 who were born to women who smoked and for women who used NRT 
during pregnancy, quit smoking during pregnancy, or did not smoke, and considering whether 
the father smoked. Diagnosis of attention-deficit hyperactivity disorder (ADHD) after age 5 was 
the primary outcome. The highest hazard ratio for the development of ADHD during followup 
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was seen for children whose mothers reported using NRT and had nonsmoking fathers (HR 2.26 
[ 95% CI 1.48 to 3.51]) with a comparison group of nonsmoking mothers and fathers. However, 
the results are based on small numbers, resulting in wide confidence intervals and unstable 
estimates. Only seven ADHD cases were identified among children in the NRT group with a 
smoking father and 22 ADHD cases among children in the NRT group with a nonsmoking 
father. The estimate was not statistically significant for children with mothers using NRT and 
fathers who smoked. There also were several differences between the study groups, some 
accounted for using statistical adjustments, and likely unmeasured confounders that could 
account for the differences observed.184   
 
A large, good-quality cohort study (n=1,017,731) conducted in two states in Australia examined 
whether use of NRT, bupropion, or varenicline during pregnancy compared with a propensity 
score-matched unexposed group was associated with risk of adverse perinatal and major 
congenital anomalies.183 The risk of any adverse perinatal event was not significantly different 
between NRT-exposed and unexposed (44.8% vs. 46.3%, hazards ratio [HR] 1.02 [95% CI, 0.84 
to 1.23]) and bupropion-exposed and unexposed women (39.2% versus 39.3%, HR 0.93 [95% 
CI, 0.73 to 1.19]), but it was significantly lower in women exposed to varenicline (36.9% vs. 
40.1%, HR 0.86 [95% CI, 0.77 to 0.97]). Additionally, varenicline-exposed infants were less 
likely than unexposed infants to be born premature, be small for gestational age, and have severe 
neonatal complications. Among infants exposed to varenicline in the first trimester, 2.9% had a 
major congenital anomaly vs. 3.5% in unexposed infants (HR 0.91 [95% CI, 0.72 to 1.15]).183  
 
Finally, a good-quality population-based cohort study in Denmark and Sweden compared the 
risk of congenital malformations from birth to the first year of life among infants whose mothers 
were dispensed varenicline during pregnancy versus infants whose mothers were unexposed to 
varenicline, but exposed to maternal smoking in utero.182 Major congenital malformations were 
detected among 3.6 percent of exposed infants vs. 4.3 percent of unexposed infants (adjusted 
OR, 0.80 [95% CI 0.545 to 1.42). Furthermore, there was no increased risk of other adverse birth 




The Chamberlain review found that behavioral smoking cessation interventions have minimal 
adverse effects, including the possibility of a paradoxical effect (i.e., increased smoking).185 Four 
studies that measured whether women increased their smoking following exposure to the 
intervention showed mixed results with two studies reporting an increase in smoking behavior 
among women who did not quit. Thirteen trials reported postintervention psychological outcome 
measures, and none reported any negative psychological effects. Other potential harms of these 




We identified no trials that addressed the harm of e-cigarettes among pregnant women that met 
our eligibility criteria.  
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Chapter 4. Discussion 
 
Summary of Evidence 
 
We conducted an overview of reviews to update the evidence on the benefits and harms of 
tobacco cessation interventions among the general adult population and pregnant adults. This 
approach allowed us to summarize the evidence on health outcomes, cessation outcomes, and 
harms of pharmacotherapy (NRT in various forms, bupropion, and varenicline), a variety of 
primary care-applicable behavioral interventions, and various combinations of pharmacotherapy 
and behavioral intervention approaches from 67 relevant systematic reviews, with more than 
1500 RCTs and observational studies represented. We supplemented the overview of reviews 
approach with a primary search for studies evaluating the use of e-cigarettes for smoking 
cessation, given the more recent emergence of this technology and the existing USPSTF 
determination of insufficient evidence for this approach.1 Similarly, we conducted a primary 
search for literature to locate all recent studies related to the use of bupropion among adults 
given no updated review on the subject and of all pharmacotherapy among pregnant women, 
given the small evidence base we previously identified and potential harms related to these 
medications among this population.  
 
The results of our review are consistent with the conclusions of the 2020 Surgeon General’s 
report on Smoking Cessation.14  
 
General Adult Population 
 
Available evidence on the impact of tobacco cessation interventions on health outcomes (KQ 1) 
from systematic reviews among general adults represented a single behavioral intervention 
(physician advice) with no pharmacological treatment (Table 13). Our ratings of “low” and 
“insufficient” for this key question reflect the lack of evidence on health outcomes presented in 
the included reviews, not a lack of confidence in the beneficial association between quitting 
smoking and improved health outcomes. The research field has largely moved past the question 
of whether tobacco cessation interventions improve health outcomes, given that the health 
benefits of quitting smoking are already firmly established. Within the included reviews, most 
included studies reported smoking cessation as the primary outcome and emphasized improved 
validity through biochemical verification of use or more stringent definitions of abstinence. 
 
We have moderate to high confidence that all seven FDA-approved medications for tobacco 
cessation, a variety of behavioral support and counseling approaches, and the combination of 
pharmacotherapy plus behavioral support—all interventions that may be readily available to 
primary care patients and clinicians—can significantly increase the rate of smoking cessation at 
6 months and longer compared with usual care or brief self-help materials (KQ 2) (Table 13). 
Treatment effects appear to be comparable in a range of populations, settings, and types of 
behavioral support. Furthermore, despite adding nearly 5 more years of research, the effect 
estimates for each pooled comparison have been remarkably stable for at least the past three 
decades (i.e., the time period in which these reviews have been completed and updated). 
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Analyses of combined pharmacotherapy and behavioral counseling interventions suggested 
an increase in smoking cessation by 68 to 98 percent (RR 1.83) compared with usual care or 
brief cessation advice or self-help. Likewise, there was clear evidence of effectiveness of 
pharmacotherapy on smoking abstinence. Based on research involving almost 65,000 smokers, 
nicotine replacement therapy in any form was effective in increasing relative quit rates by 49 to 
61 percent (RR 1.55) compared with placebo or no NRT. A smaller yet still robust body of 
evidence (27 trials representing over 12,000 smokers) comparing varenicline with placebo found 
relatively larger effects on smoking cessation (RR 2.24 [95% CI, 2.06 to 2.43]) (defined 
stringently as 100% biochemically verified continuous abstinence). The absolute differences in 
mean cessation rates between the medication and control arms was 6.4 percent (16.9% vs. 
10.5%), 8.2 percent (19.7% vs. 11.5%), and 14.5 percent (25.6% vs. 11.1%), for NRT, 
bupropion, and varenicline, respectively. Certain combinations of these medications (e.g., long-
term NRT patch plus NRT gum, NRT patch plus bupropion) may also increase quit rates 
compared with no intervention or a single medication; but fewer trials have tested each 
combination. Direct comparisons of these drugs, including those with the EAGLES trial,161 
consistently showed that 12 weeks of treatment with varenicline produced higher statistically 
significant absolute and relative effects on rates of smoking cessation versus NRT and 
bupropion. No differences have been found between the relative effectiveness of NRT and 
bupropion in direct or indirect comparisons.  
 
Although often reported as “pharmacotherapy” interventions in our report for brevity, we note 
that these interventions almost always include some level of behavioral support that is offered to 
both medication and placebo arms. In trials, the level of behavioral support is often more intense 
than what is seen in real world settings where most smokers who use cessation medications do 
not access any type of behavioral support.29 Robust observational studies have found no 
relationship between the use of medications and smoking abstinence, especially when not paired 
with brief advice or behavioral support.188, 189 The incremental effect of adding additional 
behavioral support to pharmacotherapy versus pharmacotherapy alone or with minimal 
behavioral support was found to be small but statistically significant (RR, 1.15 [95% CI, 1.08 to 
1.22]). In these trials, both arms on medication achieved high rates of quitting (mean quit rates in 
intervention vs. control, 19.5% vs. 17.1%), and the incremental difference in intensity of the 
behavioral support between arms was quite modest, about a 0.5 to 5 hours difference in 
intervention contact time. 
 
Research on behavioral support interventions spans a broad range of approaches, including in-
person advice and support from health care clinicians or tobacco cessation counselors to a 
plethora of non-face-to-face formats (tailored and nontailored self-help materials, quitlines, 
outreach or “proactive” telephone counseling, mobile phone-based interventions, and internet 
interventions). Compared with various controls, these behavioral interventions produced modest 
increases in relative smoking cessation at 6 months or more (15% to 88%). Physician or nurse 
advice, even brief, resulted in a significant relative increase in smoking cessation compared with 
usual care or self-help materials (RR 1.76 [95% CI, 1.58 to 1.96] and RR 1.29 [95% CI, 1.21 to 
1.38], for physician and nurse advice, respectively). These results suggest that there are many 
effective approaches to aid cessation, and that because of the wide array of options, smokers – 
with their clinicians – can choose an option that works best for them. 
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Within and between reviews, there was no strong evidence that specific study, population, or 
intervention characteristics predicted larger effects or that certain types of behavioral support 
were more effective than others. The direct evidence on such comparisons was synthesized in 
many of the reviews but is based on far fewer trials. Furthermore, very few reviews presented 
direct comparisons of the effects of tobacco cessation interventions between specific subgroups 
of adults (e.g., those at high risk vs. not at high risk for cardiovascular disease, men vs. women, 
those with vs. without severe mental illness). Twenty-one reviews summarized the effectiveness 
of pharmacotherapy and/or behavioral interventions for specific subpopulations of adults (e.g., 
studies limited to smokeless tobacco users, indigenous populations, those with schizophrenia). 
None of these reviews suggested findings that differed in direction or magnitude of effects on 
smoking cessation.  
 
The mean quit rates in the control groups across all the reviews was highly variable, ranging 
from approximately 5 percent (in trials among smokers receiving usual care in primary care) to 
approximately 11 to 15 percent (in trials including minimal tobacco cessation behavioral support 
to control groups). However, the relative effects of the interventions were much less variable and 
the general absence of substantial heterogeneity between trials within given bodies of evidence 
makes for reliable estimate of relative effects. If we assume an unassisted quit rate of 5 percent at 
12 months in a population of adults attending primary care and use the confidence intervals of 
interventions using physician advice, 1.58 to 1.96, the result is a number needed to treat (NNT) 
of 21–34 for additional benefit. If we use the pooled estimate from nurse advice versus usual 
care, we would decrease the lower confidence interval (1.21) and increase the upper estimate of 
the NNT to 95. If we assumed a higher quit rate in the usual care control groups (e.g., 10%), less 
smokers would be needed to treat to see an additional benefit of more intensive advice and/or 
medications (<20). 
 
There was no evidence of an increased risk of serious AEs, including major cardiovascular AEs 
and serious neuropsychiatric AEs, among the general adult population associated with NRT, 
bupropion, or varenicline (KQ 3) (Table 13). NRT was associated with a higher rate of any 
cardiovascular event, although this was largely driven by low-risk events, typically tachycardia 
(a well-known risk). Reviews that included AEs related to medication use among individuals 
with severe mental illness found no difference between study groups in the rates of AEs, 
including a worsening of psychiatric symptoms or serious psychiatric events (suicide or suicidal 
ideation).  
 
In contrast to the robust evidence on pharmacotherapy and behavioral interventions for smoking 
cessation, our review identified only four RCTs that provide data on the use of e-cigarettes 
versus placebo e-cigarettes or NRT for quitting conventional smoking at 6 or more months’ 
followup (Table 13). We did not identify any primary evidence on the use of e-cigarettes as 
tobacco cessation interventions that reported health outcomes. In two of the five trials (n=2008), 
smokers randomized to e-cigarettes containing nicotine (with or without the co-use of NRT) 
were found to have statistically significantly greater rates of abstinence than those randomized to 
NRT alone or NRT plus non-nicotine e-cigarettes at 6- to 12-months followup. In both trials, 
continued use of e-cigarettes was high at 6- and 12-months followup (~3-9 months after the 
treatment phase) with 45 to 80 percent of participants still using nicotine-based e-cigarettes as 
opposed to only 9 to 40 percent of participants still using NRT. Another trial compared the use of 
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e-cigarettes (two arms using different nicotine concentrations) with placebo at 12 months and 
found 11 percent abstinence in the nicotine containing e-cigarette groups compared to 4 percent 
abstinence in the placebo group (p=0.04) but 27 percent of those who quit smoking continued to 
use e-cigarettes at 1 year. The remaining trial reported no clear difference in the rates of smoking 
cessation among those randomized to nicotine e-cigarettes versus placebo e-cigarettes at 6 to 12 
months’ followup. Surprisingly few trials (8 identified in this review) and no large (n>1000) 
observational cohort studies reported on the potential AEs of e-cigarette use when used to try to 
quit smoking. This is particularly concerning given the apparent longer-term use of e-cigarettes 
for cessation compared to pharmacotherapy. The paucity of trial data on AEs related to e-
cigarette use is part of the ongoing debate regarding the appropriateness of their use as a 
cessation tool. However, none of the included trials reported statistically significant differences 
in rates of serious AEs between intervention and control groups. A 2019 outbreak of e-cigarette, 
or vaping, product use-associated lung injury (EVALI) involving more than 2800 cases, 




Evidence on the potential benefits and harms of pharmacotherapy for smoking cessation during 
pregnancy is limited, with few efficacy trials and limited power for detecting both potential 
benefits and harms (Table 14). Our review identified seven trials (five of which were placebo 
controlled) that evaluated the potential benefits and harms of NRT among pregnant women; our 
review included no trials evaluating other pharmacotherapies. Across the included trials, there 
were mixed findings for birth outcomes (KQ 1). Only one small trial had statistically significant 
findings of a benefit across birthweight, low birthweight (<2500 grams) and preterm birth (<37 
weeks) outcomes. The largest trial provided evidence from 2-year followup data that survival 
without impairment was higher with NRT vs. placebo. However a separate study found no 
association between maternal smoking status and infants’ development impairment at 2 years 
(thus, that there was no evidence of better infant development among infants born to women who 
were randomized to NRT resulted from smoking cessation induced by nicotine patch use). The 
trials reported other rare outcomes such as stillbirth but were underpowered for detecting 
differences in potential adverse consequences of NRT use in pregnancy. Evidence from five 
large cohort studies did not find differences in stillbirth, birth outcomes, or any congenital 
anomaly for infants born to mothers with exposure to NRT, bupropion, or varenicline versus 
those who were unexposed to medications but whose mothers smoked, but incomplete 
adjustment for confounding limit these findings. Based on the evidence, we could not rule out 
the possibility of health benefits or of potential harms of smoking cessation medication use in 
pregnancy. 
 
There was evidence of statistically significant infant health benefits from behavioral tobacco 
cessation interventions among pregnant women (KQ 1). In pooled analyses, the mean 
birthweight of infants was modestly higher in the intervention group when considered across all 
types of interventions and when limited to counseling interventions. Consistent with this finding, 
the risk for low birthweight (<2500g) was also reduced with behavioral interventions. Meta-
analysis of the trials reporting preterm birth resulted in statistical uncertainty for the estimate of a 
small potential benefit of behavioral interventions compared with controls. The number of trials 
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reporting outcomes and event rates for very low birthweight, stillbirth, and neonatal death was 
too low to estimate effects with enough precision to draw conclusions.  
 
In terms of the effects of interventions on smoking cessation outcomes, there was considerably 
more evidence available on the effects of behavioral interventions during pregnancy than for 
pharmacotherapies (Table 14). Based on pooled data from trials among over 26,000 women, 
behavioral interventions were more effective than usual care or minimal support for smoking 
cessation in late pregnancy (RR 1.35 [95% CI, 1.23 to 1.48]). Although the most common type 
of intervention was counseling, trials of financial incentive interventions, feedback, and health 
education had consistent findings of benefit, including some significant individual trials. There 
was some evidence that the positive effects on smoking cessation in late pregnancy continued 
into the postpartum period until approximately 18 months postpartum, although the smaller 
effect sizes show that many women who did quit during pregnancy relapsed postpartum. 
 
In contrast, there was no evidence of NRT efficacy for validated smoking cessation in late 
pregnancy based on the currently available evidence (five placebo-controlled trials), although 
most trials reported slightly more cessation events in the intervention group. The low adherence 
to NRT reported in the trials hinders interpretation of the evidence since potential benefits and 
harms from exposure to NRT are more difficult to discern when exposure is limited and variable.  
 
In terms of potential harms related to NRT cessation interventions used during pregnancy, the 
available evidence is somewhat reassuring in terms of common health outcomes, such as 
birthweight, but there was limited power to rule out potential rare harms (KQ 3) (Table 14). 
While there was no evidence showing differences in rare outcomes such as miscarriage, 
stillbirth, and neonatal death, these data are sparse and limited. There was no evidence of AEs 




Laboratory tests of e-cigarette ingredients, in vitro toxicological tests, and short-term human 
studies suggest that e-cigarettes are likely less harmful in the short-term than combustible 
tobacco cigarettes. The 2018 National Academies of Sciences, Engineering, and Medicine 
(National Academies) report on the “Public Health Consequences of E-Cigarettes” concluded 
that there was substantial evidence that except for nicotine, under typical conditions of use, 
exposure to potentially toxic substances from e-cigarettes is significantly lower compared with 
combustible tobacco cigarettes.5 However, due to the lack of long-term epidemiological studies 
and large clinical trials, the associations between e-cigarette use and morbidity and mortality, 
especially in the long-term, are not yet clear. Furthermore, much is unknown about their absolute 
safety profile including concerns about the toxic properties of the variable combination of 
chemicals present in e-liquids and the additional chemicals generated during the aerosolization of 
e-liquids.  
 
From August 2019 to February 2020, CDC, the FDA, state and local health departments, and 
public health and clinical stakeholders investigated a nationwide outbreak of e-cigarette, or 
vaping, product use–associated lung injury (EVALI).191 As of February 18, 2020, a total of 2,807 
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hospitalized cases of EVALI and 68 deaths had been reported to the CDC from all 50 states, the 
District of Columbia, and 2 U.S. territories (Puerto Rico and U.S. Virgin Islands).190 The number 
of EVALI cases reported to CDC peaked during the week of September 15, 2019, and steadily 
declined since that time.190 
 
Laboratory data, including analyses of bronchoalveolar lavage (BAL) fluid samples of patients 
with EVALI, show that vitamin E acetate was strongly linked to the EVALI outbreak. Vitamin E 
acetate is an additive in some tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, 
products.192  A study analyzed samples from 51 EVALI cases from 16 states and a comparison 
group of samples from 99 individuals without EVALI for vitamin E acetate and other toxicants; 
vitamin E acetate was identified in BAL fluid samples from 48 of 51 EVALI patients, but not in 
the BAL fluid from the comparison group.192 In an analysis among those hospitalized with 
EVALI, 82 percent reported using THC-containing products (with 33% reporting exclusive use 
of THC-containing product) and 57 percent reported using nicotine-containing products (14% 
was exclusive use of nicotine).193 National and state data from patient reports and product sample 
testing showed  THC-containing e-cigarette, or vaping, products, particularly from informal 
sources like friends, or family, or in-person or online dealers, were linked to most of the cases 
and played a major role in the outbreak.193 Given this data, the CDC and FDA recommend that 
people not use THC-containing e-cigarette, or vaping, products, particularly from informal 
sources like friends, family, or in-person or online dealers193. Additionally, CDC and FDA 
recommend Vitamin E acetate should not be added to any e-cigarette, or vaping, products and 
people should not add any other substances not intended by the manufacturer to products, 
including products purchases through retail establishments. CDC recommends that adults using 
nicotine-containing e-cigarettes or vaping products as an alternative to cigarettes should not go 
back to smoking; they should weigh all available information and consider using FDA-approved 
cessation medications.193 Guidance also suggests that healthcare providers evaluating patients 
with respiratory symptoms should ask them about e-cigarette, or vaping, product use, evaluate 
whether they require hospital admission, consider empiric use of antimicrobials, including 
antivirals, and  consider cautious use of corticosteroids.194 Those hospitalized for EVALI should 
be followed up, optimally within 48 hours of discharge, to reduce the risk of rehospitalization 
and death.195 
 
Finally, the nicotine in the e-liquid can be hazardous if mishandled and is toxic to children. A 
national review of over 4000 e-cigarette related poison center calls found that monthly calls 
regarding e-cigarette exposures in children increased by almost 16 times during the three-year 
study period. Compared with other tobacco products, children exposed to e-cigarettes had 5.2 
times high odds of health care facility admission and 2.6 times higher odds of a severe 
outcome.196 Studying the toxicity and safety of e-cigarettes is complicated by the large variation 
in devices and cartridge fluids available, and the new products rapidly entering the market.  
 
Understanding the public health implications of e-cigarette use at the population level 
necessitates consideration of not only the risks of e-cigarettes on individual health outcomes, but 
also the relationship between e-cigarette use and the use of other tobacco products – namely 
combustible cigarettes. The context surrounding e-cigarette use is markedly different in 
adolescents and young adults versus middle-aged and older adults. Among high school students, 
current e-cigarette use fell from 2015 to 2016 before increasing from 2016 to 2017 and 
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increasing sharply from 2017 to 2018; among middle school students, current e-cigarette use fell 
from 2015 to 2016 and from 2016 to 2017 before increasing sharply from 2017 to 2018.197 Some 
of the main conclusions of the National Academies 2018 report was that there was substantial 
evidence that e-cigarette use increases risk of ever using combustible tobacco cigarettes among 
youth and young adults and moderate evidence that e-cigarette use increases the frequency and 
intensity of subsequent combustible tobacco cigarette smoking among those who had ever used 
combustible cigarettes.5  
 
The relationship between e-cigarette use and combustible tobacco use among adult smokers 
could take many pathways, including promoting cessation of combustible cigarette smoking 
(transitioning to e-cigarette use alone or quitting both products), causing former smokers to 
relapse to combustible smoking after e-cigarette use, or in facilitating dual use of both products 
simultaneously.5 Among adults, nearly all e-cigarette users report having started e-cigarette use 
after having been a regular smoker198 and most report that quitting smoking and health 
improvement are major reasons for starting e-cigarettes use.199, 200 Given what we know about 
the relative safety of e-cigarettes compared with combustible cigarettes, established combustible 
tobacco smokers who completely switch to using e-cigarettes would be expected to reduce their 
tobacco-related health risks. Unfortunately, more than half of adults who report using e-
cigarettes also report current smoking.201 Additional benefit would be expected if e-cigarette 
users subsequently stopped using both e-cigarettes and combustible tobacco products. 
Unfortunately, we found no studies meeting inclusion criteria that reported on potential health 
benefits related to e-cigarette use for quitting smoking among current smokers (Table 13). Our 
review identified five RCTs that examined use of e-cigarettes (with or without NRT) for 
conventional cigarette cessation at 6 months or longer. Evidence from two recent trials indicated 
that nicotine-based e-cigarettes (with or without co-use of NRT) may be superior in effectiveness 
to FDA-approved forms of NRT alone or e-cigarettes that contain no nicotine. The observed self-
reported quit rates at 6 months in these two trials varied considerably: one trial reported 35 
percent of e-cigarette users (versus 25% in the NRT group) quitting combustible smoking 
whereas the other reported 18 percent of e-cigarette plus patch users (versus 8% of patch users) 
quitting smoking. Though the treatment phase in both studies was 12 weeks, more than half of 
participants continued using e-cigarettes at 6 to 12 months followup, substantially more than 
subjects who were assigned NRT. 
 
None of the nine trials included in our review to evaluate harms reported any serious AEs 
considered to be plausibly related to e-cigarette use. Moreover, we found no trials or large cohort 
studies reporting on long-term health outcomes of e-cigarettes. The paucity of long-term data on 
AEs and health outcomes related to use is of concern given the recent reports of severe lung 
injury and the uncertainty about how long persons who use e-cigarettes to quit smoking continue 
their e-cigarette use even after quitting smoking.  
 
Limitations of the Review 
 
Our review has several limitations, including our overview of reviews approach, the methods and 
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The comprehensiveness of our overview of reviews is inevitably limited by the recency and 
quality of the source reviews. Although most of the primary reviews that served as the basis for 
the Primary results included evidence at least through 2015, there may be evidence on population 
and intervention subsets that has been published after each review’s last search date. If this 
occurred, the respective bodies of evidence may not reflect these newer studies. Given the 
consistency of the effects within each group over time, however, we expect that any new trials 
regardless of their sample size and effect estimates would have little bearing on the overall 
results of this overview of reviews.  
 
By adopting an overview of reviews approach, we relied on the data as described and assessed 
by the original reviewers. In doing this we trusted that each review generally included the full 
available and eligible evidence base, that the data abstraction was accurate, and that the analyses 
were scientifically sound. We did apply scientific judgment when choosing which reviews to 
present as the basis for the primary findings and which pooled data were appropriate to present. 
For instance, although review authors may have presented several pooled analyses based on 
various subgroups within the main analysis, we carefully chose which data to include in our 
synthesis based on our a priori questions of interest (e.g., type and intensity of intervention, 
setting and provider, participant selection, verification of abstinence measures). We did not 
reassess the risk of bias or quality of individual trials; instead we reviewed the risk of bias as 
presented in the review and interpreted results considering these potential biases. Although we 
did not quality-rate the reviews based on the specific choice of meta-analytic models (i.e., 
random vs. fixed effects), we were cautious about reporting pooled results for small numbers of 
studies or highly heterogeneous bodies of evidence. We did not present pooled estimates for 
meta-analyses of less than six studies except in the case of a small number of highly clinically 
and statistically homogeneous trials (e.g., NRT among pregnant women). We also narratively 
described results rather than presenting pooled estimates in cases of substantial or considerable 
statistical heterogeneity produced in meta-analyses. Twenty-seven of the 33 primary reviews 
were Cochrane reviews. The general consistency and rigor of methods employed by the review 
authors202 strengthen this overview of reviews. Furthermore, we quality-rated each review 
according to AMSTAR 2 criteria73 and relied upon the available best-quality reviews for each 
body of evidence.  
 
We did not describe or cite individual trials because of the large volume of trials represented 
among the primary reviews (over 1400). Although our text and descriptive tables provide some 
information on the types of interventions included in the bodies of evidence, we did not include a 
detailed description of each intervention or replicate the study characteristics data that were 
presented by the original review authors. More detailed information is available in the original 
reviews. 
 
Because the included reviews were not mutually exclusive in their eligibility criteria and, as a 
result, were not mutually exclusive in their included studies, there are individual trials that are 
represented in more than one review and/or meta-analysis, particularly for trials related to 
behavioral interventions in adults. We could not address this overlap by recalculating all the 
estimates reported in reviews, but we do not expect such adjustments would alter our 
conclusions. By basing our estimates on primary reviews rather than reporting results from 
multiple reviews, we likely mitigated this potential shortcoming. 
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Furthermore, our presentation of results was limited according to the categories of interventions 
that have been systematically reviewed. That is, we present pooled findings according to 
categories of interventions that were developed by the systematic reviewers themselves – namely 
the Cochrane Tobacco Group. While we believe the totality of reviews to reflect the majority of 
tobacco cessation trials that are applicable to primary care in the United States (e.g., physician 
advice, nurse advice, group counseling, telephone-based counseling), there still may be 
applicable tobacco cessation trials that are not represented in any of the source reviews given 
scoping decisions. Additionally, our reporting of stratified analyses and potential population and 
intervention effect moderators was limited by the analyses and reporting by included reviews. 
While most reviews did conduct prespecified stratified analyses and meta-regression, there were 
few variables that were explored across all reviews.  
 
While we did not re-evaluate the risk of bias within individual trials, several limitations are 
applicable to all included studies. Biochemical validation of self-reported quitting ranged from 
less than a quarter of included studies to 100 percent of trials within the included reviews. Most 
of the reviews that had a smaller percentage of included studies that required biochemical 
validation included a higher percentage of large community-based samples and included limited 
face-to-face contact (e.g., print-based self-help materials, telephone counseling, and computer-
based interventions). It should be noted that the Society for Research on Nicotine and Tobacco 
subcommittee on measurement considers that verification is not necessary under these 
conditions.220 It is also important to remember that while biochemically validated findings will 
almost always reduce the absolute quit rate, the absence of validation will only lead to an 
overestimate of effects if intervention participants are more likely to misreport abstinence than 
control group participants. The likelihood of differential misreporting is small among those 
studies of large community-based samples with limited face-to-face contact. Similarly, while 
results based on point prevalence abstinence and sustained abstinence measures are strongly 
related and almost always result in similar relative effects, the absolute rates often differ with 
sustained or continuous abstinence rates averaging around 50 to 70 percent of point prevalence 
rates.  
 
There is some evidence that industry funding is associated with greater NRT efficacy; but not for 
bupropion and is less clear for varenicline.203, 204 This association for NRT may be an indication 
of a selection bias to publish trials with positive but not negative results. The possibility of small 
studies effects or potential publication bias is supported by the review we included here that 
found some evidence of asymmetry in a funnel plot for trials included in the main NRT vs. 
placebo comparison. Another reasonable explanation, however, is that industry-funded trials 
often recruit participants who are less likely to quit without medication (heavier smokers) and 
result in much lower quit rates among control group participants. One review203 found that 
industry funding was associated with lower odds of quitting smoking among varenicline versus 
placebo conditions, but the effect was entirely due to two influential trials. Thus, it is somewhat 
unclear if industry function influences varenicline trials. 
 
Finally, the mechanism by which AEs are recorded (generally passively) makes them susceptible 
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Applicability 
 
Most of the included studies within each review were conducted in North America and, as such, 
should be applicable to the U.S. health system. Most studies enrolled only individuals who were 
smokers who were generally motivated to quit with varying degrees of baseline smoking (i.e., 
cigarettes smoked per day) and nicotine dependence. These trials took place within a very wide 
range of settings with different types of providers and included individuals with smoking-related 
disease and those with mental health conditions. The literature almost exclusively addressed 
treatment for cigarette smoking, as opposed to the use of other forms of tobacco, so the results 
may not be generalizable to all forms of tobacco. The homogeneity of results across 
interventions and specific populations reflects the general applicability of the evidence. To that 
end, we believe the body of evidence represented in this overview of reviews is very applicable 
to primary care in the United States. Synthesized information regarding the details of the types of 
behavioral support represented in this review is provided in Appendix H to provide guidance to 
those wishing to implement smoking cessation interventions.  
 
The available evidence on the use of e-cigarettes to help smokers quit smoking has very low 
applicability to clinical practice in the United States. Most importantly, giving the rapidly 
changing landscape of available products (we are currently in the fourth generation of products), 
the devices that were tested in the included trials are almost all either not available on the market 
or in the United States anymore or are not being used by most users. Furthermore, within trials, 
investigators are typically providing specific e-cigarette devices with predefined nicotine doses 
and schedules; whereas, clinically, we have no guidance on the appropriate devices, delivery of 
nicotine (e.g., liquid, salt), or dose that would be most effective to prescribe.  
 
Future Research Needs 
 
The findings of these reviews, and the estimated sizes of the treatment effects, have remained 
remarkably stable over nearly three decades of evidence for the majority of smoking cessation 
interventions. For instance, in the original Cochrane review on nurse advice to support tobacco 
cessation published in 1999, 15 studies contributed to the main analysis, with a pooled RR of 
1.30 (95% CI, 1.16 to 1.44). The number of studies and participants have more than doubled 
(now 44 trials and over 20,000 participants) and thus narrowed the CIs but have had very little 
impact on the point estimate, which in this most recent update is essentially the same as it was in 
1999 (RR 1.29 [95% CI, 1.21 to 1.38]). Likewise, the Cochrane review on NRT was first 
published in 1996. Despite the number of included studies more than doubling over this time, the 
effect estimate has remained stable (and represents 136 trials) and per the Cochrane Tobacco 
Addition group, this latest review on NRT compared with placebo will be its final review on this 
subject. The review states: “In summary, based on 20 years of research and 136 randomized 
controlled trials in over 64,000 participants, we believe the question of whether NRT helps 
people to quit smoking to be definitively answered. We consider that further research is highly 
unlikely to change our confidence in the effect of NRT, and funders and researchers should give 
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This is not to say that all questions about tobacco cessation interventions have been answered. 
Evidence is still needed to compare different forms, doses, and durations of drugs; to compare 
drugs with one another; and to test interventions in special populations for which we may 
reasonably hypothesize that effectiveness differs from that in the general population (e.g., 
pregnant women, persons with current severe mental illness, those with physical disabilities, 
nondaily and intermittent smokers), including direct subgroup comparisons. Furthermore, given 
the promising results of a few trials testing the effectiveness of cytisine and its widespread use in 
other countries,205 more research on its effectiveness, comparative effectiveness, and harms are 
warranted. More trial evidence on the effectiveness of medications to stop smoking with and 
without behavioral support (including NRT bought over-the-counter) would help elucidate the 
potential generalizability of the broader evidence base as applied to populations for which 
intense behavioral support is not being provided or sought alongside medication-based treatment. 
Additionally, though the evidence has grown over the past 5 years in these areas, more research 
is warranted on the effectiveness of remotely delivered interventions such as internet- and mobile 
phone-based interventions. Though a few reviews sought to include trials evaluating tobacco 
cessation smartphone applications, none were identified that met inclusion criteria. Given the 
plethora of these programs that are publicly available,206 future research should be conducted to 
evaluate their effectiveness on long-term smoking rates. More research is also needed on 
adapting interventions for diverse populations. Most research in this area has focused on 
cessation of cigarette smoking. More research is needed on interventions to help people quit 
other tobacco products such as cigars, smokeless tobacco, and e-cigarettes. Finally, there is a 
pressing need for future research on relapse prevention to aid in long-term cessation as well as 
the optional duration of treatment to maximize long-term abstinence.  
 
Given the variation and the limited evidence available from well-designed studies on the 
association between e-cigarette use and smoking cessation, further research is clearly needed. To 
definitively answer the question of e-cigarette efficacy for tobacco cessation, trials must compare 
an e-cigarette intervention with no intervention and with the most effective known combination 
of pharmacotherapy and behavioral support. Only such a comparative effectiveness study could 
address how e-cigarette use for cessation compares with known effective intervention. 
Furthermore, before such research is conducted, additional strategies and research to help 
standardize and quantify e-cigarette use and nicotine levels is imperative. Future studies should 
test the more recent generation of products (namely pod mods including JUUL) or the standard 
research e-cigarette being developed by the National Institute on Drug Abuse and supported 
through a small business innovation research contract to NJOY.207 Additionally, research on 
other new tobacco products, including heated tobacco products such as IQOS and nicotine 
pouches, which were recently authorized for marketing in the U.S. by the FDA,208 are 
encouraged. Studies of older variants of e-cigarettes which are no longer available or not being 
used by the public are not as helpful in the context of informing clinical practice. Work to 
understand the types of e-cigarettes and the e-cigarette use patterns, if any, that may be 
associated with greater success in using e-cigarettes for smoking cessation is needed as is the 
types, if any, of behavioral support that are associated with greater success in using e-cigarettes 
for smoking cessation. Research on interventions to help dual users of conventional cigarettes 
and e-cigarettes quit both products is necessary as is research on potential relapse back to 
cigarette use among former smokers who use e-cigarettes. Urgent work is needed to better define 
the causes of acute, severe lung injuries associated with e-cigarette use. Research on the causes 
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and frequency of poisonings from e-cigarette fluid and injuries from exploding devices is also 
needed. The long-term health effects of use have not been reported from any study to date. In 
addition, research is needed to examine the longer-term transition rates of young e-cigarette users 
to conventional cigarettes and the relapse rates of smokers who have employed e cigarettes as 
cessation tools. We identified several clinical trials currently under way or planned that address, 
or will address, the effectiveness and safety of e-cigarettes as a tobacco cessation aid that may be 
of interest to the USPSTF in the future (Appendix I Table 1). 
 
Finally, further research on the effectiveness and safety of cessation medications among pregnant 
women is warranted. Careful collection of AEs and systems for deriving long-term consequences 
of exposure during pregnancy is important in future trials, and data on adherence to medications 
and levels of nicotine exposure from NRT relative to what occurs with smoking would also be 
valuable. Despite the established importance of medications in aiding cessation in general 
populations, few studies of pharmacotherapy use have been conducted during pregnancy. For 
NRT, this is likely due to concerns about the potential harms of nicotine for fetal and child 
development mostly inferred from animal studies or extrapolated from observed effects of 
smoking in pregnancy. Since exposure to nicotine is present with smoking, shifting from 
smoking to NRT during pregnancy could reduce the risk of adverse infant health outcomes 
known to be caused by smoking. A recent systematic review and meta-analysis provides 
evidence that the nicotine exposure from standard-dose NRT is lower than the levels seen with 
smoking.209 Moreover, if NRT were found to increase the likelihood of long-term cessation after 
pregnancy, reduced exposure to second-hand smoke during infancy and childhood would further 
increase the health benefits. Recent evidence of child health benefits from 2-year followup on the 
largest NRT trial highlight the importance of further research. In the absence of clear evidence 
that NRT increases cessation in pregnancy, however, it is encouraging that behavioral counseling 
interventions alone are effective for some women. 
 
For behavioral and NRT interventions, an effort to identify and enroll more representative 
samples of women into trials is needed to ensure intervention effects are observed in less select 
populations, or to simply report clearly on the characteristics of women approached who 
declined participation. Others have noted the importance of qualitative and observational 
research to understand why adherence to NRT in pregnancy is low.210 The effects of smoking 
cessation interventions on perinatal health outcomes are not recorded uniformly, and future 
behavioral trials should collect a comprehensive set of key outcomes, similar to those provided 
in the most recent, larger NRT trials. Well-powered trials of behavioral therapies that show 
promise for strong effects could serve to make important contributions to maternal and child 
health. Although few have been conducted, trials using incentives to aid smoking cessation 
efforts suggest possibly strong effects, but it is unknown how long-term cessation efforts are 
affected by this kind of short-term motivation. Different interventions spanning pregnancy, the 
postpartum period, and beyond may also be beneficial and should include longer-term trials that 
combine multiple interventions in sequence and their consequences for fetal, infant, child, and 
maternal health. Unfortunately, we identified few registered studies that appear to address these 
questions (Appendix I Table 2). 
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Conclusions 
 
There is extensive evidence that confirms the effectiveness of a range of pharmacological and 
behavioral interventions, alone and in combination, for smoking cessation in adults. Though 
there has been no decline in the production, sales, or use of e-cigarettes since our previous 
review on this subject, research on the potential benefits of these devices to help adults quit 
smoking is still lacking. Furthermore, more research is desperately needed on the absolute safety 
profile of e-cigarettes and the long-term health consequences of their use among former smokers 
as well as dual users of both combustible and electronic cigarettes. There is evidence that 
behavioral interventions can help pregnant women to quit smoking in late pregnancy and into the 
postpartum period but limited evidence on the benefits and harms of pharmacotherapy in 
pregnant women.  
 
Further studies of medications and behavioral support among the general adult population are 
unlikely to yield new information that would change the direction and magnitude of effects of 
the findings of this overview of reviews. Clinicians have an array of tools to offer, refer, or 
prescribe, improving the likelihood that patients will find an acceptable option to which they can 
adhere. Continued research on the evolving landscape of available tobacco products and their 
role in helping smokers quit combustible cigarette use, along with the long-term risks associated 
with these products.  
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Table 1. U.S. Preventive Services Task Force Summary of Recommendations for Tobacco 
Cessation in Adults 
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Population Recommendation Grade 
Adults who are not pregnant The USPSTF recommends that clinicians ask all adults about 
tobacco use, advise them to stop using tobacco, and provide 
behavioral interventions and U.S. Food and Drug Administration 
(FDA)–approved pharmacotherapy for cessation to adults who use 
tobacco. 
A 
Pregnant women The USPSTF recommends that clinicians ask all pregnant women 
about tobacco use, advise them to stop using tobacco, and provide 
behavioral interventions for cessation to pregnant women who use 
tobacco. 
A 
Pregnant women The USPSTF concludes that the current evidence is insufficient to 
assess the balance of benefits and harms of pharmacotherapy 
interventions for tobacco cessation in pregnant women. 
I 
All adults, including pregnant 
women 
The USPSTF concludes that the current evidence is insufficient to 
recommend electronic nicotine delivery systems (ENDS) for tobacco 
cessation in adults, including pregnant women. The USPSTF 
recommends that clinicians direct patients who smoke tobacco to 
other cessation interventions with established effectiveness and 
safety (previously stated). 
I 
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201896 X High NRT July-2017 136  X X 
Lindson, 2019a104 X High NRT, different doses, durations, and combinations Apr-2018 63  X X 
Mills, 2010114‡ X Moderate NRT (Harms only) Nov-2009 120   X 
Howes, 202098 X High Bupropion April-2019 115  X X 
Cahill, 201685 X Moderate Varenicline May-2015 44  X X 
Agboola, 201579  Low Varenicline Sept-2013 19  X  
Sterling, 2016128  X Low Varenicline (Harms only) June-2015 38   X 
Thomas, 2015131 X High Varenicline (Harms only) May-2014 44   X 
Chang, 201587 X Moderate Varenicline + NRT Nov-2014 3  X X 
Windle, 2016140  Moderate NRT, bupropion, varenicline July-2015 123  X X 
Mills, 2014113‡ X Moderate NRT, bupropion, varenicline (Harms only) Mar-2013 63   X 




61  X  








201995 X High 
Behavioral support as an adjunct to 
pharmacotherapy June-2018 83  X  
Stead, 2013125‡ X High Physician advice Jan-2013 42 X X  
Rice, 2017119 X High Nurse support Jan-2017 59  X  
Lancaster, 2017103 X High Individual behavioral counseling May-2016 49  X  
Stead, 2017126 X Moderate Group behavioral therapy May-2016 66  X  
Lindson, 2019b 106 X High Motivational interviewing Aug-2018 37  X  
Denison, 201790  Moderate Cognitive therapy Nov-2016 21  X  
Moyo, 2018115 X Moderate Decision aids July-2017 7  X  
Livingstone-Banks, 
2019b109 X Moderate Print-based interventions Mar-2018 75  X  
Matkin, 2019110 X Moderate Telephone counseling May-2018 104  X  
Danielsson, 201489  Low Telephone- or internet-based support May-2013 74  X  
Tzelepis, 2019134 X High Real-time video counseling Aug-2019 2  X  
Palmer, 2018117  Moderate Mobile phone-based support Jan-2016 18  X  
Whittaker, 2019138 X High Mobile phone text messaging and app- Oct-2018 26  X  
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Do, 201891  Moderate Mobile phone- and Internet-based interventions Mar-2017 108  X  
McCrabb, 2019111  Moderate Internet-based interventions Sept-2017 45  X  
Taylor, 2017129 X High Internet-based interventions Aug-2016 77  X X 
Graham, 201694  Moderate Internet-based interventions Apr-2015 40  X  
Notley, 2019116 X High Incentives July-2018 33  X X 
Giles, 201493  Moderate Financial-based incentives Apr-2012 8  X  
Clair, 201988 X Moderate Biomedical risk assessment Sept-2018 20  X  
Ussher 2019135 X High Exercise May-2019 24  X  
Klinsophon, 2017102  Moderate Exercise Nov-2016 19  X  
White, 2014137‡ X High Acupuncture Oct-2013 38  X  
Barnes, 2019 82 X High Hypnotherapy July-2018 14  X X 
Boyle, 201484 X High Electronic health records support July-2014 16  X  






Lindson, 2019c105 X High Reduce-to-quit interventions Oct-2018 51  X X 
Benefits and 










pregnant persons  
(5 reviews) 
Chamberlain, 
2017185 X High 
Any behavioral support among 
pregnant persons Nov-2015 102 X X X 
Griffiths, 2018186  Moderate Digital interventions among pregnant persons May-2017 12  X  
Livingstone-Banks, 
2019a108 X Moderate 
Relapse prevention among pregnant 
persons Feb-2018 77  X  
Notley, 2019116  High Incentives among pregnant persons July-2018 10  X X 
Wilson, 2018187  Moderate Psychotherapy or incentive-based interventions July-2017 22  X  
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Wu, 2015141  Moderate Subgroup: Adults not motivated to quit  Any tobacco cessation intervention Apr-2015 14  X X 
Appolonio, 201681  High 
Subgroup: Adults with alcohol or drug 
dependence 
Any tobacco cessation intervention 
Aug-2016 34  X  
Thurgood, 2016132  High 
Subgroup: Adults with alcohol or drug 
dependence 
Any tobacco cessation intervention 
Aug-2014 17  X  
Wilson, 2017139  Moderate Subgroup: Disadvantaged persons Any behavioral support Jan-2017 24  X  
Boland, 201683  Low 
Subgroup: Disadvantaged persons 
Mobile phone- or internet-based 
support 
May-2016 13  X  
Liu, 2013107‡  Low 
Subgroup: Ethnic minorities 
Adapted interventions for ethnic 
minorities 
Apr-2013 28  X  
Subgroups 
continued 
Johnston, 201399‡  Low Subgroup: Ethnic minorities Any tobacco cessation intervention May-2012 5  X  
Carson, 201286‡  High Subgroup: Ethnic minorities Any tobacco cessation intervention April-2011 4  X X 
Schuit, 2017122  High 
Subgroup: Genetic biomarker 
differences 
NRT, bupropion, varenicline 
Aug-2016 18  X  
Khanna, 2016100  High Subgroup: Persons with SMI Advice Apr-2015 0  X  
Tsoi, 2013133‡  High Subgroup: Persons with SMI Any tobacco cessation intervention Oct-2012 34  X X 
van der Meer, 
2013136‡  Moderate 
Subgroup: Persons with SMI 
Any tobacco cessation intervention Apr-2013 49  X  
Peckham, 2017118  Moderate Subgroup: Persons with SMI Any tobacco cessation intervention Sept-2016 26  X X 
Roberts, 2016120  Moderate Subgroup: Persons with SMI NRT, bupropion, varenicline Dec-2014 14  X X 
Ahmed, 201880  Moderate Subgroup: Persons with SMI Varenicline July-2018 4  X X 
Kishi, 2015101  Moderate Subgroup: Persons with SMI Varenicline (Harms only) Aug-2014 7   X 
Wu, 2016142  High Subgroup: Persons with SMI Varenicline (Harms only) Sept-2015 8   X 
Smith, 2016124  Low Subgroup: Sex differences NRT, bupropion, varenicline Dec-2015 28  X  
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McKee, 2016112  High Subgroup: Sex differences Varenicline Dec-2014 16  X  
Ebbert, 201592  High Subgroup: Smokeless tobacco users Any tobacco cessation intervention June-2015 34  X X 
Schwartz, 2016123  Low Subgroup: Smokeless tobacco users Varenicline Feb-2014 3  X X 
* Primary reviews are those that represented the most current and/or applicable evidence within each population and intervention subgroup and served as the basis for the main 
findings of this report.  
† Review credibility assessed using AMSTAR-273 
‡ Included in previous USPSTF review and has not been updated 
 
Abbreviations: KQ = key question; NRT = Nicotine replacement therapy; SMI = severe mental illness
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Any form, dose, 
duration, schedule of 
NRT use 
Any other forms, 
doses, durations, 






due to AEs 
























due to AEs 



















































Usual care Smoking 
abstinence; 
AEs 











Any form of NRT 
(lozenge, skin patch, 
gum, nasal spray, 
inhaler, and tablet) 
Placebo or 
standard of care 
AEs Any Any RCTs and 
observation
al studies 
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Population Specific intervention 
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NRT, bupropion, or 
varenicline 












Varenicline at the 
maximum dosage (1 






















































access to a smoking 
cessation 
pharmacotherapy 





than the control 
condition 
Any behavioral 

























Physician advice Physician advice to 
stop smoking. 
Advice was defined 
as verbal 
instructions from the 




whether or not 
information was 
provided about the 






Any ≥6 months RCTs or 
quasi-RCTs 
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Population Specific intervention 
Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 











Nurse support Nursing intervention, 
defined as the 
provision of advice, 
counseling, and/or 
strategies to help 
people quit smoking. 
Advice was defined 
as verbal 
instructions from the 




the harmful effects 
of smoking 



















consisting of a face-
to-face encounter 
between a smoker 
and a counselor 
trained in assisting 
smoking cessation, 
including counseling 


















therapy in which 
smokers met for 
scheduled meetings 
and received some 
form of behavioral 





delivered over at 














≥6 months RCTs 
Table 3. Inclusion Criteria of Primary Systematic Reviews on the Effectiveness and Adverse Events of Tobacco Cessation Interventions, 
by Intervention Type 






Population Specific intervention 
Intervention 






















any length or 
intensity, another 









Adult smokers Decision aids Any tool a 
healthcare provider 
used to share with 
and inform people 
about treatment 
options, including 




without the use 
of shared 
decision-making 
and decision aids 
Smoking 
abstinence 
























as any manual or 
program designed to 
be used by 
individuals to assist 
a quit attempt that is 
not aided by health 
professions, 




















counselling alone, in 
combination with 
self-help materials, 




















Any intervention that 
could be considered 
predominantly a 
mobile phone-based 
program (such as 
NR Smoking 
abstinence 
NR ≥6 months RCTs or 
quasi-RCT 
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Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 




















either the primary 
intervention or an 
adjunct to other 
smoking cessation 
treatments. Studies 
were eligible where 





technology or other 






Tango (or both) or 
























NR ≥6 months RCTs 
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Adult smokers Incentives Incentive schemes, 
lotteries, raffles, and 
contingent or non-
contingent 






























assessment in which 
a physical 
measurement, such 




plaque imaging, or 
genetic testing was 
used to increase 
smoking cessation 
Any control 













wishing to quit, 
or recent 
quitters 
Exercise Interventions aimed 
at increasing 
exercise, either 
alone or as an 





program alone or 





NR ≥6 months RCTs 
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Population Specific intervention 
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of any age 













known spots that 


















wishing to stop 
smoking 
Hypnotherapy Hypnotherapy for 
smoking cessation 

























patients who use 
tobacco, either by 
directly prompting 
clinician, clinic, or 
health system action 
or by measuring and 











≥6 months RCTs or 
observation
al studies 
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Population Specific intervention 
Intervention 









any age who 
are receiving 







by organizations to 
integrate the 
identification of all 






behavioral, or both) 
into the routine 





















or support for 
participants to 
reduce the number 
of cigarettes with an 


















any age who 


























NR ≥6 months RCTs or 
quasi-RCTs 
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Population Specific intervention 
Intervention 






































a primary aim of the 




















interventions, as well 
as dissemination 
trials 

























* Includes studies among smokers and non-smokers 
† Excludes studies of counseling delivered by doctors or nurses and studies of motivational interviewing as those studies are captured in other reviews 
‡ Interventions that include at least one of the following six system-level strategies: 1. Implement a system for identifying smokers and documenting tobacco-use status in every 
clinic and hospital; 2. Provide education, resources and feedback to promote provider interventions; 3. Dedicate staff to provide smoking cessation treatment and assess its delivery 
in staff performance evaluations; 4. Promote hospital policies that support and provide smoking cessation services; 5. Provide evidence-based tobacco dependence treatments (both 
counselling and pharmacotherapy); 6. Reimburse providers for the delivery of effective tobacco dependence treatments and include these services among their defined duties. 
 
Abbreviations: AE = Adverse event; mg = milligram; MI = motivational interviewing; NR = Not reported; NRT = Nicotine replacement therapy; RCT = Randomized controlled 
trial; SAE = Serious adverse event
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Tobacco Cessation Interventions, by Intervention Type 
Tobacco Cessation in Adults 105  Kaiser Permanente EPC 























53 15 – 
5887 
31 – 65 11 – 31 Typical intervention involved multiple contacts 
with a specialist cessation adviser or 
counsellor, with most participants using some 
pharmacotherapy and receiving multiple 
contacts. However, there was a great deal of 
variation, including some interventions which 
involved making pharmacotherapy and 
behavioral components available to a large 
population in which take-up of treatment was 
low, or providing a brief intervention to all 
participants and offering stepped care for 
those willing to set a quit date. One 
intervention was delivered entirely by mail or 
prerecorded phone messages, using an 
expert system for tailoring contact and two by 
telephone counselling alone. All others 
included some face-to-face contact but 
additional sessions was sometimes provided 
by telephone. More than half the trials (n = 
28, 53%) offered between four and eight 
sessions and a quarter (n = 13) over eight 
sessions. The modal category for contact 
time was 91 to 300 minutes (n = 22, 42%), 
with 17 (32%) offering between 31 and 90 
minutes and eight (15%) over 300 minutes. 
We categorized interventions according to the 
maximum planned contact unless session 
duration was not described, so the typical 
time per participant would have been smaller, 
even in studies where the take-up of 







































NRT 136 50 – 
8000 
15 – 62 8 – 38 Most trials comparing nicotine gum to control 
provided the 2 mg dose. A few provided 4 mg 
gum to more highly addicted smokers, and 
two used only the 4 mg dose. In three trials 
the physician offered nicotine gum but 
participants 
did not necessarily accept or use it. In one 
trial participants self-selected 2 mg or 4 mg 
doses. The treatment period was typically two 













specified as a 
GP but mostly 
not specified) 
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Intervention description Setting Providers 
to 12 months. Some trials did not specify how 
long the gum was available. Many of the trials 
included a variable period of dose tapering, 
but most encouraged participants to be gum-
free by six to 12 months. In nicotine patch 
trials the usual maximum daily dose was 15 
mg for a 16-hour patch, or 21 mg for a 24-
hour patch. Thirty-two studies used a 24-hour 
formulation and nine a 16-hour product; the 
rest did not specify. One study offered, 
among other dosage options, a 52.5 mg/24-
hour patch. The minimum duration of therapy 
ranged from three weeks, to three months. 
There are eight studies of nicotine sublingual 
tablets or lozenges. Three used 2 mg 
sublingual tablets. One used a 1 mg nicotine 
lozenge. One used 2 mg or 4 mg lozenges 
according to dependence level based on 
manufacturers’ instructions , and one used 2 
mg or 4 mg based on participants’ time to first 
cigarette of the day (TTFC); smokers whose 
TTFC was more than 30 minutes were 
randomized to 2 mg lozenges or placebo , 
whilst smokers with a TTFC less than 30 




Centers,  and 
recruited people 
with cardiac 












hospital in- or 
outpatients, 











(OTC) use of 
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most of whom 
had volunteered 
in response to 
media 
advertisements, 















17 – 38 Trials addressed a range of questions relating 
to the effectiveness of different types and 
uses of NRT. The variations on NRT use 
















to a lung health 







(k=1), a number 
of studies used 
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115 5-8144 16 – 57 5 – 48 Details of interventions not synthesized.  
 
 
Bupropion vs. control (k=46) 
Comparing different bupropion doses (k=3) 
Bupropion as an adjunct to NRT vs. NRT 
(k=16) 
Bupropion as an adjunct to varenicline vs. 
varenicline (k=6) 
Bupropion vs. NRT (k=10) 
Bupropion vs. varenicline (k=10 trials) 
Bupropion vs. nortriptyline (k=3) 











































Cahill, 201685 Varenicline 44 32 – 
8144 
38 – 57 NR 33 studies used the standard 12-week 
regiment of varenicline, routinely titrating the 
first week up to the recommended daily dose 
of 1 mg twice a day; 3 trials compared 
different dosage arms of varenicline against a 
placebo arm; 1 trial in non-responders 
regulated dosage up to the target quit date 
(day 21) to a maximum of 5 mg a day; 1 
allowed participants to regulate their own 
dosage throughout the treatment phase; 5 
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Intervention description Setting Providers 
and provided a 12-week course, reducing the 
dosage as a weaning process; 2 trials 
provided an 8-week course, one of which 
progressively reduced the dosage at the end 
of treatment; 1 trial gave a 24-week course of 
NRT, tailored to the level of nicotine 
dependency, and matched to the duration of 
the placebo and varenicline arms of the trial; 
5 trials used Bupropion SR at 150 mg twice a 









NR One study administered trial patch two weeks 
before the Target Quit Date (TQD), while the 
other two studies started patch use on the 
TQD. Two studies used a 15 mg/16 hours 
patch, while the other used a 21 mg/24 hours 
patch. The use of varenicline was similar 
among the studies: All started at 0.5 mg per 
day one week before TQD, with increase to 2 
g/day on TQD, and continued for 12 weeks. 
One study tapered the dose of varenicline on 
the 13th week. All studies provided concurrent 








10 40 – 
928 
32- 49 NR The interventions typically provided 
information on the rationale for, and 
emphasized the importance of, adherence to 
medication, and aided participants in 
developing strategies to overcome problems 
and barriers to maintaining adherence. As 
such, they included a combination of two 
intervention strategies: a) instruction for 
patients on medication use or b) counselling 
about smoking, and the value of medication 
in overcoming addiction. 
Clinic settings 











Mills, 2010114 NRT (Harms 
only) 






NR 21 – 35 Details of interventions not synthesized.  
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NRT combination (k=35) 
*59 RCTs included co-interventions  
Counseling (k=20) 
Behavioral or psychological treatment (k=19) 
Advice (k=12) 
Education (k=3) 
Additional NRT/placebo (k=4) 






NRT combination (k=8) 
*Majority of observational studies included 
co-interventions 
Counseling (k=12) 
Behavior/behavior modification (k=3) 
Education (k=3) 
Self-help booklet (k=1) 




63 32 – 
3,296 
NR 17 – 31 Details of interventions not synthesized. 
 
NRT vs. placebo (k=19)  
Bupropion vs. placebo (k=27)   
Varenicline vs. placebo (k=18) 
High-dose NRT vs. placebo (k=1) 
Combination NRT vs. control (k=1)  
Bupropion vs. varenicline (k=2) 
Bupropion vs. NRT (k=3)  






44 9 – 
1210 



















The most common dose of varenicline was 1 
mg twice daily, with some studies in which 
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Intervention description Setting Providers 
treatment with varenicline ranged from 1 to 
52 weeks, with the majority of studies treating 






an adjunct to 
pharmacoth
erapy 
83 30 – 
4614 
17 – 61 21.2 NRT was offered in the majority of studies, 
with 41 providing nicotine patch only. Most 
provided a supply of NRT for between eight 
and 12 weeks. Eight studies used nicotine 
gum only, one used sublingual tablets and 
three did not specify the type. Five studies 
offered patch and/or gum. Seven studies 
provided bupropion alone, one provided 
nortriptyline alone and four provided 
varenicline alone. Three studies offered a 
choice of pharmacotherapy; NRT or 
bupropion, or NRT, bupropion, or varenicline. 
Three studies provided combination therapy 
of both NRT and bupropion. The intensity of 
the behavioral support, in both the number of 
sessions and their duration, was very varied 
for both intervention and control conditions. In 
seven trials, there was no counselling contact 
for the controls. In 30 studies, the control 
arms had between one and three contacts 
(which could be face-to-face or by telephone) 
and most of these had a total contact duration 
of between four and 30 minutes. In 34 
studies, the control group was scheduled to 
receive between four and eight contacts, with 
all except eight involving a total contact 
duration of over 90 minutes. Twelve studies 
offered over eight contacts for the controls. 
Typically, the intervention involved only a little 
more contact than the control, so that the 
most intensive interventions were compared 
with more intensive control conditions. In five 
trials, the intervention consisted of between 
one and three sessions, with a total duration 
of 31 to 90 minutes. Forty-five studies tested 
interventions of between four and eight 
sessions, about half of which were in the 91- 
to 300-minute-duration category. The 
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Intervention description Setting Providers 
remaining 32 studies offered more than eight 
sessions, typically providing over 300 minutes 







42 60 – 
3,215 
NR 13 – 25 The definition of what constituted ’advice’ 
varied considerably. In one study participants 
were asked whether they smoked and were 
given a leaflet if they wanted to stop. The 
control group were not asked about their 
smoking status until followup. In all other 
studies the advice included a verbal ’stop 
smoking’ message. This verbal advice was 
supplemented by provision of some sort of 
printed ’stop smoking’ material (27 studies), 
or additional advice from a support health 
worker or referral to a cessation clinic or both. 
Four studies described the physician 
intervention as behavioral counselling with a 
stop-smoking aim. One study compared 
motivational consulting (based on information 
from theoretical models) with simple advice. 
In two studies the smoker was encouraged to 
make a signed contract to quit. One study 
provided an incentive (a telephone card) to 
those who successfully quit. Three studies 
included an intervention which involved a 
demonstration of the participant’s pulmonary 
function), or expired air carbon monoxide. 
One study, using a cluster design, compared 
information and a letter alone to advice from 
a pediatrician to mothers of babies attending 
well-baby clinics with a view to reducing 
exposure of the children to passive smoke. 
One study used a computer-generated 
tailored report to assist with cessation, and 
another study compared brief advice to 
computer-generated tailored letters and to no 
intervention. One study compared brief 
advice, tailored letters and the combination of 
both. It only contributed to the direct 
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Intervention description Setting Providers 
Rice, 2017119 Nurse 
support 




12 – 23 Nine studies examined a smoking cessation 
intervention as a component of multiple risk 
factor reduction interventions in adults with 
cardiovascular disease; 36 interventions were 
considered high-intensity (i.e., initial contact 
lasted more than 10 minutes, there were 
additional materials or strategies or both, 
other than simple leaflets, and usually 
participants had more than one follow-up 
contact and 7 were considered low intensity 
(i.e., advice was provided with or without a 
leaflet during a single consultation lasting 10 
minutes or less, with up to one follow-up 
visit). Eleven studies compared two different 
interventions including a nursing intervention, 
testing additional components or different 
intensities of the intervention. 
Recruited from 





















49 39 – 
2095 
24 – 63 8 – 29 Counselling interventions typically included 
the following components: review of a 
participant’s smoking history and motivation 
to quit, help in the identification of high-risk 
situations, and the generation of problem-
solving strategies to deal with such situations. 
Counsellors may also have provided non-
specific support and encouragement. Some 
studies provided additional components such 

























66 45 – 
2720 
21 – 61 13 – 32 Most programs used between six and eight 
sessions, with the first few sessions devoted 
to discussion of motivation for quitting, health 
benefits, and strategies for planning a quit 
attempt. Specific components at this stage 
may include signing a contract to quit, or 
making a public declaration, and nicotine 
fading (changing the type of cigarette smoked 
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Intervention description Setting Providers 
also keep records of the number of cigarettes 
smoked and the triggers for smoking (self-
monitoring). Part of the group process also 
includes discussion and sharing of 
experiences and problems (intra-treatment 
social support). Participants may also be 
instructed on ways to seek appropriate 
support from friends, colleagues and family 
(extra-treatment social support). A range of 
other problem-solving skills may also be 
introduced, including identifying high-risk 
situations for relapse, generating solutions 
and discussing or rehearsing responses. 
Some programs incorporate more specific 
components intended to help manage poor 













37 56 – 
4614 
15 – 63 2 – 30 All of the studies included in this review made 
explicit reference to using MI principles 
defined by Miller and Rollnick. Most studies 
merely specified that the intervention was 
carried out according to established MI 
techniques, rather than providing a more 
detailed description of counselling content. MI 
was conducted in one to 12 sessions, with 
the total duration of MI ranging from five to 
315 minutes across studies. MI was delivered 
in face-to-face sessions in 17 of the 37 
studies; in another 12 studies, the counselling 
was delivered in a combination of face-to-
face and telephone sessions, usually with an 
initial session or sessions conducted face-to-
face, followed by follow-up counselling over 
the phone. Six studies provided counselling 
over the phone only; a further study had an 
MI intervention group that received calls and 
text messages based on CBT and MI and 
another MI group that received text 
messages only, and a final study provided MI 
counselling for adolescents in an online 
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Intervention description Setting Providers 
offered or recommended the use of 
pharmacotherapy for smoking cessation to 
all, or a subset of participants. 
Moyo, 2018115 Decision 
aids 
7 8 – 
1014 
NR NR Only two decision aids were delivered directly 
by a healthcare provider. The other studies all 
evaluated a decision aid where provider 
follow-up was optional based on the 
participant’s decision after use of the aid. The 
decision aids in all of the included studies 
were used at a single time point and included 
web- or computer-based aids, videos, print 












75 40 – 
6697 
34 – 57* 15 – 32 Thirty-four of the included studies compared 
standard self-help materials with no 
intervention or provided standard materials as 
an adjunct to advice. The other studies 
compared targeted or tailored self-help 
methods or compared other variations of 
programs. Some studies used multiple 
interventions, testing the effects of different 
types of information or of increasing amounts 
of material. Studies of self-help materials 
were carried out in a range of settings. Some 
studies provided the materials without face-
to-face contact or any additional motivating 
strategy. Some studies tested the use of 
materials for people who had called quitlines 
(self-help materials were the main form of 
support offered) or the use of materials as an 
adjunct to counselling. In healthcare settings, 
studies more frequently provided self-help 
materials as an adjunct to brief advice to quit. 
Some studies described as testing self-help 
materials included relatively high levels of 
face-to-face support, although less than 
informal counselling programs. Most studies 
did not specify an interest in quitting as a 
selection criterion. The content and format of 
the self-help programs varied. The most 
frequently used materials were the American 
Studies of self-
help materials 
were carried out 
in a range of 
settings 
NR 
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Intervention description Setting Providers 
Lung Association (ALA) cessation manual: 
Freedom from Smoking in 20 days, and the 
maintenance manual: A Lifetime of Freedom 
from Smoking. Most other programs were not 
named or described fully. Materials have 
tended to become more complex over time 
and to incorporate more techniques from 
behavior therapy approaches. Most recent 
studies have used computerized expert 
systems to provide tailored materials judged 
to be relevant to the characteristics of each 
smoker, using baseline data. We specified 
that materials should contain a structured 











Most of the studies were trials of proactive 
calls from a counsellor, or from an automated 
interactive voice response system (IVR). Only 
five assessed interventions that did not 
involve a counsellor contacting a participant. 
Some studies included participants who had 
called helplines that provide smoking 
counselling (quitlines). Other studies included 
people who had not called quitlines, but 
received calls from counsellors or other 
healthcare providers. 
Some studies provided telephone counselling 
alone, but many others provided telephone 
counselling along with minimal support such 
as self-help leaflets, or more active support 
such as face-to-face counselling, or with stop-
smoking medication. The number of calls 
offered ranged from a single call to 12 calls. 
Some studies only recruited people trying to 
stop smoking, while others offered support 
even to those not actively trying to stop. The 
number, duration and content of the 
telephone calls was variable. The potential 
number of calls ranged from one to 12 and in 
some studies was flexible. The duration of the 
calls also varied; 10 to 20 minutes was 
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Intervention description Setting Providers 
longer. The call schedule could be spaced 
over weeks or months. We grouped trials into 
three broad categories: trials of interventions 
for smokers who contacted a helpline; trials 
assessing the effect of providing access to a 
helpline; and trials that offered support 
proactively in other settings. There are 10 
trials that do not fit into any of these 







26 49-8000 18.2-57 14.5 All studies tested automated text messaging 
interventions. Eighteen studies used text 
messaging (SMS) as a central component of 
the intervention. One study sent text 
messages containing links to theoretically 
driven video messages from ‘ordinary’ role 
models coping with quitting. Several studies 
paired text messages with in-person visits or 
assessments. The text message interventions 
varied in length from one week to five weeks, 
six weeks, eight weeks, three months, and six 
months, or were variable. Eight studies did 
not state that text messages were tailored to 
the individual. In other studies using text 
messages, the degree of individual tailoring 
varied. One study tailored messages to 
include first name, quit date, top three 
reasons for quitting, money saved by quitting, 
and use of quit-smoking medications. Two 
studies tailored messages to the stage of 
readiness to quit. Another study’s program 
could be interacted with by reporting changes 
in smoking behavior (e.g. a quit attempt, 
relapse), so that appropriate stage-specific 
messages could be sent. One study tailored 
their intervention text messages to contain 
advice and encouragement tailored to 
participants’ current quit status (preparing to 
quit, first week of the quit attempt, second 
week of attempt etc.). Two studies tailored 
the messages to information collected at 
baseline about the individual. One study 
Community NR 
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Intervention description Setting Providers 
individually tailored messages using 24 items 
from the iQuit questionnaire and information 
on smoking status at three and seven weeks. 
Another study matched participant 
characteristics to messages by keyword to 
create an individualized program. One study’s 
participants selected the role model from 
whom they wished to receive messages. A 
number of text messaging interventions 
included interactive components such as the 
ability to text for more support in the instance 
of cravings or lapses, an optional Quit Buddy, 
a Quit support network, polls and quizzes, 
regular checking in on smoking status, and 
one study included some degree of choice. 
Participants received offers of support via a 
personalized tailored Internet program, a text 
message program, both programs, a choice 








17.0 Both studies delivered real-time video 
counselling for smoking cessation individually 
and not in a group format. In one study, the 
video counselling intervention consisted of 
eight sessions, while in the other study the 
intervention comprised four sessions. The 
length of the video treatment was eight weeks 
in both studies. One study used 10- to 30-
minute video sessions, while the other study 
did not report video session duration. One 
study delivered the real-time video 
counselling intervention via 
videoconferencing equipment located at 
primary care clinics, so participants were 
required to travel to receive video 
counselling, while the other study delivered 
the video counselling intervention via 
software installed on the participants’ own 
smartphones. One study delivered the video 
counselling intervention between 2009 and 
2011 and the other study between 2016 and 
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Intervention description Setting Providers 
video counselling intervention with a 
telephone counselling intervention for 
smoking cessation, and delivered the 
telephone counselling interventions directly to 
participants via their own telephones. The 
intended number and timing of sessions, 
length of treatment and duration of sessions 
in the telephone counselling interventions 
were identical to those of the video 
counselling interventions delivered in each 
study. One study based the counselling 
content for both the video counselling and 
telephone counselling interventions on a 
behavioral therapy foundation, guided by 
Bandura’s Social Cognitive Theory and, the 
other study on a combination of motivational 
interviewing and CBT. A tobacco treatment 
specialist and a trained graduate student 
delivered the counselling in one study, and 
trained counsellors delivered the counselling 
in the other. One study provided all 
participants with nicotine patches. The other 
study provided information about the 
cessation medications covered by 
participants’ insurance plan or public 
assistance program, and study staff assisted 
income-eligible participants with no insurance 
coverage to apply for cessation medications 
from the pharmacy assistance programs of 






77 66 – 
12,000 
16 – 63 NR Range of interventions provided, from a very 
low intensity intervention providing a list of 
websites for smoking cessation, to highly 
intensive interventions consisting of Internet-, 
email- and mobile phone-delivered 
components. Tailored Internet interventions 
differed in the amount of tailoring, from a 
bulletin board facility, a multimedia 
component, tailored and personalized access 
to very high depth tailored stories and highly 
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also included counselling or support from 
nurses, peer coaches or tobacco treatment 
specialists. Other trials also incorporated 
online social networks, such as Facebook, 
Twitter, and WeChat, and online forums, chat 
rooms, and support groups. Two 
interventions were very distinct from the rest. 
In addition to brief smoking advice, one study 
used an Internet-based three-dimensional 
face age progression simulation software 
package to create a stream of aged images 
of faces from a standard digital photograph. 
The resulting aged image was adjusted to 
compare how the participant aged as a 
smoker versus as a non-smoker. In one 
study, the authors used an online version of 
the approach-avoidance task, where 
participants used the computer mouse to pull 
(i.e. approach, leading to an enlarged picture) 
or push (i.e. avoid, leading to a reduced 
picture) neutral or smoking-related pictures. 
We also identified nine trials of lifestyle 
interventions that included a smoking 
cessation component. These interventions 
included content on a range of topics, 
including diet and healthy eating, physical 
activity and fitness, alcohol and drug use, 
sexual behavior, unpleasant sexual 
experiences, bullying, mental health, patient-








8 – 26 Approximately half of studies offered cash for 
abstinence (contingent rewards), or monetary 
incentives in the form of vouchers. Four 
studies used entry into a prize drawing 
alongside a guaranteed reward. Two studies 
used self-deposited money as the reward 
incentive and a further four studies used a 
combination of deposit arms with cash 
rewards or mixed-rewards arms for 
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Intervention description Setting Providers 
included more complex payment schedules, 
especially with a ’reset’ option, meaning that 
a non-abstinent biochemically confirmed 
outcome at any time point would reset the 
escalating schedule of reinforcement to a 
lower level, thus reinforcing continued 
abstinence. 
Clair, 201988 Biomedical 
risk 
assessment 






One included study tested two interventions: 
the intervention was feedback about genetic 
susceptibility combined with CO 
measurement, which could either be 
compared to a control group of CO 
measurement alone, or to a control group 
without biomarker feedback, thereby testing 
the combination of the two interventions.) Out 
of the 21 interventions, five tested feedback 
on smoking exposure, each measuring the 
effect of exhaled CO measurements. Five 
studies tested feedback on smoking-related 
disease risk; of these, four tested feedback 
about genetic susceptibility to cancer, and 
one tested feedback about genetic 
susceptibility to Crohn’s disease. Eleven 
studies assessed feedback on smoking-
related harm: four tested the combination of 
exhaled CO measurement and spirometry; 
five tested the effect of spirometry alone, or 
with the addition of feedback on lung age; two 
tested the effect of undergoing an 
ultrasonography of carotid arteries (and 
femoral arteries for one study) with 
photographic demonstration of atherosclerotic 












Physician (k=5)  



















Exercise 24 20 - 
2318 
28 - 59 16.76 - 
32 
Most of the trials employed supervised, 
group-based cardiovascular-type exercise 
supplemented by a home-based exercise 
program and combined with a multi-session 
cognitive behavioral smoking cessation 
program. The comparator in most cases was 
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Intervention description Setting Providers 
cessation program alone. 
White, 
2014137 
Acupuncture 38 18 - 651 NR NR All acupuncture studies used a traditional 
approach to acupuncture in choosing points 
nominated as specific for smoking cessation. 
Five studies used facial acupuncture and ten 
used auricular acupuncture alone. All but 
three of these used some form of continuous 
stimulation, either needle or pressure device. 
Eight studies combined body and auricular 
acupuncture. Three used continuous 
stimulation with either indwelling needles or 
seeds. One study used facial, body, 
indwelling, and sham auricular acupuncture in 
different groups. Five studies used 
acupressure alone, three studies used laser; 
three studies investigated electrostimulation 
given over the mastoid bone; and four studies 
gave electrostimulation to the ear (one also 






14 20 – 
360 
30 – 40 20 – 24 The studies varied in the method of hypnotic 
induction used, number of hypnotherapy 
sessions, and duration of hypnotic 
treatments. The number of hypnotherapy 
sessions varied from a single session to up to 
8 sessions and the total duration of hypnosis 
ranged from 30 min to 9 hrs. Seven studies 
provided hypnotherapy in a group format. 
NR NR 




16 NA NA NR 6 RCTs: In each of these studies treatment 
conditions tested an electronic health record 
(EHR) with enhancements intended to 
facilitate the provider interaction with a 
smoker patient. One study provided 
intervention clinics with additional tools within 
the EHR and clinical staff were reminded to 
use them. In one, the enhancement was 
based on information in an existing EHR. 
Clinical staff (physicians and medical 
assistants) in the intervention clinics received 
feedback reports on their use of the existing 









Table 4. Descriptive Characteristics of Included Studies Within the Primary Reviews on the Effectiveness and Adverse Events of 
Tobacco Cessation Interventions, by Intervention Type 
Tobacco Cessation in Adults 123  Kaiser Permanente EPC 















Intervention description Setting Providers 
also provided additional tools for clinical staff 
in the EHR system with some restrictions on 
use of the tools by the control clinics. The 
dental study created text boxes or scripts 
within the intervention clinic dental record. 
The scripts served as language the dental 
providers could use based on patient-specific 
information obtained during the dental 
encounter. In the other studies, the 
intervention clinics were able to link patients 
through the EHR to a telephone quitline, and 
the quitline proactively called the patient. 
Other studies: Of the other ten studies, three 
used a control condition or comparison clinic. 
In one study, the comparison clinic was a 
paper records-based clinic without an 
electronic health record. Another study used 
four control clinics, two were based on usual 
care and two had access to a new electronic 
health record vital sign screen but were 
provided no training or support on the use of 
the screen. One study randomly assigned 
patients in one clinic to either intervention or 
usual care based on their family medical 
record number. The seven additional studies 
measured outcomes before and after the 
introduction of an enhancement to an existing 
electronic health record, without any 
comparison group. One study was conducted 
in a family practice clinic and a pulmonary 
specialty clinic within the same health 
system. Another study was conducted in a 
single primary care clinic. One study studied 
the intervention in a single hospital. Two 
other studies each involved 3 clinics, and 
another study studied one large health 
system with 18 primary care clinics. Two 
studies involved retrospective cohorts. 
Followup: There was wide variation in the 
type and length of follow-up across the 
studies. For example, one study made 
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Intervention description Setting Providers 
telephone contact with dental patients a few 
days after a dental visit to measure 
intervention effects but no other follow-up 
was conducted. One study collected follow-up 
data through a patient survey about two 
weeks after a medical care visit during an 
eight month study period. One study collected 
data during a three-month period, and 
another study collected 12 month outcome 
data. One study followed patients to 19 
months. Another study provided data one 
year before and one year after the 
intervention. One study examined outcomes 
four months before and after implementation. 
Another study followed a cohort for eight 
months. One study included patients with two 
or more visits during a six-month post 
intervention period. Another study collected 
outcome data from electronic records 6 






7 1980 - 
66516 
30 - 64 NR All studies included system-level 
interventions that involved identifying all 
smokers, training staff, and providing free 
evidence-based treatment (i.e., NRT or other 
pharmacotherapy). Five of the included 
studies also implemented organizational 
policies to improve access to cessation 
interventions (e.g., referrals). All included 
studies provided clinicians with training 

























11 - 31 Reduction methods varied greatly: some 
studies simply asked participants to reduce 
the amount they smokers whereas others 
provided detailed instructions or suggestions 
on how to do so, including a goal number of 
cpd, gradually increasing time between 
cigarettes, increasing time in the morning 
before first cigarette, reducing scenario-
specific smoking, or replacing cigarette 
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77 11 - 
18010 
19 - 60 10.2 - 
29.9 
Pharm interventions consisted of varenicline, 
rimonabant, NRT, and bupropion; behavioral 
interventions consisted of brief interventions 
(phone calls, mailings, written pamphlets), 
pharm in conjunction with behavioral support, 
a 50-minute in person training session, self-















































6 - 18 Interventions: 
Smoking cessation interventions 
implemented during pregnancy differ 
substantially in their intensity, their duration, 
and the people involved in their 
implementation. In 57/106 study arms the 










staff involved in 
routine 
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Intervention description Setting Providers 
intervention was coded as a single 
intervention, therefore the ’main intervention 
strategy’ most accurately reflects the type of 
intervention. However, in 36 study arms the 
intervention was coded as ’multiple’, where 
other components of the intervention were 
offered to all women. In 12 studies the 
intervention was coded as ’tailored’ whereby 
different intervention components were 
offered and tailored to women’s needs. Of the 
56 study arms coded as counselling, most 
involved face-to-face contact, using a variety 
of strategies either alone or in combination 
(such as motivational interviewing, cognitive 
behavioral therapy, stages of change). Four 
trials with the main intervention strategy 
coded as counselling included a lottery 
chance for women who reported quitting; nine 
included support from peers and/or partners 
with three of these including support for 
partners to quit. The duration and frequency 
of the intervention also varied considerably 
and has generally increased over time. 
Twenty of the interventions involved 
telephone counselling and in five of these 
studies all counselling was provided via 
telephone, and one had only brief additional 
face-to-face contact. Thirty-eight study arms 
included self-help manuals as part of the 
intervention, and in 27 study arms there was 
a brief introduction to the manuals (less than 
five minutes) and the intervention was 
therefore coded as counselling, with 
sensitivity analysis conducted to assess the 
independent effect of these studies. In 10 
study arms the intervention involved use of a 
video; 11 study arms included use of 
computers in the intervention. Studies using 
tools or technology where there was no clear 
personal contact were coded as health 







studies), and in 
70 study arms 
the intervention 
was provided by 
dedicated 
research project 
staff (coded as 
efficacy 
studies), with 11 
coded as 
unclear or not 
applicable as 
dissemination 




or provided by 
use of other 
materials (e.g. 
mail-outs). 
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Intervention description Setting Providers 
messaging; audiotape; and computer. Three 
other studies that reported the intervention 
consisted of advice to quit only, either in 
person or by post were coded as health 
education. Among all 120 study arms with 
and without outcomes: six dissemination trials 
were identified, carried out in Australia, the 
US, and Europe. Three trials reported only 
dissemination outcomes, and not the primary 
outcomes of abstinence in late pregnancy, 
therefore outcomes not able to be included in 
the meta-analysis are reported in Table 1. 
Nine studies (with 12 study arms) were 
cluster-randomized at service level, providing 
an indication of implementation under routine 
care conditions; while four studies were 
cluster-randomized at provider level.  
 
Comparisons: 
Women in the control arms in 56 of 106 study 
arms with primary outcome data received 
’usual care’ in relation to smoking cessation, 
which generally included information about 
the risks of smoking and advice to quit. In 44 
study arms the comparison group received 
some kind of ’less intensive’ intervention, 
which included studies where a dedicated 
research team consistently provided what 
they considered to be ’usual care’ for women 
in the comparison group. In six study arms 
the comparison group received an ’alternative 
intervention’, which was categorized as 
having the same intensity (duration and 
frequency) as the intervention group, 
providing a comparison as close to a 
’placebo-controlled trial as is feasible for 
psychosocial interventions, to assess the 
independent effect of the intervention 
component). One was a counselling 
intervention using cognitive behavioral 
therapy compared with traditional health 
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Intervention description Setting Providers 
education, one compared two types of text 
messaging strategies, and four compared 
provision of incentives, contingent or not 
contingent on smoking status. As expected, 
the intensity of both interventions and 
controls has increased over time, as indicated 
by the change in frequency and duration of 
contact during the interventions. In many 
cases the comparison/control group was 
described as receiving ’usual care’ without 
specifying further what constituted usual 
practice (at a particular time and in a 
particular setting) with respect to advice and 
assistance. 
*1 trial ~47% mean age <30; 1 trial ~62% fell between ages 20-39; 1 trial ~44% were >50 
†Evidence for general (non-pregnant) adults only 
 
Abbreviations: BL = Baseline; CBT = Cognitive behavioral therapy; CO = Carbon monoxide; CPD = Cigarettes per day; GP = General practitioner; HIV = Human 
immunodeficiency virus; HMO = Health maintenance organization; mg = milligram; MI = Motivational interviewing; NR = Not reported; NRT = Nicotine replacement therapy; 
RCT = Randomized controlled trial; SAMe = S-adenosyl-L-methionine; SMS = Short message service; TTFC = Time to first cigarette of the day; WIC = Women, infants, and 
children
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events CG N 
CG quit 
rate‡ 









Brief advice or 




NRT, any form Placebo or no drug 133 64,640 5574 32,918 16.9% 3315 31,722 10.5% 1.55 (1.49, 1.61) 39% 
NRT, gum Placebo or no drug 56 22,581 1732 10,596 16.3% 1196 11,985 10.0% 1.49 (1.40, 1.60) 40% 
NRT, patch Placebo or no drug 51 25,754 2160 13,773 15.7% 1131 11,981 9.4% 1.64 (1.53, 1.75) 24% 
NRT, inhaler Placebo or no drug 4 976 84 490 17.1% 44 486 9.1% 1.90 (1.36, 2.67) 0% 
NRT, intranasal 
spray 
Placebo or no 
drug 4 887 107 448 23.9% 52 439 11.8% 2.02 (1.49, 2.73) 0% 
NRT, tablets Placebo or no drug 8 4439 488 2326 20.9% 273 2113 12.9% 1.52 (1.32, 1.74) 71% 
NRT, participant's 
choice 
Placebo or no 
drug 7 8288 793 4179 19.0% 569 4109 13.8% 1.37 (1.25, 1.52) 42% 
Lindson, 
2019a104  NRT combination NRT single form 14 11,356 881 5218 16.9% 852 6138 13.9% 1.25 (1.15, 1.36) 4% 
Howes, 
202098 Bupropion 
Placebo or no 
drug 46 17,866 1846 9714 19.0% 900 8152 11.0% 1.64 (1.52, 1.77) 15% 
Cahill, 
201685 Varenicline Placebo 27 12,625 1695 6632 25.6% 668 5993 11.1% 2.24 (2.06, 2.43) 60% 
Hughes, 
2014211 Nortriptyline Placebo 6 975 96 480 20.0% 49 495 9.9% 2.03 (1.48, 2.78) 16% 
Howes, 
202098 Bupropion NRT, any form 10 9230 681 3563 19.1% 987 4667 21.1% 0.99 (0.91, 1.09) 18% 
Howes, 
202098 Bupropion Varenicline 6 6286 474 3096 15.3% 677 3190 21.2% 0.71 (0.64, 0.79) 0% 
Cahill, 











therapy as an 
adjunct to 
pharmacotherapy 
Pharmacotherapy 65 23,331 2291 11,630 19.5% 2006 11,701 17.1% 1.15 (1.08, 1.22) 8% 
Stead, 
2013125 Physician advice Usual care 26 22,239 1008 12,583 8.0% 462 9656 4.8% 1.76 (1.58, 1.96) 40% 
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CG quit 
rate‡ 






























12 4167 399 2134 18.7% 306 2033 15.1% 1.07 (0.85, 1.36) 47% 
Moyo, 












No self-help 32 28,451 983 11,114 8.8% 794 13,337 6.0% 1.06 (0.95. 1.19) 25% 
Print-based, non-
tailored self-help 
materials with no 
face-to-face 
contact 

















Control (various) 65 41,233 2924 21,001 13.9% 2229 20,232 11.0% 1.25 (1.15, 1.35) 52% 
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CG quit 
rate‡ 








Usual care of 
minimal 
intervention 


















Self-help or usual 
care 8 6786 516 4020 12.8% 356 2766 12.9% 1.15 (1.01, 1.30) 58% 
Notley, 
2019116 Incentives 








Usual care or 
minimal 
intervention 




Usual care or 
minimal 
intervention 




Usual care or 
minimal 
intervention 
11 3314 239 1646 14.5% 195 1668 11.7% 1.26 (0.99, 1.61) 34% 
Ussher, 




acupuncture 9 1892 122 997 12.2% 97 895 10.8% 1.10 (0.86, 1.40) 23% 
Barnes, 
201982 Hypnotherapy 
No intervention or 
other cessation 
intervention 





No change to 
















interventions 22 9219 584 4922 11.9% 528 4297 12.3% 1.01 (0.87, 1.17) 29% 
*Used strictest available criteria to define abstinence (i.e., continuous, sustained, or prolonged abstinence was preferred over point prevalence abstinence and biochemically 
validated rates were used where available).  
†Each review pooled data from the longest followup time point reported at 6 or more months followup 
Table 5. Smoking Cessation* Results at 6 or More Months† (KQ 2) From Reviews of Tobacco Cessation Interventions Among Adults, by 
Type of Intervention 
Tobacco Cessation in Adults 132  Kaiser Permanente EPC 
‡Weighted average quit rates 
§ Includes 3 RCTs and 4 quasi-experimental studies 
‖ No meta-analysis performed. Six studies reported the effects of the intervention on smoking cessation. Only one study reported a statistically significant benefit of the use of a 
decision aid versus usual care on smoking cessation at 6 months. 
¶ Irrespective of level of contact and support common to control group # No overall meta-analysis performed given variation in intensity of the hypnotherapy tested, little 
information on the hypnotherapy used, and large variation in control conditions  
** In general, this review found no evidence of a difference in smoking cessation at 6 months’ or greater followup among trials that compared hypnotherapy versus no intervention 
or other smoking cessation interventions. In the group with the most trials, there was no overall difference in smoking cessation rates between groups at 6 months or greater 
followup between hypnotherapy versus attention-matched smoking cessation behavioral intervention (RR 1.21 [95% CI, 0.91 to 1.61]; k=6; n=957; I2=36%) 
††Includes 7 RCTs and 9 non-randomized observational studies  
‡‡ Only one RCT (n=9589) reported effects on smoking cessation, as captured in the EHR, and found that more intervention vs. control clinic smokers quit (5.3% vs. 1.9%, 
p<0.001). The remaining studies focused on the impact of EHR changes on smoking support actions by clinicians, clinics, and health systems with most studies reporting improved 
processes following EHR-facilitated intervention implementation. 
§§ Four trials (n=7142) reported the effects of the intervention on smoking cessation finding mixed results. Across all 7 trials, there was mixed evidence on secondary process 
outcomes such as documentation of smoking status and provision of counseling. 
 
Abbreviations: CG = control group; CI = confidence interval; EHR = electronic health record; I2 = percentage of the variability in effect estimates that is due to heterogeneity 
rather than sampling error; IG = intervention group; N = number; RCT = randomized controlled trial; RR = risk ratio
Table 6. Study and Population Characteristics for Evidence on the Use of Electronic Cigarettes for Tobacco Cessation, Sorted by KQ 







Country N rand 
Brief population 













657  Age ≥18 years, had 
smoked >10 CPD for 
at least the past year. 
 
Wanted to stop 
smoking  
 
E-cig with 16 mg nicotine/ml plus 
behavioral support (voluntary 
quitline) for 13 weeks  
 
Device: Elusion e-cigarette with 
nicotine solution cartridges 
CG1: NRT patch (21 mg 
nicotine per 24 hours) 
plus behavioral support  
 
CG2: E-cig device with 
placebo (nicotine-free) 
cartridges plus 






• Tobacco use 








Italy 300  Ages 18–70 years, 
had smoked >10 CPD 




attempting to quit 
smoking or wishing to 
do so in the next 30 
days  
 
IG1: E-cig with 7.2 mg nicotine 
cartridges used at will for 12 weeks 
 
IG2: E-cig with 7.2 mg nicotine 
cartridges used at will for 6 weeks 
and E-cig with 5.4 mg nicotine 
cartridges for 6 weeks  
 
Followed for 1 year (8 visits total) 
 




















No strong preference 
to use or not to use 
NRT or e-cigarettes 
E-cig starter pack with 30 ml bottle 
of tobacco-flavored e-liquid with 18 
mg nicotine per ml (follow up use of 
any flavor or strength of e-liquid 
purchased by participant) for 1 year 
plus 4 weeks of behavioral support 
 
Device: One Kit (Aspire) and One 
Kit 2016 (Innokin) 
NRT (any kind, any 










• Tobacco use 






Korea 150 Male adults over 18 
years, smoked at 
least 10 CPD during 
preceding year, had 
smoked for at least 3 
years, and were 




E-cig (0.01 mg/mL), distributed in 




in 12-wk supply plus 50-
min edu support 
• Tobacco 
abstinence at 
9 to 24 weeks 
• Adverse 
events 
Table 6. Study and Population Characteristics for Evidence on the Use of Electronic Cigarettes for Tobacco Cessation, Sorted by KQ 







Country N rand 
Brief population 









1124 Ages ≥18 years, 
current tobacco 
smokers (any amount) 
 
Currently motivated to 
quit but no use of 
cessation products in 
the past year 
21 mg, 24-hour nicotine patches + 
E-cigarette starter kit with a 14 -
week supply of 18 mg/mL e-liquid 
plus 6 weeks of withdrawal-oriented 
behavioral support 
 
Device: eVOD (2nd gen) 
CG1: 21 mg, 24-hour 
nicotine patches + E-
cigarette starter kit with 
a 14 -week supply of no 





CG2: 21 mg, 24-hour 
nicotine patch for 14 









• Tobacco use 
outcomes at 6 
months 
Included for 







Age ≥18 years, 
current smoker of ≥5 
CPD for 1 year.  
 
At least some concern 
for health effects of 
smoking 
 
IG1: E-cig with 16mg nicotine 
cartridges used at will for 3 weeks 
 
IG2: E-cig with 24mg nicotine 
cartridges used at will for 3 weeks 
 
After 3-week sampling period, both 
groups followed for 3 months (3 
follow up visits) 
 
Device: BluCig and BluPlus+ 
No intervention 




















t 2:  
40 
 
Age 21 - 65 years, 5-
30 CPD for at least 
one year.  
 
Established smokers 
not trying to stop 
smoking or with quit 
intentions 
Cohort 1: E-cig with 2.7 mg nicotine 
capsules (menthol or tobacco 
flavor) for 12 weeks 
 
Cohort 2: E-cig with 2.7 mg nicotine 
capsules (menthol or tobacco 
flavor) with 12 weeks plus 1-week 
inpatient confinement at onset 
 
Device: E-cig Prototype from 
Fontem Ventures B.V. 









plus 1-week inpatient 









Aged ≥55 years; 
smoked ≥10 CPD for 
the past 10 years.  
 
IG1: E-cig with 8mg/mL nicotine 
concentration - no more than 1 mL 
of consumption per day – plus 
behavioral counseling for 3 months 




Table 6. Study and Population Characteristics for Evidence on the Use of Electronic Cigarettes for Tobacco Cessation, Sorted by KQ 







Country N rand 
Brief population 
description Intervention/ Exposure Comparison 
Outcomes of 
interest 
High motivation to 
stop smoking  
IG2: E-cig-like device with nicotine 
free capsules plus behavioral 
counseling for 3 months 
 
Device: VP5 electronic cigarette 
and use 










Age 21–35 years, 
smoked ≥ 10 CPD.  
 
Interested in reducing 
cigarette consumption 
E-cig (disposable, 4.5% nicotine) for 
3 weeks plus behavioral counseling 
to reduce CPD 
 
Device: NJOY and King Bold 
Placebo E-cig device 
plus behavioral 







outcomes at 3 
weeks (not 
abstracted)† 
*Defined as no more than 5 conventional cigarettes in the 2 weeks after a subject’s target quit date. 
†Tobacco abstinence outcomes only included for followup ≥6 months 
 
Abbreviations:  ASCEND = A Study of Cessation using Electronic Nicotine Devices; CG = control group; CPD = cigarettes per day; ECLAT = EffiCiency and safety of an 
eLectronic cigAreTte; eCO = expired carbon monoxide; E-cig = electronic cigarette; edu = education; KQ = key question; IG = intervention group; rand = randomized; TEC = 
Trial of Electronic Cigarettes
Table 7. Smoking Cessation Results at 6 or More Months (KQ 2) for Electronic Cigarettes for Tobacco Cessation, by Author 








































RR 1.26  
(0.68, 2.34) 
IG: 38% (8/21)  





6  21 289 7.3% 3 73 4.1% RR 1.77  
(0.54, 5.77)  


















































6  155 438 35.4% 112 446 25.1% RR 1.40  
(1.14, 1.72) 
 







12 79 438 18.1% 44 446 9.9% RR 1.83  
(1.30, 2.58) 
 
ARR§ 1.75  
(1.24, 2.46) 
IG: 80% (63/79) 





















6 35 500 7.0% 20 499 4.0% RR 1.75 
(1.02, 2.98); 
p=0.038‖ 
Use of both 
patch and e-cig 







Use of e-cig 
only at 6 
months:#  
Table 7. Smoking Cessation Results at 6 or More Months (KQ 2) for Electronic Cigarettes for Tobacco Cessation, by Author 




































6 35 500 7.0% 3 125 2.0% RR 2.92 
(0.91, 9.33); 
p=0.05⁋ 
Use of e-cig 







Use of patch 







Note(s): Abstinence measured as continuous abstinence and biochemically validated with expired carbon monoxide for all trials. 
* Not applicable due to low (0) event rate. 
† Group A=7.2 mg E-cig for 12 weeks; Group B=7.2 mg E-cig for 6 weeks and 5.4 mg E-cig for 6 weeks. 
‡ Calculated 
§Adjusted for trial center, marital status, age at smoking initiation, and score on the Fagerström Test for Cigarette Dependence. 
‖ Results based on self-reported quit rate were consistent with 18% of the patch plus nicotine e-cig group versus 11% of the patch plus nicotine-free e-cig group reporting 
abstinence at 6 months (RR 1.68 [95% CI, 1.22 to 2.30]; p=0.001). Per protocol sensitivity analyses also showed a statistically significant difference (p=0.020). 
⁋ In contrast, results based on self-reported quit rate showed statistically significantly greater abstinence at 6 months (RR 2.23 [95% CI, 1.19 to 4.15]; p=0.007) among patch plus 
nicotine e-cig group (18%) versus patches-only group (8%).The per protocol sensitivity analysis did not yield a statistically significant difference (p=0.11). 
# Adherence was defined as having used the allocated product since last contact. Findings relate to allocated treatment only, in participants for whom adherence data were 
available. Data does not include adherence in those who crossed-over to an e-cig or those who changed their type of e-cig. 
 
Abbreviations: ARR=adjusted relative risk; CG = control group; eCO=expired carbon monoxide; E-cig = electronic cigarette; IG = intervention group; mg = milligram(s); MI = 
mental illness; mo = months; NA = not applicable; NR = not reported;  NRT = nicotine replacement therapy; RR = relative risk
Table 8. Adverse Event Results (KQ 3) From Systematic Reviews on Pharmacotherapy, by Comparison 
Tobacco Cessation in Adults 138  Kaiser Permanente EPC 






estimate (95% CI) I2 










- 15 11,074 165 6673 62 4401 OR=1.88 (1.37, 2.57) 10% 
Mills, 2014113 CV AEs - 21 11,647 202 6329 83 5318 RR=1.81 (1.35, 2.43) 0% 
Major CV AEs - 21 11,647 12 6329 7 5318 RR=1.38 (0.58, 3.26) 0% 
NRT: combo vs. 
single 






SAEs - 3 1173 NR NR NR NR NA* NA 
NRT, patch: high 
vs. low dose Lindson, 2019
104 SAEs - 2 1023 7 511 1 512 RR=5.01 (0.87, 28.82) 0% 
NRT: combo vs. 
single 
Lindson, 2019104 Withdrawals due 
to treatment 
- 7 3070 18 1169 23 1901 RR=1.12 (0.57, 2.20) 73% 
NRT, fast-acting 
vs. NRT, patch Lindson, 2019
104 Withdrawals due to treatment 
- 4 1482 18 740 4 742 RR=4.23 (1.54, 11.63) 0% 
NRT, patch: high 
vs. low dose Lindson, 2019
104 Withdrawals due to treatment 












Howes, 202098 SAEs - 21 10,625 139 6094 107 4531 RR=1.16 (0.90, 1.48) 0% 
Bupropion vs. 
placebo 
Mills, 2014113 CV AEs - 27 10,402 50 5947 42 4455 RR=1.03 (0.71, 1.50) 0% 
Major CV AEs - 27 10,402 15 5947 25 4455 RR=0.57 (0.31, 1.04) 0% 
Roberts, 2016120 Discontinuation 
due to AEs 
SMI 6 201 6 114 6 87 OR=0.93 (0.18, 4.74) NR 
Bupropion + 
NRT vs. placebo 
+ NRT 
Roberts, 2016120 Discontinuation 
due to AEs 
SMI 1 51 2 25 2 26 OR=1.04 (0.14, 8.04) NR 
Table 8. Adverse Event Results (KQ 3) From Systematic Reviews on Pharmacotherapy, by Comparison 
Tobacco Cessation in Adults 139  Kaiser Permanente EPC 






estimate (95% CI) I2 
Varenicline vs. 
placebo 
Cahill, 201685 SAEs - 29 15,370 269 8125 196 7245 RR=1.25 (1.04, 1.49) 0% 




- 23 8955 41 4920 43 4035 RR=0.82 (0.57, 1.19) 0% 
Mills, 2014113 Major CV AEs - 18 9072 22 5469 13 3603 RR=1.44 (0.73, 2.83) 0% 
CV AEs - 18 9072 63 5469 41 3603 RR=1.24 (0.85, 1.81) 0% 
Sterling, 2016128 Mortality - 38 12,706 11 7213 9 5493 RR=0.88 (0.50, 1.52) 0% 
CV SAEs - 38 12,706 57 7213 43 5493 RR=1.03 (0.72, 1.49) 0% 
Thomas, 2015131 Suicide and 
attempted 
suicide 
- 31 9830 4 5352 2 4478 OR=1.67 (0.33, 8.57) 10.3% 
Suicidal ideation - 20 2990 15 799 18 2191 OR=0.58 (0.28, 1.20) 0% 
Depression 
events 
- 31 9843 163 5356 139 4487 OR=0.96 (0.75, 1.22) 0% 
Mortality - 36 10,647 13 5760 11 4887 OR=1.05 (0.47, 2.38) 38.7% 
Roberts, 2016120 Discontinuation 
due to AEs 
- 5 222 14 131 7 91 OR=1.29 (0.47, 3.56) NR 
Kishi, 2014101 Discontinuation 
due to all causes 
- 7 439 NR NR NR NR RR=0.92 (0.54, 1.56) 44% 
Discontinuation 
due to side 
effects 
- 7 439 NR NR NR NR RR=1.29 (0.67, 2.48) 0% 
Thomas, 2015131 Suicidal ideation Age 40 
years and 
older 









27 9318 144 5050 129 4268 OR=0.99 (0.77, 1.27) 0% 
Suicidal ideation Age less 
than 40 
years 






4 525 19 306 10 219 OR=0.96 (0.75, 1.22) 0% 
Suicidal ideation 50% male 14 3660 12 2097 14 1563 OR=0.57 (0.25, 1.30) 0% 
Table 8. Adverse Event Results (KQ 3) From Systematic Reviews on Pharmacotherapy, by Comparison 
Tobacco Cessation in Adults 140  Kaiser Permanente EPC 












24 8145 93 4406 89 3739 OR=0.89 (0.66, 1.21) 0% 
Suicidal ideation Less than 
50% male 





7 9843 163 5356 139 4487 OR=0.96 (0.75, 1.22) 0% 
Suicidal ideation 50% White 
or greater 





24 8083 117 4378 95 3705 OR=0.95 (0.72, 1.27) 1.6% 
Suicidal ideation Less than 
50% White 





4 931 27 562 27 369 OR=0.82 (0.43, 1.58) 0% 
Suicidal ideation 100% with 
psychiatric 
illness 






5 809 31 416 20 393 OR=1.49 (0.84, 2.65) 0% 
Suicidal ideation 10%-20% 
psychiatric 
illness 






1 192 6 86 14 106 OR=0.51 (0.20, 1.30) NA 
Suicidal ideation No 
psychiatric 
illness 
14 3989 4 2297 6 1692 OR=0.34 (0.09, 1.29) 0% 
Varenicline vs. 
placebo 





25 8842 126 4854 105 3988 OR=0.91 (0.69, 1.21) 0% 
Wu, 2016142 Suicidal ideation SMI 4 203 9 124 5 79 RR=1.06 (0.40, 2.82) 0% 
Depressed mood SMI 3 198 13 121 6 77 RR=1.45 (0.45, 1.64) 28.6% 
Anxiety SMI 4 267 13 155 14 112 RR=0.77 (0.28, 2.17) 33.7% 
Kishi, 2014101 Discontinuation 
due to side 
effects 
SMI 7 439 NR NR NR NR RR=1.29 (0.67, 2.48) 0% 
Table 8. Adverse Event Results (KQ 3) From Systematic Reviews on Pharmacotherapy, by Comparison 
Tobacco Cessation in Adults 141  Kaiser Permanente EPC 






estimate (95% CI) I2 
Discontinuation 
due to all causes 
SMI 7 439 NR NR NR NR RR=0.92 (0.54, 1.56) 44% 
Roberts, 2016120 Discontinuation 
due to AEs 
SMI 5 222 14 131 7 91 OR=1.29 (0.47, 3.56) NR 
Schwartz, 
2015123 
Mood disorders Smokeless 
tobacco 
users 
3 744 6 370 9 374 RR=0.71 (0.26, 1.90) 0% 
* None of the comparisons based on duration of patch therapy showed a clinically or statistically significant difference for SAEs. 
† Not pooled due to substantial heterogeneity; no significant differences in either study 
 
Abbreviations: AE = Adverse event; CG = Control group; CI = Confidence interval; CV = Cardiovascular; IG = Intervention group; NA = Not applicable; NR = Not reported; 
NRT = Nicotine replacement therapy; OR = Odds ratio; RR = Risk ratio; SAE = Serious adverse event; SMI = Serious mental illness
Table 9. Adverse Event Results (KQ 3) for Primary Evidence on the Use of Electronic Cigarettes for Tobacco Cessation 























































IRR 1.05  


















































3 NR 200 NR NR 100 NR NR 
No difference 











12 NR 200 NR NR 100 NR NR  
No difference 













12 0 200 NA 0 100 NA NA 
Table 9. Adverse Event Results (KQ 3) for Primary Evidence on the Use of Electronic Cigarettes for Tobacco Cessation 




























General AE Rate E-cig 
(16mg) 









22 NR NR 
E-cig 
(24mg) 



















8 22 36% NR 
E-cig 
(24mg) 





General AE Rate E-cig 
(2.7 mg) 
















No Intv 3  5 events 
among 5 
persons 
306 NR 0 102 0 NR 
Respiratory Coughing E-cig 
(2.7 mg) 
No Intv 3  52 306 17.0% 8 102 7.8% NR 
Sore Throat E-cig 
(2.7 mg) 





No Intv 3  34 306 11.1% 8 102 7.8% NR 
Neurologic Headache E-cig 
(2.7 mg) 
No Intv 3  145 306 47.4% 34 102 33.3% NR 
Table 9. Adverse Event Results (KQ 3) for Primary Evidence on the Use of Electronic Cigarettes for Tobacco Cessation 



































12 27 438 6.2% 22 446 4.9% NR 




12  97 314 30.8% 111 279 39.8% RR 0.8  







12  66 314 21.0% 64 279 22.9% RR 0.9  





12 74 314 23.5% 59 279 21.1% RR 1.1  














12 79 314 25.1% 103 279 36.9% RR 0.7  







12 137 438 31.3% 169 446 37.9% RR 0.83  







12 279 438 63.7% 303 446 67.9% RR 0.94  




General Number of 
participants 
with any AE 





















3 4 70 5.7% 2 70 2.9% NR 


















3 0 70 NA 0 70 NA NR 
















E-cig Placebo 3 wk 11 50 22.5% 5 49 10.3% p=0.14 
Table 9. Adverse Event Results (KQ 3) for Primary Evidence on the Use of Electronic Cigarettes for Tobacco Cessation 



























































500 4.0% 4 events 
in 3 
people 
125 3.0% IRR 0.86 
(0.29, 2.53); 
p=0.78 
Note: No intervention control groups continued smoking with conventional cigarettes and received no behavioral intervention component.  
* Defined as any event requiring unscheduled visits to a physician or hospitalization. 
‡Group A=7.2 mg E-cig for 12 weeks; Group B=7.2 mg E-cig for 6 weeks and 5.4 mg E-cig for 6 weeks. 
 
Abbreviations: AE = adverse event; E-cig = electronic cigarette; Intv = intervention; NA = not applicable; NR = not reported; NRT = nicotine replacement therapy; RR = relative 
risk
Table 10. Primary Evidence on Pharmacotherapy Among Pregnant Individuals: Study and Population Characteristics, by Study Design 


















France 403 Pregnant smokers aged 18 
years or more with a 
gestational age of between 
nine and 20 weeks of 
amenorrhea who smoked at 
least five cigarettes a day 
and were motivated to quit 
NRT patch (10-15 mg/day) plus 





• Low BW 
• Mean BW 









UK 1051 Pregnant smokers aged 
16–50 years, between 12 
and 24 weeks’ pregnant, 
smoked at least 10 
cigarettes per day before 
pregnancy and continued to 
smoke at least five 
cigarettes per day 






• Low BW 
• Mean BW 







US 194 Pregnant smokers, ≤26 
weeks pregnant and 
smoked ≥ 1 cpd 






• Low BW 
• Mean BW 







US 154 Pregnant women who 
smoked ≥5 cigarettes daily 






• Low BW 
• Mean BW 







Denmark 250 Pregnant smokers, who 
smoked ≥ 10 cigarettes 
after first trimester 
NRT patch (15 mg/ 16 hrs for 8 






• Low BW 
• Mean BW 
• Preterm birth 
• Tobacco 
cessation 
Table 10. Primary Evidence on Pharmacotherapy Among Pregnant Individuals: Study and Population Characteristics, by Study Design 






















US 52 Pregnant African American 
smokers ≥18 years, and 
<30 weeks pregnant with a 
desire to quit 
Trans-dermal NRT, 14-21mg for 10 
wks depending on cpd. 
Maximum of six clinical visits. 
Behavioral 
counseling 
• Low BW 
• Mean BW 








US 181 Pregnant smokers between 
13 and 25 weeks pregnant 
and smoked ≥ 5 CPD 
Choice of NRT from patch (7-12mg/ 
16hrs depending on cpd), gum 
(2mg/each cpd), or lozenge (2mg/ 





• Low BW 
• Mean BW 
• Preterm birth 
• Tobacco 
cessation 






Canada 1288 Quebec Pregnancy Cohort 
data 
Bupropion alone with or without 















UK 220,630 Cohort of singleton 
pregnancies ending in live 
or stillbirth between 2001 
and 2012 from The Health 
Improvement Network UK 
general practice database 













885,185 Nationwide health and 
administrative registry data 
for cohort including 
live‐born and stillborn 
infants from 1 May 2007 to 
31 December 2012 



















• Fetal growth 
restriction 
• Preterm birth 








Smoking MUMS cohort; 
perinatal and 
pharmaceutical dispensing 





• Any adverse 
perinatal 
event* 
Table 10. Primary Evidence on Pharmacotherapy Among Pregnant Individuals: Study and Population Characteristics, by Study Design 
















data for all deliveries in 
New South Wales and 
Western Australia between 
2003 and 2012. 













Denmark 84,803 Danish National Birth 
Cohort data 
NRT (mother) plus smoker (father) or 






• ADHD (child) 
* Any adverse perinatal event was a composite of 10 individual birth outcomes, including preterm birth (< 37 weeks, medically indicated or spontaneous), small for gestational age 
(SGA, birthweight < 10th percentile sex- and gestational age-specific), Apgar score at 5 min < 7, admission to neonatal special care (NSC), severe neonatal morbidity 
complications, emergency caesarean section, severe maternal morbidity complications, preterm premature rupture of membranes (PPROM), placental abruption and perinatal death 
(stillbirth or 28-day neonatal death). 
 
Abbreviations: ADHD = attention deficit/hyperactivity disorder; BW = birth weight; CG = control group; CPD = cigarettes per day; hr = hour(s); IG = intervention group; NRT = 
nicotine replacement therapy; mg = milligram(s); RCT = randomized controlled trial; UK = United Kingdom; US = United States
Table 11. Summary of Perinatal Health Outcome Results (KQ 1) of Behavioral Tobacco Cessation Interventions Among Pregnant 
Women, Psychosocial Interventions vs. Any Control (Within Chamberlain, 2017 Review185) 
Tobacco Cessation in Adults 149  Kaiser Permanente EPC 
Outcome Intervention  K Total n analyzed 
IG 
events IG n 
CG 




Any psychosocial intervention 26 11,338 3207.5 5756 3146.9 5582 MD=55.60 (29.82, 81.38) 31% 
Counseling 14 5471 3080.7 2698 3744.9 2733 MD=42.17 (11.79, 72.55) 0% 
Health education 2 1172 3330.9 685 3255.1 487 MD=27.35 (-53.88, 108.58) 33% 
Feedback 2 3006 3418.7 1501 3221.1 1505 MD=79.43 (-53.05, 211.91) 58% 
Incentives 6 834 3150.5 451 3088.2 383 MD=114.01 (63.91, 164.11)  23% 
Social support 1 142 3100 67 3072 75 MD=28.0 (-152.48, 208.48) NA 
Exercise 1 713 3132.4 354 3146.8 359 MD=-14.40 (-104.15, 75.35) NA 
Low 
birthweight 
Any psychosocial intervention 18 9402 355 4743 429 4659 0.83 (0.72, 0.94) 0% 
Counseling 8 7339 151 2090 200 2249 0.83 (0.68, 1.01) 0% 
Health education 2 1172 40 685 37 487 0.87 (0.49, 1.55) 40% 
Feedback 1 2848 99 1423 121 1425 0.82 (0.63, 1.06) NA 
Incentives 5 252 22 156 21 96 0.63 (0.37, 1.08) 0% 
Social support 1 79 5 36 6 43 1.00 (0.33, 2.99) NA 
Exercise 1 712 38 353 44 359 0.88 (0.58, 1.32) NA 
Preterm births Any psychosocial intervention 19 9222 337 4705 363 4517 0.93 (0.77, 1.11) 18% 
Counseling 8 3447 99 1672 117 1775 0.93 (0.71, 1.20) 0% 
Health education 2 1170 29 684 25 486 0.92 (0.55, 1.56) 40% 
Feedback 2 3111 115 1572 150 1539 0.60 (0.28, 1.29) 63% 
Exercise 1 704 35 356 26 348 1.32 (0.81, 2.14) NA 
Incentives 6 790 59 421 45 369 0.91 (0.52, 1.59) 33% 
Stillbirths Any psychosocial intervention 8 6170 40 3053 33 3117 1.20 (0.76, 1.90) 0% 
Counseling 5 2454 16 1197 14 1257 1.14 (0.55, 2.33) 0% 
Feedback 2 2960 22 1479 17 1481 1.28 (0.69, 2.39) 0% 
Exercise 1 756 2 377 2 379 1.01 (0.14, 7.10) NA 
* Presented as mean in grams; weighted means (g) calculated 
 
Abbreviations: CG = control group; CI = confidence intervals; IG = intervention group; MD = mean difference; NA = not applicable
Table 12. Summary of Tobacco Cessation Outcomes (KQ 2) of Behavioral Tobacco Cessation Interventions Among Pregnant Women 
(Within Chamberlain, 2017 Review185) 
Tobacco Cessation in Adults 150  Kaiser Permanente EPC 
Intervention Control K N analyzed IG IG N 
IG quit 





Any control 97 26,637 2332 14,192 16.4% 1518 12,445 12.2% 1.35 (1.23, 1.48) 44% 
Counseling Any control 51 18,276 1376 9510 14.5% 950 8766 10.8% 1.31 (1.16, 1.47) 40% 
Health 
education Any control 11 2142 195 1275 15.3% 107 867 12.3% 1.22 (0.97, 1.55) 7% 
Feedback Any control 6 859 94 513 18.3% 31 346 9.0% 1.92 (1.16, 3.17) 7% 
Incentives Any control 13 1752 222 995 22.3% 89 757 11.8% 1.88 (1.12, 3.14) 66% 
Social support Any control 14 2629 405 1409 28.7% 310 1220 25.4% 1.16 (0.96, 1.40) 23% 
Exercise Any control 1 785 30 392 7.7% 25 393 6.4% 1.20 (0.72, 2.01) NA 
Other 
(behavioral) Any control 1 194 10 98 10.2% 6 96 6.3% 1.63 (0.62, 4.32) NA 
Counseling 
Usual care 30 12,432 771 6350 12.1% 546 6082 9.0% 1.44 (1.19, 1.73) 49% 
Less intensive 
intervention 18 5657 494 2897 17.1% 368 2760 13.3% 1.25 (1.07, 1.47) 28% 
Alterative 
intervention 1 257 58 128 4.5% 51 129 4.0% 1.15 (0.86, 1.53) NA 
Health 
education 
Usual care 5 629 41 310 13.2% 25 319 7.8% 1.59 (0.99, 2.55) 0% 
Less intensive 
intervention 4 1282 116 759 15.3% 72 523 13.8% 1.20 (0.85, 1.70) 33% 
Alterative 
intervention 1 31 2 16 12.5% 1 15 6.7% 1.88 (0.19, 18.60) NA 
Feedback 
Usual care 2 355 33 198 16.70% 6 157 3.80% 4.39 (1.89, 10.21) 0% 
Less intensive 
intervention 3 439 42 276 15.2% 19 163 11.7% 1.29 (0.75, 2.20) 0% 
Incentives Usual care 5 NR NR NR NR NR NR NR NR, subtotals only NR 
Social support Less intensive intervention 7 781 102 405 25.2% 73 376 19.4% 1.21 (0.93, 1.58) 0% 
Exercise Usual care 1 785 30 392 7.7% 25 393 6.4% 1.21 (0.72, 2.01) NA 
Abbreviations: CG = control group; CI = confidence intervals; IG = intervention group; NA = not applicable; NR = not reported
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0 NA NA NA Insufficient NA 
Pharm 0 NA NA NA Insufficient NA 
Behavioral 1 review  
(1 RCT, 
n=1445) 
One trial found favorable effects on 
all-cause and coronary disease 
mortality and lung cancer incidence 
and mortality 20 years following an 
intensive behavioral intervention, 
although results were not 
statistically significant.  
NA Only one review 
reported the results of 
one intervention in men. 
Within that trial, the rate 
of smoking among 
control group 
participants declined 







One trial conducted 
among civil servant 
men aged 40-59 
years in the UK with 




place in the 1970’s. 
Electronic 
cigarettes 










Combined pharmacotherapy and 
behavioral interventions 
increased smoking quit rates by 
68-98% compared with no or 
minimal treatment (RR 1.83 [95% 







May be risk of bias due 






appear to be 
comparable in a 
range of 
populations, 
settings and types 
of interventions 
and in smokers 









as opposed to the 
use of other forms 
of tobacco, so 
results may not be 
generalizable to all 
forms of tobacco. 
Table 13. Summary of Evidence for the General Adult Population 











Other limitations Strength of evidence† Applicability 
Pharm 5 reviews 
(336 RCTs, 
n>159,000) 
NRT, bupropion, and varenicline 
significantly increased the 
chances of quitting smoking 
compared with placebo or no 
medication. Reviews suggested 
that NRT might increase smoking 
abstinence at 6 months or longer 
by 49-61% (RR 1.55 [95% CI, 
1.49 to 1.61]); bupropion by 49-
76% (RR 1.62 [95% CI, 1.49 to 
1.76]); and varenicline by 106-
143% (RR 2.24 [95% CI, 2.06 to 
2.43]). 
 
Absolute quit differences 
averaged 6.4% for NRT; 8.2% for 
bupropion, and 14.5% for 
varenicline. 
 
Using a combination of NRT 
products increased quitting more 
than the use of a single NRT 
product (RR 1.25 [95% CI, 1.15 to 
1.36]). 
 
Direct comparisons between 
drugs suggested that varenicline 
may be superior to NRT and 
bupropion in achieving smoking 








publication bias but 
unlikely that the 
presence of additional 
studies with lower 
relative risks would 
alter the findings given 
large number of studies 
and consistency in 
findings for each type 







appear to be 
comparable in a 
range of 
populations, 
settings and types 
of interventions 
and in smokers 









as opposed to the 
use of other forms 
of tobacco, so 
results may not be 
generalizable to all 
forms of tobacco. 
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Other limitations Strength of evidence† Applicability 
 Behavioral 20 reviews 
(830 RCTs, 
n>500,000) 
Health provider advice and 
counseling, individual counseling, 
group-based interventions, 
telephone counseling, mobile 
phone-based interventions, 
tailored and interactive internet-
based interventions, and 
incentives showed significant 
increased smoking cessation at 6 
or more months relative to 
controls (15% to 88%). For 
example, for physician advice 
versus minimal controls or usual 
care: RR 1.76 (95% CI, 1.58 to 
1.96). 
 
Providing more intense adjunctive 
behavioral support to smokers 
receiving pharmacotherapy may 
increase cessation by 8-22% (RR 
1.15 [95% CI, 1.08 to 1.22]). 
 
Evidence on the use of 
motivational interviewing, 
decision aids, print-based, 
nontailored self-help materials, 
real-time video counseling, 
biomedical risk assessment, 
exercise, complementary and 
alternative therapies, and system-
level interventions was limited 







Individual trials may be 
represented in more 
than one review and/or 
meta-analysis.  
 
Indication of possible 
publication bias for 













appear to be 
comparable in a 
range of 
populations, 
settings and types 
of interventions 
and in smokers 









as opposed to the 
use of other forms 
of tobacco, so 
results may not be 
generalizable to all 
forms of tobacco. 
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Other limitations Strength of evidence† Applicability 
Relapse 
prevention 
1 review  
(77 RCTs, 
n=67,285) 
Analyses of behavioral 
interventions among abstainers 
did not detect an effect in both 
studies of assisted abstainers 
(RR 0.99 [95% CI, 0.87 to 1.13]; 
I2=56%; k=10; n=5408) and 
unaided abstainers (RR 1.06 
[95% CI, 0.96 to 1.16]; I2=1%; 
k=5; n=3561) from the general 
population. 
 
There was some evidence that 
extending varenicline could be 
beneficial in preventing relapse, 
but it was only reported by two 
studies. NRT was found to help in 
unassisted abstainers, but no 
difference was seen among those 
who achieved abstinence with 
NRT. None of the six studies that 
examined the use of bupropion to 
prevent relapse found a 




Highly variable study 

















of no benefit 
of bupropion 






may not be 
applicable to the 
general adult 
population.  
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Two trials (n=2008) found 
statistically significantly greater 
rates of smoking abstinence in 
those using e-cigarettes 
containing nicotine (with or 
without the co-use of NRT) 
compared with NRT alone or NRT 
plus non-nicotine e-cigarettes at 
6- to 12-months followup, 
although continued use of e-cigs 
remained high after the treatment 
phase. Another trial (n=300) 
found a borderline statistically 
significant higher quit rate among 
those receiving nicotine-
containing e-cigs (11%) vs no 
nicotine e-cigs (4%) at 12 months 
(p=0.04), but 27 percent of those 
who quit smoking continued to 
use e-cigarettes at 1 year. The 
remaining two trials found no 
statistically significant difference 
in biochemically verified 
abstinence at 6 months between 
those receiving e-cigs vs nicotine 





power to detect 
differences and 
differential loss to 
followup in all five trials 
(22-50%). 
 
Wide variance of 
nicotine concentrations 
in e-cig interventions 
(7.8mg vs. 18mg) 
Insufficient All five trials took 
place outside of 
the US, Korea, in 
New Zealand, 
Italy, and the UK. 
 
Two trials used 
older models of e-






wanting to quit. 
3: Harms Combined 
pharm and 
behavioral 




Pharm 15 reviews# 
 
NRT, bupropion, and varenicline 
were not associated with an 
increased risk in major CV or 
neuropsychiatric adverse events. 
NRT was associated with a 
higher rate of any CV adverse 
events largely driven by low-risk 
events, typically bradycardia and 
arrhythmia. There was no 
evidence of a difference in harms 






Many trials that report 
cessation effectiveness 
do no report AEs, 




AEs typically measured 
through passive 











with severe mental 
illness.  
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Other limitations Strength of evidence† Applicability 
those with versus without severe 
mental illness.  
underreporting. 
Behavioral 3 reviews# There was no evidence that 
behavioral tobacco cessation 
interventions are associated with 
serious adverse events.  
NA Very few reviews 













No trials reported serious AEs in 
either the intervention or control 
groups related to product use and 
no significant differences in the 
frequency of AEs among study 
groups. Coughing, nausea, throat 
irritation and sleep disruption 
were the most commonly 






power to detect 
differences and 
differential loss to 




One study did not 
report methods for AEs 
reporting. 
Insufficient The two US trials 




Two trials used 
older models of e-
cigs, one of which 
is no longer 
available, one trial 
used an e-cig that 
is not available in 
US markets, and 
one trial used a 
prototype. 
* Number of included studies reflects the number of systematic reviews designated as primary evidence for that body of evidence as well as the summed total number of included 
studies and observations from each review.  
† For our review-of-reviews method, we adopted the strength of the overall body of evidence assigned within the primary systematic review. In most cases, these grades were 
based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group definitions which consider study limitations, consistency of effect, 
imprecision, indirectness and publication bias. Where strength of evidence grades were not available, we adapted the EPC approach to assign an overall strength of evidence grade 
based on consensus discussions involving at least two reviewers.78   
‡ Some evidence of asymmetry in a funnel plot; excess of small trials detecting larger effects. However, in a sensitivity analysis, removing smaller studies did not markedly 
decrease the pooled estimate. 
§ Sensitivity analysis including only those studies judged to be a low risk of bis did not impact the pooled results for any comparison; for NRT and bupropion, the funnel plots 
showed some evidence of asymmetry. However, given the large number of trials in these reviews, this does not suggest the results would be altered significantly were smaller 
studies with lower RRs included.  
‖ Evidence from existing systematic reviews as well as the EAGLES trial indicate that adult smokers randomized to varenicline have a statistically significant higher likelihood of 
quitting smoking at 6 months compared with those randomized to NRT or bupropion. In the EAGLES trial (n=8144) 21.8% of smokers randomized to varenicline quit smoking at 
6 months compared with 15.7% randomized to NRT (OR 1.52 [95% 1.29 to 1.78]) and 16.2% randomized to bupropion (OR 1.45 [95% CI, 1.24 to 1.70]).161 
¶ Quality of the evidence differs for each specific type of intervention, but generally reflects moderate to high certainty grades. Most common reasons for downgraded the quality 
of evidence were unexplained statistical heterogeneity, several studies with high or unclear risk of bias, or inconsistency in the evidence base. 
# Total number of studies and observations not estimated 
Table 13. Summary of Evidence for the General Adult Population 
Tobacco Cessation in Adults 157  Kaiser Permanente EPC 
** Despite the relatively limited number of reviews that reported harms related to interventions, we are moderately confident that there are no serious harms related to combined 
pharmacotherapy and behavioral counseling interventions or behavioral counseling alone for tobacco cessation. 
 
Abbreviations: AE = adverse event; CI = confidence interval; CV = cardiovascular; e-cig = electronic cigarette; mg = milligrams; NA = not applicable; NRT = nicotine 
replacement therapy; pharm = pharmacotherapy; RCT = randomized controlled trial; RR = risk ratio; UK = United Kingdom; US = United States
Table 14. Summary of Evidence for Pregnant Women 
Tobacco Cessation in Adults 158  Kaiser Permanente EPC 











Pharm 7 RCTs (n=2285) 
 
 
Limited evidence of NRT 
on perinatal and child 
health benefits. Five 
placebo controlled NRT 
trials reported preterm 
births with the three 
largest trials reporting 
effects close to null and 
two reporting reduced 
risk with NRT. These five 
trials also reported 
birthweight; the two 
largest placebo-
controlled trials reported 
no difference with NRT, 
and two trials reported 
higher mean birthweights 
associated with NRT. 
The risk for low 
birthweight was lower in 
the smallest trial, and 
results were mixed but 
null for the others. 
 
Followup data from the 
largest NRT trial found 
higher rate of ‘survival 
with no impairment’ at 2 
years among children of 
women assigned to NRT 
intervention vs placebo 
(73% vs 65%; OR 1.40 
[95% CI 1.05 to 1.86]).  
 







outcomes and few 
trials of NRT 
limited statistical 
precision and 




on the women 
approached for 
participation that 
declined, and low 
participation rates. 
 




among trials which 
may affect the 
amount of time 
women were 
exposed to the 
intervention as 
well as those lost 






































and willing to 
participate in 





Behavioral 1 review (26 
RCTs, n=12,338) 
Suggestive benefit of 
behavioral interventions 
on mean birthweight 
(mean difference, 55.60 










risk of preterm 
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and low birthweight (RR 
0.83 [95% CI 0.72 to 
0.94]), vs. usual care or 
control. 
 
Uncertain evidence on 
the effect of behavioral 
interventions on preterm 
birth (RR 0.93 [95% CI, 
0.77 to 1.11]) and 
stillbirths (RR 1.20 [95% 




0 NA NA NA Insufficient NA 
2: Cessation 
outcomes 
Pharm 7 RCTs (n=2285) 
 
No statistical evidence of 
NRT efficacy for 
validated smoking 
cessation in late 
pregnancy (RR 1.11, 
95% CI 0.79 to 1.56) in 
pooled analysis of five 
placebo-controlled trials. 
Limited power, and all 
trials in the direction of 
benefit including two 
trials with no NRT control 
conditions.  
 













































Behavioral 1 review (97 
RCTs, n=26,637) 
The pooled estimate 
from 97 trials suggested 
an increased risk of 




with controls (RR 1.35 
[95% CI, 1.23 to 1.48]), 








the number of 
women who 
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when limited to the most 
common intervention 
(counseling) versus 
usual care (RR 1.44 
[95% CI 1.19 to 1.73]) 
 
Heterogeneity was 
moderate for the pooled 
effect (44%), but there 
was no definitive 
evidence of subgroup 












which may affect 
the amount of 
time women 
were exposed to 
the intervention 
as well as those 
lost to followup. 
who disclose 
smoking status 
and willing to 
participate in 







1 review (18 
RCTs, n=5545) 
No clear clear benefit on 
relapse prevention at the 
end of pregnancy (RR 
1.05 [95% CI, 0.99 to 
1.11]; k=8; n=1523; 
I2=0%) or during the 
postpartum period ( RR 
1.02 [95% CI, 0.94 to 








Low evidence of 





0 NA NA NA Insufficient NA 
KQ3: Harms Pharm 7 RCTs (n=2285) 
 
5 cohort studies 
(n=1,293,379) 
Limited evidence of 
perinatal harms from 
NRT; mixed findings on 
birth outcomes from 
trials, but most in 
direction of benefit rather 
than harm (KQ 1). Two-
year followup from one 
NRT trial did not suggest 
harms (KQ 1). No trials 







Few trials of NRT 








studies may not 




Low evidence of 
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did not indicate harms of 
major congenital 
anomalies, stillbirth, 
premature birth, or low 
birthweight associated 
with NRT, bupropion, or 
varenicline.  
differences 






Behavioral 1 review  
(13 RCTs, 
n=5831) 
There did not appear to 
be any adverse effects 
from the psychosocial 
interventions. Five of 13 
trials evaluating 
psychological impact 
reported an improvement 
in women’s 
psychological well-being 
and none reported a 

















0 NA NA NA Insufficient NA 
* Number of included studies reflects the number of systematic reviews designated as primary evidence for that body of evidence as well as the summed total number of included 
studies and observations from each review.  
† For our review-of-reviews method, we adopted the strength of the overall body of evidence assigned within the primary systematic review. In most cases, these grades were 
based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group definitions which consider study limitations, consistency of effect, 
imprecision, indirectness and publication bias. Where strength of evidence grades were not available, we adapted the EPC approach to assign an overall strength of evidence grade 
based on consensus discussions involving at least two reviewers.78   
 
Abbreviations: NA = not applicable; NRT = nicotine replacement therapy; pharm = pharmacotherapy; US = United States; vs = versus 
 
 
Appendix A. Detailed Methods 
 
Tobacco Cessation in Adults 162 Kaiser Permanente EPC 
Literature search strategies for overview of reviews: Tobacco cessation in adults 
Sources searched (2014-present):  
Agency for Healthcare Research and Quality 
Canadian Agency for Drugs and Technologies in Health 
Cochrane Database of Systematic Reviews 
Community Guide 
Database of Abstracts of Reviews of Effects 
Health Technology Assessment   
Health and Medicine Division (HMD) of the National Academies of Sciences, Engineering, and Medicine 
(formerly Institute of Medicine) 





Canadian Agency for Drugs and Technologies in Health 
Pharmacological based strategies for Smoking Cessation (2016) 
https://cadth.ca/pharmacologic-based-strategies-smoking-cessation  
 





Smoking cessation interventions for patients with severe mental illnesses: A review of clinical 




Cochrane Database of Systematic Reviews   
Issue 5 of 12, May 2019 
  
#1 tobacco:ti 1800 
#2 smoking:ti 8736 
#3 smoker*:ti 3237 
#4 smokeless:ti 167 
#5 nicotine:ti 2830 
#6 cigar*:ti 1822 
#7 (vape or vaping or vapour):ti 148 
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7 with Cochrane Library publication date Between Jan 2014 
and Dec 2019, in Cochrane Reviews, Cochrane Protocols 67 
 
NHS HTA Programme 
Pharmacological interventions for promoting smoking cessation during pregnancy 2018 [in progress] 
https://www.journalslibrary.nihr.ac.uk/programmes/sr/NIHR128783/#/  
 
Relapse prevention interventions for smoking cessation (2019) [waiting to start] 
Appendix A. Detailed Methods 
 
Tobacco Cessation in Adults 163 Kaiser Permanente EPC 
https://www.journalslibrary.nihr.ac.uk/programmes/sr/NIHR128787/#/  
 
The Filter FE Challenge: pilot trial and process evaluation of a multi-level smoking prevention 
intervention in further education settings (2017) 
https://www.journalslibrary.nihr.ac.uk/programmes/phr/134202/#/  
 
A multi-centred Trial of physical Activity assisted Reduction of Smoking (TARS) (2017) 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/1511101/#/  
 
Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS) (2015) 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/0916101/#/  
 




A randomised controlled trial to examine the efficacy of e-cigarettes compared with nicotine replacement 
therapy, when used within the UK stop smoking service (2014) [waiting to publish] 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/12167135/#/  
 
A randomised trial to increase the uptake of smoking cessation services using Personal Targeted risk 
information and Taster Sessions (2017) 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/085802/#/  
 
Barriers and facilitators to smoking cessation in pregnancy and following childbirth: literature review and 
qualitative study (2017) 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/119301/#/  
 
Exploring the uptake and use of electronic cigarettes provided to smokers accessing homeless centres: a 
feasibility study (2018) [in progress] 
https://www.journalslibrary.nihr.ac.uk/programmes/phr/174429/#/  
 




Feasibility randomised controlled trial of a smoking cessation smartphone app that delivers 'context 
aware' behavioural support in real time (2019) 
https://www.journalslibrary.nihr.ac.uk/programmes/phr/179231/#/  
 
The London Exercise And Pregnant smokers (LEAP) trial: a randomised controlled trial of physical 
activity for smoking cessation in pregnancy with an economic evaluation (2015) 
https://www.journalslibrary.nihr.ac.uk/hta/hta19840/#/abstract  
 
Nicotine preloading for smoking cessation: the Preloading RCT (2018) 
https://www.journalslibrary.nihr.ac.uk/hta/hta22410/#/abstract  
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Smoking Cessation Intervention for Severe Mental Ill Health Trial (SCIMITAR): a definitive randomised 
evaluation of a bespoke smoking cessation service (2015) 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/1113652/#/  
 
Mixed methods systematic review to identify the determinants of nicotine replacement therapy use and of 
vaping in pregnancy (2018) 
https://www.journalslibrary.nihr.ac.uk/programmes/sr/NIHR128785/#/  
 
PubMed search strategy 
 
Search Query 
#11 Search #8 OR #10 
#10 Search #7 AND #9 AND ("2014"[Date - Publication] : "3000"[Date - 
Publication]) AND English[Language] 
#9 Search (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR 
systematic literature review [ti] OR this systematic review [tw] OR pooling 
project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis 
[ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research 
review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus 
development conference [pt] OR practice guideline [pt] OR drug class reviews 
[ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health 
technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system 
rev implement rep [ta]) OR (clinical guideline [tw] AND management [tw]) OR 
((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] 
OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR 
behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation 
studies[pt] OR validation studies[pt] OR guideline [pt] OR pmcbook)) OR 
((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection 
[tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR 
exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care 
[tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR 
overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR 
handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR 
(reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) 
AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication 
[tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR 
pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR 
database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR 
scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* 
[tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR 
treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article 
[pt]) 
#8 Search #7 AND systematic[sb] AND ("2014"[Date - Publication] : "3000"[Date 
- Publication]) AND English[Language] 
#7 Search #4 NOT #6 
#6 Search ("Child"[Mesh] OR "Adolescent"[Mesh]) NOT #5 
#5 Search ("Adult"[Mesh]) AND ("Child"[Mesh] OR "Adolescent"[Mesh]) 
#4 Search #1 OR (#2 AND #3) 
Appendix A. Detailed Methods 
 
Tobacco Cessation in Adults 165 Kaiser Permanente EPC 
Search Query 
#3 Search (cessat*[tiab] OR stop*[tiab] OR quit*[tiab] OR reduce*[tiab] OR 
reduction[tiab] OR relapse*[tiab]) 
#2 Search (smoking[ti] OR smoker*[ti] OR tobacco[ti] OR nicotine[ti] OR 
cigar*[ti] OR vape[ti] OR vaping[ti] OR vapour[ti] OR smokeless[ti]) 
#1 Search "Tobacco Use Disorder"[Mesh:NoExp] OR "Smoking 
Cessation"[Mesh:NoExp] OR "Tobacco Use Cessation"[Mesh:NoExp] OR 
"Smoking/prevention and control"[Mesh] OR "Tobacco Use Cessation 
Products"[Mesh:NoExp] OR "Nicotinic Agonists"[Mesh:NoExp] OR "Tobacco, 
Smokeless"[Mesh:NoExp] OR "Nicotine Chewing Gum"[Mesh:NoExp] OR 
"Electronic Nicotine Delivery Systems"[Mesh:NoExp] OR "Smoking 
Prevention"[Mesh:NoExp] 
 
PsycINFO  <1806 to April Week 4 2019> 
  
1     exp Tobacco Smoking/ (29913) 
2     exp Smoking Cessation/ (12420) 
3     exp Smokeless Tobacco/ (792) 
4     exp Electronic Cigarettes/ (909) 
5     (smoking or smoker* or tobacco or nicotine or cigar* or vape or vaping or vapour or smokeless).ti. 
(34380) 
6     1 or 2 or 3 or 4 or 5 (39898) 
7     limit 6 to "300  adulthood <age 18 yrs and older>" (22887) 
8     limit 7 to ("0830  systematic review" or 1200 meta analysis) (95) 
9     limit 8 to (english language and yr="2014 -Current") (46) 
 
Literature search strategies for primary literature. Tobacco cessation in adults: Electronic Cigarettes 
 
Sources searched: 
Cochrane CDSR Trials, via Wiley  
PsycInfo, via Ovid 
PubMed 
Scopus 2020 and 2019 
 
Key: 
* = truncation 
ab = word in abstract 
id = keyword 
kf = keyword heading [word not phrase indexed] 
kw = keyword 
ti = word in title 
Cochrane 
Issue 6 of 12, May 2020 
 
#1 (electronic next cigarette*):ti,ab,kw 379 
#2 (e next cigarette*):ti,ab,kw 432 
#3 "electronic nicotine":ti,ab,kw 157 
#4 (e next liquid):ti,ab,kw 57 
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Tobacco Cessation in Adults 166 Kaiser Permanente EPC 
#5 (vape or vaping):ti,ab,kw 129 
#6 (vaporizer* or vapourizer*):ti,ab,kw 2042 
#7 (nicotine or tobacco or cigar*):ti,ab,kw 15956 
#8 #6 and #7 62 
#9 #1 or #2 or #3 or #4 or #5 or #8 with Publication Year from 2013 to 2020, with Cochrane Library 
publication date Between May 2019 and Dec 2020 193 
 
PsycINFO 
Datatabase: APA PsycInfo <1806 to June Week 3 2020> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Electronic Cigarettes/ (1332) 
2     electronic cigarette*.ti,ab,id. (1097) 
3     e-cigarette*.ti,ab,id. (1601) 
4     electronic nicotine.ti,ab,id. (215) 
5     e-liquid*.ti,ab,id. (114) 
6     (vape or vaping).ti,ab,id. (417) 
7     (vaporizer* or vapourizer*).ti,ab,id. (64) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (2057) 
9     limit 8 to (english language and yr="2013 -Current") (1874) 
10     (201905* or 201906* or 201907* or 201908* or 201909* or 201910* or 201911* or 201912* or 
2020*).up. (191834) 




(((((((("Electronic Nicotine Delivery Systems"[MeSH Terms:noexp] OR "Vaping"[MeSH Terms:noexp]) 
OR (((("e-cigarette"[Title/Abstract] OR "e-cigarettes"[Title/Abstract]) OR "electronic 
cigarette"[Title/Abstract]) OR "electronic cigarettes"[Title/Abstract]) OR "electronic 
nicotine"[Title/Abstract])) OR "e-liquid"[Title/Abstract]) OR ("vape"[Title/Abstract] OR 
"Vaping"[Title/Abstract])) OR (("vaporizer*"[Title/Abstract] OR "vapourizer*"[Title/Abstract]) AND 
(("nicotine"[Title/Abstract] OR "tobacco"[Title/Abstract]) OR "cigar*"[Title/Abstract]))) NOT 
("Animals"[MeSH Terms] NOT ("Animals"[MeSH Terms] AND "Humans"[MeSH Terms]))) AND 





6  #1 OR #2 OR #3 OR #4 OR #5 AND ( LIMIT-TO ( PUBYEAR , 2020) OR LIMIT-TO ( PUBYEAR , 
2019)) AND LIMIT-TO ( LANGUAGE , "English" )  
 
5 ( TITLE-ABS-KEY ( vaporizer* OR vapourizer* ) AND TITLE-ABS-KEY ( nicotine OR tobacco OR 
cigar* ) )  
 
4  TITLE-ABS-KEY (( vape OR vaping )  
  
3  TITLE-ABS-KEY ( "electronic nicotine" )  
  
2  TITLE-ABS-KEY ( "electronic cigarette*" )  
 
1  TITLE-ABS-KEY ( "e cigarette*" ) 
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Literature search strategies for primary literature. Tobacco cessation in adults: Pharmacologic 
interventions in pregnant women 
 
Sources searched: 
Cochrane Central Register of Controlled Clinical Trials, via Wiley  
MEDLINE, via Ovid  
PsycInfo, via Ovid 
PubMed, publisher-supplied  
 
Key: 
* = truncation 
$ = truncation 
ab = word in abstract 
exp = explode 
id = keyword 
kf = keyword heading [word not phrase indexed] 
kw = keyword 
sb=subset 
ti = word in title 
 
COCHRANE 
Issue 6 of 12, June 2020 
 
#1 (pregnan* or prenatal or "pre natal" or perinatal or "peri natal" or antenatal or "ante natal" or 
antepartum or "ante partum" or postnatal or "post natal" or postpartum or "post partum" or 
puerperal):ti,ab,kw 70929 
#2 nicotine:ti,ab,kw next replacement*:ti,ab,kw 1741 
#3 nicotine:ti,ab,kw near/3 (transdermal or intravenous* or patch* or gum* or spray* or inhaler* or 
lozenge*):ti,ab,kw 2338 
#4 (Nicotrol or Nicoderm or Habitrol or Prostep or Nicorette):ti,ab,kw 131 
#5 (Bupropion or Wellbutrin or Zyban or Varenicline or Chantix or Champix):ti,ab,kw 2477 
#6 pharm*:ti and (smoking or smoker* or tobacco or nicotine or cigarette*):ti,ab,kw 875 
#7 #2 or #3 or #4 or #5 or #6 6091 
#8 #1 and #7 with Publication Year from 2014 to 2020, with Cochrane Library publication date 
Between May 2019 and Dec 2020 34 
 
Medline Non-Indexed 
Database: Ovid MEDLINE(R) Epub Ahead of Print <June 19, 2020>, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations <1946 to June 19, 2020> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     Pregnancy/ (0) 
2     Pregnant women/ (0) 
3     Prenatal care/ (0) 
4     Perinatal care/ (0) 
5     Postnatal care/ (0) 
6     Postpartum period/ (0) 
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7     Peripartum period/ (0) 
8     Maternal Health Services/ (0) 
9     Pregnancy complications/ (0) 
10     Puerperal Disorders/ (0) 
11     pregnan$.ti,ab,kf. (51260) 
12     prenatal.ti,ab,kf. (10184) 
13     pre natal.ti,ab,kf. (140) 
14     perinatal.ti,ab,kf. (7292) 
15     peri natal.ti,ab,kf. (25) 
16     antenatal.ti,ab,kf. (4824) 
17     ante natal.ti,ab,kf. (131) 
18     antepartum.ti,ab,kf. (544) 
19     ante partum.ti,ab,kf. (75) 
20     postnatal.ti,ab,kf. (8795) 
21     post natal.ti,ab,kf. (805) 
22     postpartum.ti,ab,kf. (6998) 
23     post partum.ti,ab,kf. (1365) 
24     new mother$.ti,ab,kf. (256) 
25     puerperal.ti,ab,kf. (977) 
26     or/1-25 (71058) 
27     "Tobacco Use Cessation Products"/ (0) 
28     Nicotinic Agonists/ (0) 
29     Bupropion/ (0) 
30     Varenicline/ (0) 
31     nicotine replacement$.ti,ab,kf. (445) 
32     (nicotine adj3 (transdermal or intravenous$ or patch$ or gum$ or nasal spray$ or inhaler$ or 
lozenge$)).ti,ab,kf. (230) 
33     (Nicotrol or Nicoderm or Habitrol or Prostep or Nicorette).ti,ab,kf. (6) 
34     (Bupropion or Wellbutrin).ti,ab,kf. (505) 
35     Zyban.ti,ab,kf. (11) 
36     Varenicline.ti,ab,kf. (273) 
37     Chantix.ti,ab,kf. (11) 
38     Champix.ti,ab,kf. (12) 
39     pharm$.ti. and (smoking or smoker$ or tobacco or nicotine or cigarette$).ti,ab,kf. (258) 
40     stop smoking med$.ti,ab,kf. (10) 
41     "Tobacco Use Disorder"/dt or smoking/dt or cigarette smoking/dt or "tobacco use"/dt (0) 
42     or/27-41 (1369) 
43     26 and 42 (66) 
44     Animals/ not (Humans/ and Animals/) (1) 
45     43 not 44 (66) 
46     limit 45 to (english language and yr="2014 -Current") (47) 





Appendix A. Detailed Methods 
 
Tobacco Cessation in Adults 169 Kaiser Permanente EPC 
Medline Indexed 




1     Pregnancy/ (873141) 
2     Pregnant women/ (8225) 
3     Prenatal care/ (27513) 
4     Perinatal care/ (4574) 
5     Postnatal care/ (5607) 
6     Postpartum period/ (25355) 
7     Peripartum period/ (1159) 
8     Maternal Health Services/ (13798) 
9     Pregnancy complications/ (90581) 
10     Puerperal Disorders/ (11242) 
11     pregnan$.ti,ab,kf. (470582) 
12     prenatal.ti,ab,kf. (86283) 
13     pre natal.ti,ab,kf. (1045) 
14     perinatal.ti,ab,kf. (64796) 
15     peri natal.ti,ab,kf. (166) 
16     antenatal.ti,ab,kf. (30838) 
17     ante natal.ti,ab,kf. (424) 
18     antepartum.ti,ab,kf. (5276) 
19     ante partum.ti,ab,kf. (376) 
20     postnatal.ti,ab,kf. (95526) 
21     post natal.ti,ab,kf. (6547) 
22     postpartum.ti,ab,kf. (47023) 
23     post partum.ti,ab,kf. (10555) 
24     new mother$.ti,ab,kf. (1505) 
25     puerperal.ti,ab,kf. (5840) 
26     or/1-25 (1069952) 
27     "Tobacco Use Cessation Products"/ (1786) 
28     Nicotinic Agonists/ (7272) 
29     Bupropion/ (3025) 
30     Varenicline/ (1280) 
31     nicotine replacement$.ti,ab,kf. (2991) 
32     (nicotine adj3 (transdermal or intravenous$ or patch$ or gum$ or nasal spray$ or inhaler$ or 
lozenge$)).ti,ab,kf. (3118) 
33     (Nicotrol or Nicoderm or Habitrol or Prostep or Nicorette).ti,ab,kf. (131) 
34     (Bupropion or Wellbutrin).ti,ab,kf. (3824) 
35     Zyban.ti,ab,kf. (119) 
36     Varenicline.ti,ab,kf. (1480) 
37     Chantix.ti,ab,kf. (72) 
38     Champix.ti,ab,kf. (43) 
39     pharm$.ti. and (smoking or smoker$ or tobacco or nicotine or cigarette$).ti,ab,kf. (2476) 
40     stop smoking med$.ti,ab,kf. (45) 
41     "Tobacco Use Disorder"/dt or smoking/dt or cigarette smoking/dt or "tobacco use"/dt (1952) 
42     or/27-41 (18199) 
43     26 and 42 (953) 
44     Animals/ not (Humans/ and Animals/) (4675588) 
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45     43 not 44 (574) 
46     limit 45 to (english language and yr="2014 -Current") (181) 
47     remove duplicates from 46 (181) 
48     Smoking Cessation Agents/ (147) 
49     48 not 43 (138) 
50     limit 49 to (english language and yr="2014 -Current") (132) 
51     50 not 44 (122) 
52     (201905* or 201906* or 201907* or 201908* or 201909* or 201910* or 201911* or 201912* or 
2020*).ed. (1095231) 
53     47 and 52 (39) 
54     51 or 53 (161) 
 
 
PsycInfo     
Database: APA PsycInfo <1806 to June Week 3 2020> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Pregnancy/ (41840) 
2     exp Expectant Mothers/ (710) 
3     exp Prenatal Care/ (2070) 
4     exp Perinatal Period/ (2836) 
5     exp Postnatal Period/ (4650) 
6     pregnan*.ti,ab,id. (47446) 
7     prenatal.ti,ab,id. (19454) 
8     pre natal.ti,ab,id. (251) 
9     perinatal.ti,ab,id. (10625) 
10     peri natal.ti,ab,id. (66) 
11     antenatal.ti,ab,id. (3565) 
12     ante natal.ti,ab,id. (57) 
13     antepartum.ti,ab,id. (351) 
14     ante partum.ti,ab,id. (12) 
15     postnatal.ti,ab,id. (20144) 
16     post natal.ti,ab,id. (1112) 
17     postpartum.ti,ab,id. (12024) 
18     post partum.ti,ab,id. (1240) 
19     puerperal.ti,ab,id. (509) 
20     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
(96764) 
21     exp Tobacco Smoking/ (32427) 
22     exp Smoking Cessation/ (13149) 
23     exp Smokeless Tobacco/ (850) 
24     nicotine.ti,ab,id. (16823) 
25     (smoking or smoker* or tobacco or nicotine or cigarette*).ti,ab,id. (69408) 
26     21 or 22 or 23 or 24 or 25 (69649) 
27     Drug Therapy/ or pharm*.ti. (145315) 
28     26 and 27 (3410) 
29     exp Bupropion/ (966) 
30     nicotine replacement*.ti,ab,id. (1727) 
31     (nicotine adj3 (transdermal or intravenous* or patch* or gum* or nasal spray* or inhaler* or 
lozenge*)).ti,ab,id. (1789) 
32     (nicotrol or nicoderm or habitrol or prostep or nicorette).ti,ab,id. (48) 
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33     (bupropion or wellbutrin).ti,ab,id. (2178) 
34     zyban.ti,ab,id. (44) 
35     varenicline.ti,ab,id. (832) 
36     chantix.ti,ab,id. (43) 
37     champix.ti,ab,id. (17) 
38     28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 (7581) 
39     20 and 38 (247) 
40     limit 39 to (english language and yr="2014 -Current") (82) 
41     (201905* or 201906* or 201907* or 201908* or 201909* or 201910* or 201911* or 201912* or 
2020*).up. (191834) 
42     40 and 41 (10) 
 
 
PubMed, publisher-supplied records 
 
((pregnan*[tiab] OR prenatal[tiab] OR "pre natal"[tiab] OR perinatal[tiab] OR "peri natal"[tiab] OR 
antenatal[tiab] OR "ante natal"[tiab] OR antepartum[tiab] OR "ante partum"[tiab] OR postnatal[tiab] OR 
"post natal"[tiab] OR postpartum[tiab] OR "post partum"[tiab] OR puerperal[tiab]) AND (("nicotine 
replacement"[tiab]) OR (nicotine[tiab] AND (transdermal[tiab] OR intravenous*[tiab] OR patch*[tiab] 
OR gum[tiab] OR gums[tiab] OR spray*[tiab] OR inhaler*[tiab] OR lozenge*[tiab])) OR (nicotra[tiab] 
OR nikodem[tiab] OR habitual[tiab] OR prostej[tiab] OR Nicorette[tiab]) OR (Bupropion[tiab] OR 
Wellbutrin[tiab] OR Zyban[tiab] OR Varenicline[tiab] OR Chantix[tiab] OR Champix[tiab]) OR 
(pharm*[ti] AND (smoking[tiab] OR smoker*[tiab] OR tobacco[tiab] OR nicotine[tiab] OR 
cigarette*[tiab])))) AND publisher[sb] Filters: from 2014 – 2020  [21 results] 
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Category Include Exclude 
Aim Tobacco cessation in adults who currently use tobacco, 
regardless of readiness to quit, including relapse 
prevention 
• Primary prevention of tobacco use 
• Tobacco harm–reduction strategies 
Condition Current use of any tobacco product, including but not 
limited to: cigarettes, e-cigarettes and other electronic 
nicotine delivery systems (ENDS), cigars, cigarillos and 
filtered cigars, smokeless tobacco (including snus 
pouches), pipe tobacco, dissolvable tobacco in the form of 
strips, sticks, or lozenges, or smoking tobacco through a 
hookah or waterpipe 
 
Population Adults (age ≥18 years), including pregnant women who 
currently use tobacco 
Reviews limited to: 
• Children and adolescents 
• Persons with other comorbid health 
conditions (e.g., chronic obstructive 
pulmonary disease, cardiovascular 
conditions, cancer, HIV) 
Interventions Primary care–relevant tobacco cessation interventions 
that can be provided in primary care or are feasible to 
refer to from primary care, including pharmacotherapy, 
behavioral interventions, and e-cigarettes or ENDS, alone 
or in combination. 
Broad public health initiatives (e.g., mass 
media, communitywide campaigns) 
Setting Any setting applicable to primary care, including 
interventions that take place in settings that can be 
referred to from primary care 
Reviews limited to studies that take place in 
worksites, churches, or other settings where 
participants have existing social connections 
Comparators • No intervention 
• Usual care 
• Waitlist 
• Attention control (e.g., intervention is similar in format 
and intensity but on a different content area) 
• Minimal intervention (no more than a single brief 
contact [i.e., <5 minutes] per year, brief written 
materials, such as pamphlets, or self-help materials)  
• Active intervention (i.e., more than a single brief 




Based on self-report or biochemically validated reports 
(e.g., expired carbon monoxide; cotinine measured in 
saliva, urine, or blood; cotinine–creatinine ratio; 
thiocyanate)  
Population-based smoking rates (i.e., not 
based on study sample but on underlying 
population) 
Outcomes KQ 1 (health and other outcomes): 
Health outcomes: 
• All-cause mortality 
• Tobacco-related mortality  
• Tobacco-related morbidity (including, but not limited to: 
cancer, asthma, cardiovascular disease, chronic 
bronchitis, or other respiratory disorders) 
• Maternal and perinatal morbidity/mortality 
• Dental/oral health 
• Quality of life 
Other outcomes: 
• Health care utilization 
 
KQ 2 (behavioral outcomes): Tobacco 
cessation/tobacco abstinence (continuous or point 
prevalence abstinence) 
 
KQ 3 (harms): Serious treatment-related harms at any 
time point after the intervention began  
Reviews that only report: 
• Reduction in smoking/tobacco (based on 
frequency/quantity only) 
• Reduction in withdrawal symptoms 
• Attitudes, knowledge, or beliefs related to 
tobacco use 
• Intentions to change behavior 
• Intervention participation/compliance 
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KQs 1, 2: ≥6-month followup after quit date/start of 
intervention  
 
KQ 3: Harms reported at any point after quit date  
<6-month followup after quit date or start of 
intervention 
Study design Pharmacotherapy and behavioral interventions in adults 
and behavioral interventions in pregnant women (review-
of-reviews):  
All KQs: Systematic reviews, including review-of-reviews, 
with or without meta-analysis. A review will be considered 
“systematic” if it: 1) includes a clear statement of the 
purpose of the review; 2) describes the search strategy; 3) 
indicates the criteria used to select studies for inclusion; 
and 4) presents the findings relevant to the main purpose 
of the review, including those that did not favor the 
intervention. Systematic reviews that include experimental 
and/or observational study designs will be included. 
 
Pharmacotherapy in pregnant women; e-cigarette or 
ENDS interventions  
All KQs: Randomized and nonrandomized controlled 
trials 
 





Reviews and primary studies that primarily take place in 
countries categorized as “Very High” on the Human 
Development Index (as defined by the United Nations 
Development Programme) 
Reviews in which >50% of included studies 
take place in countries not categorized as 
“Very High” on the Human Development Index 
Publication 
language 
English Any language other than English 
Quality rating Fair- or good-quality studies Poor-quality studies 
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Study Design Adapted Quality Criteria 
Cohort studies*, adapted 
from Newcastle-Ottawa 
Scale212 
Bias arising in randomization process or due to confounding 
• Balance in baseline characteristics 
• No baseline confounding  
• No time-varying confounding 
 
Bias in selecting participants into the study 
• No evidence of biased selection of sample 
• Start of followup and start of intervention coincide 
 
Bias due to departures form intended interventions 
• Participant intervention status is clearly and explicitly defined and measured 
• Classification of intervention status is unaffected by knowledge of the outcome or risk of the outcome 
 
Bias in classifying interventions 
• Fidelity to intervention protocol 
• Participants were analyzed as originally allocated 
 
Bias from missing data 
• Outcome data are reasonably complete and comparable between groups 
• Confounding variables that are controlled for in analysis are reasonably complete 
• Reasons for missing data are similar across groups 
• Missing data are unlikely to bias results 
 
Bias in measurement of outcomes 
• Blinding of outcome assessors 
• Outcomes are measured using consistent and appropriate procedures and instruments across treatment 
groups 
• No evidence of biased use of inferential statistics 
 
Bias in reporting results selectively 
No evidence that the measures, analyses, or subgroup analyses are selectively reported 
Randomized clinical trials*, 
adapted from U.S. 
Preventive Services Task 
Force Manual74 
Bias arising in the randomization process or due to confounding 
• Valid random assignment/random sequence generation method used 
• Allocation concealed 
• Balance in baseline characteristics 
Bias in selecting participants into the study  
• CCT only: No evidence of biased selection of sample 
Bias due to departures from intended interventions 
• Fidelity to the intervention protocol 
• Low risk of contamination between groups 
• Participants were analyzed as originally allocated 
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Study Design Adapted Quality Criteria 
Bias from missing data 
• No, or minimal, post-randomization exclusions 
• Outcome data are reasonably complete and comparable between groups 
• Reasons for missing data are similar across groups 
• Missing data are unlikely to bias results 
Bias in measurement of outcomes 
• Blinding of outcome assessors 
• Outcomes are measured using consistent and appropriate procedures and instruments across treatment 
groups 
• No evidence of biased use of inferential statistics 
Bias in reporting results selectively 
No evidence that the measures, analyses, or subgroup analyses are selectively reported 
Systematic review†, 
AMSTAR 273 
• Research questions and inclusion criteria for the review included components of PICO 
• Report of the review contained an explicit statement that the review methods were established prior to the 
conduct of the review and the report justified any significant deviations from the protocol 
• The selection of the study designs for inclusion in the review was explained 
• A comprehensive literature search strategy was used 
• Study selection was performed in duplicate 
• Data extraction in was performed duplicate 
• A list of excluded studies and justifications for the exclusions were provided 
• The included studies were described in adequate detail 
• A satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the 
review was used 
• Sources of funding for the studies included were reported 
• If meta-analysis was performed, appropriate methods for statistical combination of results were performed 
• If meta-analysis was performed, the potential impact of RoB in the individual studies on the results on the MA 
or other evidence synthesis were assessed. 
• RoB in individual studies were accounted for when interpreting/discussing the results of the review 
• A satisfactory explanation for, and discussion of, any heterogeneity observed itn the results to the review was 
provided 
• If a quantitative synthesis was performed, an adequate investigation of publication bias (small study bias) was 
performed and its likely impact on the results of the review was discussed 
• Any potential sources of conflict of interest, included any funding authors received for conducting the review 
was reported  
* Good quality studies generally meet all quality criteria. Fair quality studies do not meet all the criteria but do not have critical limitations that could invalidate study findings. 
Poor quality studies have a single fatal flaw or multiple important limitations that could invalidate study findings. Critical appraisal of studies using a priori quality criteria are 
conducted independently by at least two reviewers. Disagreements in final quality assessment are resolved by consensus, and, if needed, consultation with a third independent 
reviewer. 
† Overall confidence in the results of each review was rated according to published guidance: a rating of “high” reflects that the review had zero or one noncritical weakness; 
“moderate” indicates the review was judged to have more than one noncritical weakness; “low” means the review was judged to have one critical flaw with or without noncritical 
weaknesses or multiple noncritical weaknesses; and “critically low” signifies that more than one critical flaw was present. 
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* Articles may appear under more than one Key Question 
Abbreviations: ESRs = existing systematic reviews
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* Articles may appear under more than one Key Question 
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Interventions Among Pregnant Women 
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* Articles may appear under more than one Key Question 
 
Appendix C Table 1. Inclusion Criteria of Ancillary Systematic Reviews on the Effectiveness and Adverse Events of Tobacco Cessation 
Interventions Among Adults, by Author 





Population Specific Intervention  
Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 
Agboola, 201579 Sept-2013 Adult smokers Varenicline Varenicline NR Smoking 
abstinence 
NR ≥3 months RCTs 






Varenicline Varenicline Placebo Smoking 
abstinence, 
AEs 
NR NR RCTs 
Appolonio, 201681 Aug-2016 Adult smokers 
aged 15 years or 
older with alcohol 


































Boland, 201683 May-2016 Smokers 
(excluding 
smokeless 
tobacco or e-cig 
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Population Specific Intervention  
Intervention 





or diagnosed with 
a substance use 
disorder, persons 






Carson, 201286 April-2011 Indigenous 






































NR ≥3 months RCTs or 
quasi-
RCTs 



















NR NR RCTs or 
systematic 
reviews 
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Population Specific Intervention  
Intervention 










Ebbert, 201592 June-2015 Users of any age 
of any tobacco 
product that is 
placed in the 


















NR ≥6 months RCTs or 
quasi-
RCTs 
Giles, 201493 Apr-2012 Non-clinical, adult 
(at least 50% of 
the sample aged 





















NR ≥6 months RCTs 






NR ≥1 month RCTs 
Griffiths, 2018186 May-2017 Pregnant 
smokers aged 16 




















Johnston, 201399 May-2012 Nonindigenous 
and indigenous 























NR NR RCTs, 
CCTs 
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Population Specific Intervention  
Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 
Khanna, 2016100 Apr-2015 Smokers aged 18 


















make the final 
decision". 























Varenicline Placebo AEs NR ≥8 weeks RCTs 
Klinsophon, 
2017102 
Nov-2016 Smokers of any 
age who wished 





Exercise Exercise alone 















NR ≥6 months RCTs 
Lindson-Hawley, 
2015213 
















NR ≥6 months RCTs 
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Population Specific Intervention  
Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 
Liu, 2013107 Apr-2013 Children and 



















Any NR Any 





















Any Any RCTs  
McKee, 2016112 Dec-2014 Tobacco users of 
any age 
Varenicline Varenicline Placebo Smoking 
abstinence 
NR ≥3 months RCTs 






























Any End of 
pregnancy 
RCTs 
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Population Specific Intervention  
Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 
the use of e-






















NR ≥6 months RCTs 
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Population Specific Intervention  
Intervention 
criteria Comparison Outcomes Setting Followup 
Study 
design 
Schwartz, 2015123 Feb-2014 Smokeless 
tobacco users of 
any age 
Varenicline Varenicline Placebo Smoking 
abstinence; 
AEs 
NR 12 weeks; 
6 months 
RCTs 








NR ≥6 months RCTs 


















NR ≥6 months RCTs 
























NR ≥6 months RCTs or 
quasi-
RCTs 
van der Meer, 
2013136 
Apr-2013 Adult smokers 
















Any ≥6 months RCTs 








risk youth, people 
on low income, 
























≥3 months RCTs 
Appendix C Table 1. Inclusion Criteria of Ancillary Systematic Reviews on the Effectiveness and Adverse Events of Tobacco Cessation 
Interventions Among Adults, by Author 





Population Specific Intervention  
Intervention 








Wilson, 2018187 July-2017 Pregnant 







delivered in at 
least 2 sessions 












NR ≥3 months RCTs 
Windle, 2016140 July-2015 Cigarette 
smokers of any 

















Wu, 2015141 Apr-2015 Adults smokers 






















NR ≥6 months RCTs 
Wu, 2016142 Sept-2015 Adult smokers 















NR RCTs or 
quasi-RCT 
Abbreviations: AE = Adverse event; CCT = Controlled clinical trial; NR = Not reported; NRT = Nicotine replacement therapy; OECD = Organization for Economic Cooperation 
and Development; RCT = Randomized controlled trial; SAE = Serious adverse event 
Appendix C Table 2. Descriptive Characteristics of Included Studies Within the Ancillary Reviews on the Efficacy and Adverse Events of 
Tobacco Cessation Interventions Among Adults, by Author 
Tobacco Cessation in Adults 187 Kaiser Permanente EPC 












CPD at BL 
(range) 
Intervention description Setting Providers 
Agboola, 201579 Varenicline 19 32 - 
1210 
39 - 57 NR All trials used a regimen of 0.5 mg for the first 
week of treatment followed by 1-mg tablets of 
varenicline administered twice daily for a n 
additional 11 weeks except three; one in which 
varenicline was administered for 7 weeks, 
another in which participants received varenicline 
for 52 weeks, and a third study in which 
varenicline was administered for an additional 12 
weeks as maintenance treatment following a 12 
week treatment period. All trials provided brief 
support (behavioral counseling delivered face-to-
face or via telephone) throughout the treatment 
phase, except one study in which participants 
received a personalized quit message and a 
printed information sheet at baseline only. All 
trials continued brief counseling during the non-
treatment follow-up phase, either face-to-face or 
via telephone, except two studies in which 
participants received a quit message at baseline 
only and supplies of varenicline at follow-up visits 
and access to quitlne counseling during the 
treatment phase only. Only two studies 
documented the use of specific relapse 
prevention counseling indicating that, in most of 
the included studies, relapse prevention may not 
have been a major feature of support provided. 
NR NR 
Ahmed, 201880 Varenicline 4 9 – 127 41 – 42 NR Varenicline treatment for 12 weeks NR NR 
Appolonio, 201681 Any tobacco 
cessation 
intervention 
34 36 - 575 NR NR Counseling (k=11) included one-time or multi-
session individual counseling or motivational 
interviewing sessions, cognitive behavioral 
therapy, and group counseling sessions. 
Pharmacotherapy (k=11) included naltrexone or 
topiramate, nicotine gum, nicotine patches + 
gum, bupropion, and varenicline. Combination 
therapy (k=12) included combined counseling 
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13 100 - 
2142 




Websites to deliver cessation support targeted at 
low-income smokers and HIV positive smokers 
(k=5) 
Computer program to deliver cessation advice 
and support to substance dependent smokers, 
smokers with a mental illness, and predominantly 
African American pregnant smokers (k=5) 
60-minute culturally specific cessation DVD for 
African American smokers (k=1)  
Integrated video-telephony for rural low-SES 
smokers (k=1) 
Mobile phone text-message cessation support for 
Indigenous smokers (k=1) 
Tailored intervention and study materials to 
respective disadvantaged group with the aim of 
reducing health inequalities (k=9) 
NR NR 
Carson, 201286 Any tobacco 
cessation 
intervention 




NR Intervention durations ranged from seven weeks 
to six months. One study had two days of training 
for doctors and clinical staff with no data provided 













NR Internet intervention vs. control (k=21) 
Helpline intervention vs. control (k=12) 
 
Remaining studies focused on alcohol use or 
gambling 
NR NR 
Denison, 201790 Cognitive 
therapy 
21 25 - 677 21 - 60 NR Most interventions included one or more of the 
following cognitive or cognitive‐behavioral 
content, in order of frequency: relapse 
prevention, coping skills, self‐management, 
self‐efficacy, social support, cognitive 
restructuring, problem solving, motivational 
interview, stress management, and 
rearrangement of environment‐per‐ son 
interaction. One study evaluated interventions 
based on an acceptance and commitment 
approach, and one study focused on 
environment‐person interactions. Most studies 
used individual counselling. 
NR NR 
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108 2 – 
23,213 
NR NR Majority of studies used web-based programs 
followed by wireless and mobile phone-based 
programs, and computer-assisted interventions. 
Few studies investigated social media, virtual 
chat rooms, or other electronic aids. 
NR NR 
Ebbert, 201592 Any tobacco 
cessation 
intervention 
34 42 - 
2523 









from 7.9 to 





















Pharmacologic: Bupropion SR was sustained 
release; NRT included patches, lozenges, and 
gum. In all cases, both the treatment and control 
groups received the same behavioral 
interventions. 
 
Behavioral: stratified on the basis of whether the 
intervention targeted individuals or organizations 
and included oral screening, counseling 
(telephone or group (peer-led or nursing-led)), 
mailings, posters, videos, in-person feedback, 
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8 141 - 
11,281 
NR NR Most interventions offered cash rewards and/or 
vouchers exchangeable for a specific range of 
goods or services; two studies used deposit 
contracts where participants made cash deposits 
at the start of the intervention which were only 
returned in the event of successful behavior 
change - resulting in potential financial penalties. 
Two studies also included additional uncertain 
rewards contingent on behavior change in 
addition to certain rewards. The total value of 
incentives, over and above any payments for 
study participants, ranged from $5.16 to $786 (in 
2011 US$). Intervention periods ranged from two 









NR Static web interventions: Ten trials included 
stand-alone static web components as part of the 
intervention condition. Static content was 
generally informational and non-tailored and 
contained content comparable to a printed 
cessation guide. Included in this category are 
static interventions in which the intervention is 
fully available and those that deliver intervention 
components over time. In some studies, static 
content was paired with additional features such 
as tailored feedback reports, text messaging, 
and/or social support. Tailored feedback: Tailored 
feedback consists of advice or information 
provided to users based on responses to one or 
more assessments. Eight studies examined 
interventions consisting largely of a feedback 
report. Tailoring was often performed on the 
basis of participants’ responses to an initial 
assessment and/or on the basis of participants’ 
stage of quitting. The form of tailored messages, 
however, varied greatly. In one study, participants 
could receive up to 150 tailored emails over 6–12 
months with tailoring on multiple factors. In 
contrast, another study provided participants with 
Varied NR 
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CPD at BL 
(range) 
Intervention description Setting Providers 
a single tailored letter, six to nine pages in length, 
based on a 62-item questionnaire. 
Interactive/tailored web intervention: The majority 
of studies evaluated the effectiveness of 
interactive web interventions. Interactivity was 
defined as any part of a web intervention that 
solicited/required user input and included 
features such as exercises, quizzes, cost 
calculators, tailored messages, quit planning 
tools, training in coping strategies, and self-
monitoring. A minority of the interactive 
interventions offered tailored content and/or 
guided users through the intervention based on 
information provided by the participant. Coaching 
analogs and social support: A number of trials 
included social support resources such as peers, 
coaches, or counselors. The most common form 
of social support was the provision of an 
asynchronous discussion forum. Eight trials 
included a discussion forum, either moderated by 
a peer or an expert, in at least some of the study 
arms. Seven trials included access to live 
coaching or counseling either via telephone, face-
to-face counseling, or SMS text or email. Two 
studies evaluated other methods of accessing 
social support. Other adjunctive components: 
Four trials described the use of SMS text 
messaging as part of the intervention. Two trials 
also included interactive voice response calls. 
Two other studies included an online eight 
module cognitive-behavioral mood management 
component in some arms. Another study included 
videos and the ability to create video content. 
Medication: Several studies provided 
pharmacotherapy along with the web-based 
intervention. Nicotine replacement therapy (NRT) 
was the most common form of pharmacotherapy 
and was included in seven trials. Medication 
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CPD at BL 
(range) 
Intervention description Setting Providers 
treatment ranged from a 2-week starter kit used 
in one study to a 10-week starter kit used in 
another study. Two trials included 12 weeks of 
varenicline. One study included a 9-week course 
of bupropion.  
Griffiths, 2018186 Digital 
interventions 




NR Four studies delivered digital content through text 
messages. Three studies used videotapes, and 
one study used telephone Interactive Voice 
Response Technology (IVR). Two trials used 
websites, including a contingency management 
program, and an interactive and personalized 





Johnston, 201399 Any tobacco 
cessation 
intervention 
5 226 - 
1705 
NR NR Three studies were pragmatic trials that recruited 
participants through New Zealand’s Quitline 
service with the aim of testing the effectiveness of 
enhanced protocols, specifically (a) precessation 
nicotine replacement therapy (NRT), (b) 
familiarization and choice of NRT product, and (c) 
very low nicotine content cigarettes (VLNC) 
compared with usual care. The other two studies 
trialed a smoking cessation counseling 





Khanna, 2016100 Advice 0 NA NA NA NA NA NA 
Kishi, 2015101 Varenicline 
(Harms only) 
7 9 - 128 39.9 - 
51.4 
NR All trials provided varenicline at 1-2mg/day plus 
psychotherapy 
Outpatient NR 
Klinsophon, 2017102 Exercise 19 20 - 
2318 
NR NR Details of interventions not synthesized. 
 
Aerobic exercise (k=14) 
Resistance training (k=1)  
Yoga (k=1) 
Combined aerobic and resistance exercise 
program (k=1) 
Did not specify the precise type of exercise and 
were classified as "physical activity" (k=2) 
Supervised, group-based exercise at the 
research setting plus home-based exercise (k=8) 
Supervised, group-based exercise at the 
NR NR 
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CPD at BL 
(range) 
Intervention description Setting Providers 
research setting (k=7) 
Home-based exercise (k=3) 
Remaining provided home-based exercise or 
supervised, group-based exercise in each group 




28 NR NR NR Most interventions were adapted for African 
American smokers (k=23) and the remaining 
were adapted for Chinese Americans (k=5). The 
most frequency used adaptations were to 
develop materials specifically for the target 
population, followed by the use of materials that 
reflected the target population's reading and 
literacy level, material that depicted individuals 
from the target population, appropriate graphics 
and scenarios, and intervention content that 
targeted the population's social and cultural 
values. 













20-50 NR Internet-based interventions with or without 
additional interventions components such as 
phone calls, medication, group support. 
NR NR 
McKee, 2016112 Varenicline 16 79 - 703 NR NR Majority of studies delivered 1mg bid. Varenicline 
duration was mostly 12 weeks (14/16 trial) with 1 
study at 6weeks and 1 lasting 52wks. Study 
duration ranged from 24 to 52; majority 52 wks 




Notley, 2019*116 Incentives 10 17-1014 24-30.7 NR Largest trial provided cash payments as the 
incentive. In all other cases the rewards were 
vouchers for goods or services. All the trials 
offered a program of practical cessation support, 
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18 31 - 
5800 
19 - 43 NR Twelve interventions were delivered by SMS, 
three were delivered by voice calls, one by 
interactive voice response, one by a combination 
of SMS and video messages, and one by a 



















Peckham, 2017118 Any tobacco 
cessation 
intervention 
26 5 - 298 NR NR The varenicline studies all followed a standard 
dosing schedule whereas the dose in the 
Bupropion SR studies ranged from 150 mg once 
per day to 150 mg twice per day. Smoking 
cessation counselling, whether part of the 
intervention being tested or part of the control 
arm, consisted of a range of behavior change 
techniques delivered in a variety of formats e.g. 
face-to-face one-to-one sessions, face-to-face 
group sessions or one-to-one sessions delivered 
via telephone. It is important to note that in the 
trials of varenicline and bupropion, where 
smoking cessation counselling was delivered, the 
same program was delivered in both the 
medication (varenicline or bupropion) arm of the 
trial as in the usual care arm of the trial. In the 
majority of the trials the exact content, in terms of 
the behavior change techniques employed in the 
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(range) 
Intervention description Setting Providers 
Roberts, 2016120 NRT, 
bupropion, 
varenicline 
14 5 - 128 NR NR Number of CBT sessions varied by study NR NR 
Rosen, 2018121 NRT, 
bupropion, 
varenicline 
61 36 - 
3575 
NR NR For comparators: "Some studies included more 
than two treatment groups. For 2 × 2 factorial 
designs that included a medical and a non-
medical (behavioral/ psychological) intervention, 
two separate comparisons were performed: one 
for the active non-medical intervention and one 
for the inactive non-medical intervention. In cases 
where high- and low- dependent smoker 
subgroups were randomized separately to 
intervention and control arms, each subgroup 
was treated in the meta-analysis as a separate 
study. In studies with multiple doses and a single 
control, participants assigned any non-zero dose 
were combined into a single intervention group. 
For trials with multiple intervention arms which did 
not have a clear 2 × 2 design, we compared the 
two groups that were identical on all aspects of 
the intervention except for provision of 
medication. 
NR NR 
Schuit, 2017122 NRT, 
bupropion, 
varenicline 
18 61 - 
1686 
41 - 46 NR NRT vs. placebo (k=4) 
Bupropion SR vs. placebo (k=6) 
NRT vs. bupropion SR vs. NRT + Bupropion SR 
(k=1) 
NRT vs. varenicline (k=1) 
Bupropion SR vs. NRT + Bupropion SR (k=1) 
Basic support + NRT vs. weekly support + NRT 
(k=1) 
No intervention vs. extended NRT vs. extended 
NRT + CBT vs. extended NRT vs. extended 
counselling (k=1) 
NRT, patch vs. NRT, nasal spray with group 
counseling provided to all participants (k=1)  
NRT oral dose (tailored by DNA analysis) vs. 
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Intervention description Setting Providers 
Varenicline + telephone counselling vs. 
varenicline + web intervention vs. varenicline + 
telephone counselling + web intervention (k=1) 
Schwartz, 2016123 Varenicline 3 76 - 431 34.2 - 
43.9 
NR All trials included behavioral counseling (details 
not specified) 
 
2 trials assessed at both timepoints: Varenicline 
at a dose of 0.5mg once daily on Days 1–3, 
increased to 0.5mg twice daily on Days 4–7, and 
further increased to a target dose of 1mg twice 
daily for 11 weeks; for a total of 12 weeks of 
treatment.  
 
The 3rd trial with only 12wk FU: Varenicline at a 
dose of 0.5mg once daily on Days 1–3, increased 
to 0.5mg twice daily on Days 4–7, and further 
increased to a target dose of 1mg once daily for 
11 weeks in participants weighing <55kg, and a 
target dose of 1mg twice daily in participants 
weighing ≥55kg; for a total of 12 weeks of 
treatment. 
NR NR 
Smith, 2016124 NRT, 
bupropion, 
varenicline 
28 56 - 842 NR NR All NRT trials included transdermal nicotine 
patches ranging from 14mg to 42mg per day for 6 
to 18 weeks with varying levels of counseling. All 
Bupropion SR trials provided 150mg 2/day for 6 
to 10 weeks with varying levels of counseling. 
Varenicline doses ranges from 0.3 mg 1/day to 














Thurgood, 2016132 Any tobacco 
cessation 
intervention 
17 64 - 383 34 - 50 16 - 32 The main intervention categories included 
counseling only; counseling and NRT; NRT only; 
CBT only; CBT and NRT; motivational 
interviewing; contingency management; 
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Tsoi, 2013133 Any tobacco 
cessation 
intervention 
34 9 - 298 34 - 48.7 7 – 41 The duration of drug treatment varied from 7 














van der Meer, 2013136 Any tobacco 
cessation 
intervention 
49 14 - 
5046 
24 - 57 7.9 – 32.3 In most trials, the psychosocial mood 
management component of the experimental 
intervention consisted of a format of (cognitive) 
behavioral therapy for depression. In one trial the 
psychosocial mood management component 
consisted of a cognitive behavioral analysis 
system of psychotherapy, in one trial of hypnosis 
skills, and in one trial of exercise counselling. The 
interventions of all of four of Muñoz’s trials had a 
self-help format, one trial had a group counselling 
format, two trials had an individual counselling 
format, two trials had an individual plus telephone 
counselling format, one trial had a telephone 
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CPD at BL 
(range) 
Intervention description Setting Providers 
counselling plus self-help format, and one had a 
group plus self-help format. All trials except the 
four conducted by Muñoz had interventions with 
multi-session behavioral support. Seven trials 
had time-matched comparisons. Three trials had 
additional pharmacotherapy in both arms, and six 
trials had no additional pharmacotherapy in both 
arms. 
Wilson, 2017139 Any 
behavioral 
support 




NR NRT (k=9), Bupropion SR (k=2), nortriptyline 
(k=1), behavioral therapy varied, included 
motivational interviewing, smoking cessation 
counselling, group therapy, CBT, weekly classes, 
financial incentives, exercise, computer-delivered 
programs, phone counselling, contingency 





Wilson, 2018187 Incentives 22 54 – 
941 
23 – 31 Mean: 10 Sixteen trials provided psychotherapy to smokers 
with total session time ranging from 50 min to 480 
min over 2 or more sessions. Six trials provided 
incentive-based interventions ranging from a 
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Windle, 2016140 NRT, 
bupropion, 
varenicline 
123 51 - 
3684 
16 - 63 7 - 38 NRT patch + BT vs. BT (k=15) 
Short-acting NRT + BT vs. BT (k=29 ) 
NRT + BT vs. BT (k=44) 
Bupropion SR + BT vs. BT (k=20)  
Varenicline + BT vs. BT (k=14)  
Nicotine patch + BT vs. Nicotine Patch (k=4) 
NRT + BT vs. NRT (k=6) 
Pharmacotherapy + BT vs. Pharmacotherapy 
(k=7)  
Pharmacotherapy + Intensive BT vs. 
Pharmacotherapy + Minimal BT (k=5)  
Pharmacotherapy combinations NRT + NRT vs. 
NRT monotherapy (k=7)  
Nicotine patch + Short-acting NRT vs. Nicotine 
Patch (k=5)  
Bupropion SR + NRT vs. Monotherapy (k=4) 
Pharmacotherapy + Pharmacotherapy vs. 
Pharmacotherapy (k=12) 
NR NR 
Wu, 2015141 Any tobacco 
cessation 
intervention 




NR Reduction support + medication vs. reduction 
support + placebo (k=9) 
Reduction support + medication vs.no 
intervention (k=5) 
Reduction support + medication vs. reduction 
support vs.no intervention (k=1) 
NR NR 
Wu, 2016142 Varenicline 
(Harms only) 
8 5 - 127 NR NR The selected randomized trials all compared 
varenicline with placebo. Three studies explored 
the effectiveness of varenicline alone, and the 
remaining studies evaluated varenicline in 
combination with individual behavioral 
interventions. The duration of the varenicline 
treatment varied between 8 and 12 weeks; 81% 
of participants treated with varenicline completed 
the treatment, compared with 82% in placebo 
groups. 
NR NR 
*Evidence for pregnant persons only 
Abbreviations: bid = Two times a day; BL = Baseline; BT = Behavioral therapy; CBT = Cognitive behavioral therapy; CPD = Cigarettes per day; DNA = Deoxyribonucleic acid; DVD = 
Digital versatile disc; FU = Followup; HIV = Human immunodeficiency virus; kg = kilogram; mg = milligram; NA = Not applicable; NR = Not reported; NRT = Nicotine replacement 
therapy; SES = Socioeconomic status; SMS = Short message service; ST = Smokeless tobacco; wks = weeks; US = United States; VLNC = Very low nicotine content cigarettes 
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Other SES: NE 






























41.6 Marital status: NR 
 
Education: 35.7% 






























Reduced CPD in 
past year: 
56.4% 






42.2 Marital status: NR 
 
Education: 37.1% 





employed (full- or 
part-time) 
 










15.3 NR NR Motivation to 
quit (1-10 scale): 
4.5 
Past year quit 
attempt: 33.7% 
 
Lifetime # quit 
attempts 
(mean): 4.2 
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Other SES: NR 















eCO, mean: 74.8 
ppm 
Subjects were 
















Other SES: NR 
NR 37.1 19.4 FTND†, mean: 
4.3 




eCO, mean: 14.8 
ppm 
Motivation to 
quit, mean score 






28.9 Marital status: NR 
 
Education: 32.7% 























Strong to Very 
Strong: 32.7% 
Time to first CPD 
<=5 min after 
waking: 25.5% 
 6–30 min after 
waking: 42.6% 
 31–60 min after 
waking: 21.3% 
 >60 min after 
waking: 10.6% 
Confidence in 






quit (1-10 scale), 
mean: 5.5 
Past year quit 
attempt: 42.9% 
*Score of 15 and above indicates high motivation to quit. 
† Score of 8 or greater indicates high nicotine dependence. 
‡ 1 to 5 point Likert scale where a score of 1 indicates very low motivation to quit and a score of 5 indicates very high motivation to quit. 
Abbreviations: ACEND = A study of Cessation using Electronic Nicotine Devices; AUTOS = autonomy over smoking scale; CPD = cigarettes per day; e-cig = electronic 
cigarette; ECLAT = EffiCacy and safety of an eLectronic cigarette; eCO = expired carbon monoxide; FTND = fagerstrom test of nicotine dependence; NR = not reported; PPM = 
parts per million; SES = socioeconomic status; TEC = Trial of Electronic Cigarettes 
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3 ARM 1 
Elusion e- cigs l 
with 16 mg/mL 
nicotine cartridges 
for 12 weeks 
 
Participants 
received a free e-
cig and sufficient 
nicotine cartridges 
to last for 4-5 
weeks. 
Participants 
instructed to use 
the device 
exclusively for 12 
weeks  
ARM 2 





patches were sent 






instructions to use 
patches daily, 
from 1 week 
before until 12 
weeks after their 







Placebo with 0 




cig and cartridges 
containing 0 mg 
nicotine labelled 
in such a way that 
participants 
cannot detect if 
All participants 











with a mini- mum 
of one follow-up 
support telephone 
call over 8–12 
weeks. If 
participants did 
not want to 
receive this 
support, they had 
access other 
support services 
such as ‘Txt2Quit’ 
(a mobile phone-









Total #: 4 
 
Baseline 
visit, and 3 
followup 
visits at 











both nicotine and 
placebo e-cigs 
reported having 
used an average of 
0·7 cartridges per 
day at 6 months 
 
Nicotine patches 
were used as 
instructed (an 
average of one 
21mg patch per day)  
 
At 6 months, in both 
the nicotine  
e-cig and NRT 
groups, two 
participants had 
used bupropion and 
five had used 
varenicline in the 
past month; in the 











higher in the 
nicotine e-cig 
group as 
compared with the 
NRT group 
(p<0·0001) and 




29% (71/ 241) of 
the nicotine e-cig 
group and 35% 




use, with only 8% 
(17/215) of those 
in the NRT group 
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3 ARM 1 
Categoria e-cig 
(model 401) with 
7.2 mg nicotine 
cartridges used at 




(model 401) with 
two 6-week 
supplies of 
cartridges, one of 
the 7.2 mg 
nicotine cartridges 
and a further 6 
weeks with supply 
of 5.4 mg nicotine 
cartridges; used at 






cigs and 12 
weeks supply of 
no-nicotine 
cartridges 





up visits at 
weeks 2, 4, 
6, 8, 10, 12, 


















use at 6- and 12-
month followup was 
0 (IQR 0-2) for the 
whole cohort and 
did not differ 







2 One Kit (Aspire) e-
cigs with 18mg 
nicotine cartridges 
for 52 weeks 
 
After the initial 4-
week trial period 





NRT with any 





mouth strip, and 

















Total #: 4 
 
Baseline 



















Most participants in 
the e-cig group 
started to purchase 
their own e-liquids 
from the first week 
onwards, with only 
7% requesting the 




and 8mg/ml at 4, 26 
At 12 months 





for at least five 
consecutive days 
in the past six 
months and 22.2% 
of NRT arm 
participants 
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Setting Delivered intervention details Adherence 










also free to switch 
product at any 
time during the 
follow-up period.  





levels for at least 




and 52 weeks, 
respectively.  
 




mostly patch plus 
one of the oral 
products  
reported using 








ARM 2: Nicotine, 
gum (distributed in 
12wk supply) 
e-cigarette (eGO-























in the medical 






instructed to visit 
the medical office 
every 4 weeks for 
evaluation and 
counseling by an 
independent 
health practitioner 
Total #: 7 
 






every 4 wks 








4 (Arm 1) and 14 







3 ARM 1 
eVOD e-cigarette 
(2nd gen) starter 




(2nd gen) starter 
pack with a 






Total #: 5 
 
Baseline 







Use of allocated 
treatments 
decreased over 
time. At 3 months 
followup, only 50% 
In the patch-only 
group, 15% of the 
participants 
crossed over and 
used e-cigarettes 
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Setting Delivered intervention details Adherence 
nicotine e-liquid 
cartridges used ad 
libitum for 14 
weeks + NRT (as 




used ad libitum 
for 14 weeks + 
NRT (as 









flavors of e-liquid 
in the starter 
packs, after which 
both e-cigarette 
groups were free 
to seek out new 
e-cigs and other 
e-liquids at will 
 
ARM 3 
NRT with a 21mg, 
24-hour nicotine 
patch (Habitrol); 
one patch per day 






then once a week 
for 6 weeks 
visits at 
weeks 4, 









of participants in all 
three groups were 
still using the patch 
and only 33% of 
participants 
randomized to e-




At 6 months, only 
40% of participants 
in the patches only 
group were still 
using patches and 
11% an 13% of 
participants were 
using both their 
allocated patches 
and ecigs in the 
nicotine e-cig and 




received a median 
of 3 of the 6 
scheduled support 
calls with 
participants in ARM 
1 receiving more 
calls than those in 
ARM 3. 








3 ARM 1 
BluCig Starter 











randomized to the e-
cig group used the 
Overall 
compliance was 
modest but no 
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Setting Delivered intervention details Adherence 
Fair mg/mL nicotine 
used at will (with 
minimal 





the study, the 
manufacturer of 
Blu altered the 
product and 
discontinued 
availability of the 
device, replaced 
with BluPlus+, 
with 24 mg/mL 
nicotine, again 
offered in both 
tobacco and 




visit and 6 
follow up 
visits at 
weeks 2, 3, 
4, 8, 12, 






e-cig at least once. 
Most participants 
reported a high 
frequency of use 
during the sampling 
period (>5 days per 
week), which 
decreased to about 
3 days per week 
during follow-up. 
Over the 21-day 
sampling period, 
average duration of 
e-cig use was 15.4 
days among 16 mg 
e-cig participants 
and 17.0 days 
among the 24 mg e-
cig group. Just 
under half (48%) of 
24 mg e-cig 
participants used 
product all 21 days 
of the sampling 
period, versus 30% 
of 16 mg e-cig 
participants. 
different across 








2 Prototype e-cig, 
developed by 
Fontem Ventures, 
with 2.7 mg 
nicotine capsules 
(menthol or 
tobacco flavor) for 




smoking with their 
own usual 
conventional 




NA Total #: 8 
 
Baseline 
visit and 7 
followup 
visits at 
weeks 1, 2, 
4, 6, 8, 10, 
and 12.  
Ambulatory 




Subjects in the e-cig 
arm used a mean of 
3.29 to 4.15 
capsules per day 
over the study 
weeks.  
 
The mean daily CC 
use in the CC group 
A total of 123 
subjects (40.2%) 
were classified as 
“EVP- compliant” 
and 183 (59.8%) 
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Setting Delivered intervention details Adherence 
Participants were 
provided with the 
e-cig and with 
sufficient capsules 
to last for the 




provide 40 to 60 
puffs 
nicotine yield 0.81 
mg and mean ISO 




over the 12 study 
weeks ranged from 
12.33 to 14.1 CPD.  
 
compliant subjects 







increasing CPD at 
baseline. EVP-
compliant subjects 









3 ARM 1  
 
VP5 e-cig with 
8mg nicotine 




received an e-cig 
kit and 12 10-mL 
liquid cartridges (8 
mg/mL nicotine 
concentration) 
free of charge. 
Participants were 
asked to consume 
no more than 1 ml 
of the liquid a day. 
ARM 2  
 




received an e-cig 
kit and 12 10-mL 
liquid that did not 
contain nicotine 
free of charge. 
Participants were 
asked to consume 
no more than 1 ml 


























Total #: 4 
 
Baseline 
visit, and 3 
followup 
visits at 
















Participants in Arm 
3 reported smoking 
an average of 
10.034 
cigarettes/day, while 
participants in Arm 1 
and Arm 2 showed a 
lower consumption 
(7.671 and 9.091, 
respectively).  
Usage of the e-cig 





Participants in Arm 
1 and Arm 2 had a 
similar compliance 
in the use of e-
cigs. And there 
was no significant 
difference, though 
the placebo group 
used on average 
less liquid (Arm 1 
M = 10.9 empty 
flacons; Arm 2 M = 
9.8 empty 
flacons).  
Appendix F Table 2. Intervention and Control Characteristics From Trials of Electronic Cigarettes for Tobacco Cessation 



























2 ARM 1 
NJOY, King Bold 
disposable e-cigs 
with 4.5% nicotine 
(tobacco flavor 









only) for 3 weeks  
 
Minimum EC use 
instruction was 
provided 
NR Prior to receiving 
the ECs, subjects 
were required to 
complete a 
counseling 















manage urges  
Total #: 3 
 
Baseline 


















Abbreviations: ACEND = A study of Cessation using Electronic Nicotine Devices; CC = conventional cigarettes; CPD = cigarettes per day; e-cigs = electronic cigarettes; ECLAT 
= EffiCacy and safety of an eLectronic cigarette; NR = not reported; TEC = Trial of Electronic Cigarettes 
 
Appendix G Figure 1. NRT Interventions for Smoking Cessation During Pregnancy, Preterm Birth 
at <37 Weeks 
















































Appendix G Figure 2. NRT Interventions for Smoking Cessation During Pregnancy, Mean 
Birthweight in Grams 













































Favors Placebo  Favors NRT 
0-400 400
 
NOTE: Standard deviations for Wisborn, 2000 and El-Mohandes, 2013 abstracted from review by Claire et. al, 
2020.76 
 
Appendix G Figure 3. NRT Interventions for Smoking Cessation During Pregnancy, Low 
Birthweight (<2500 Grams)* 










































Favors NRT  Favors Placebo 
1.1 10
 
NOTE: Study reported odds ratios were used when reported in original publication.
Appendix G Figure 4. NRT Interventions for Smoking Cessation During Pregnancy, Stillbirth 


































Appendix G Figure 5. NRT Interventions in Placebo-Controlled Trials for Smoking Cessation 
During Pregnancy, Smoking Cessation (KQ 2) 
Tobacco Cessation in Adults 244 Kaiser Permanente EPC 
 
NOTE: Weights are from random effects analysis







































Favors Placebo  Favors NRT 
1.1 10
 
NOTE: Pooled estimate from REML with Knapp-Hartung modification: RR= 1.11 (95% CI 0.79 to 1.56) 
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Other SES*: Annual 
household income 
(Euro), % 
<12,000: 32.6         
12,000 – 30,000: 
50.0 
30,000 – 100,000: 
16.7 







Hx of Premature 
birth(s)*: 9.5 
 
















to have scored 





attempts (≥ 1 












<HS degree: 33 
HS graduate‡: 50 




Full time: 17  
Part-time: 13  
Not employed: 69 
 
Other SES: 






Hx of Premature 
birth(s): NR 
 








Number of live 
births, mean: 2.4 
Alcohol use during 
pregnancy: 16 
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Other SES: NR 








Hx of Premature 
birth(s)*: 8.8 
 

























<HS grad: 50 





Other SES (%): 
















Hx of Premature 
birth(s): 15 
 




Other medical (%): 




Mean # CPD, 
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quit Quit Hx 
Antidepressant 
use: 7.5% 
Mental health Tx 
Hx: 41.5% 
Substance abuse 






























Hx of premature 
delivery: 10.6 
 
Hx of SGA: NR 
 
Other medical: 






No of previous 
(median) 
pregnancies: 2 


















<HS grad: 28 
HS grad‡: 31 














Hx of Premature 
birth(s)*: 15 
 
Hx of small 
gestational age*: 5 
 
Other medical: 
Number of prior 
pregnancies 
median (median, 
IQR): 2 (1,4) 
Premature rupture 





mean (SD): 3 
(1) 
"Desire to quit" 
Mean: 6 (1) 
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quit Quit Hx 
NR of membranes: 7% 
High blood 
pressure: 19% 














Years of schooling*: 
<10: 18.4 








NR Nulliparous: 42.8 
 
Hx of Premature 
birth(s): NR 
 





















 0-2: 68.8 3-
15: 31.2 
* Calculated 
† Married includes married or cohabitating 
‡ HS graduate or GED 
§ Defined as any previous pregnancy which lasted from 24 to 37 week 
ǁ The median number of days before recruitment that women last used NRT among the 47 women who reported current or past use was 31 days for the NRT group (IQR 15 to 38 
days) and 30 for the placebo group (IQR 14 to 68 days). 
 
Abbreviations: BL = baseline; CPD = cigarettes per day; HS = high school; hx= history; IQR = interquartile range; NR = not reported; SES = socioeconomic status; Tx = 
treatment; yrs = years 
 
Appendix G Table 2. Intervention Characteristics From NRT Trials for Smoking Cessation Among Pregnant Women, by Study Design 





















NRT, patch 10 
mg and 15 mg; 




Participants received behavioral support 
at each visit. Although the personalized, 
individual behavioral interventions were 
not specifically standardized, and the 
participating maternity wards could use 
their discretion to apply their own 
standard methods, these interventions 
were based on the national consensus 
document. The study’s website along 
with flyers in waiting rooms provided 
information that participants would 
receive personalized (not within groups) 
interventions by healthcare professionals 
specialized in smoking cessation. The 
core feature of the behavioral 
interventions included motivational 
interviewing, arrangement for follow-ups, 
behavioral counselling, establishment of 
good doctor-patient and midwife-patient 
relationships, and a clear definition of 
treatment aims. 
Total #: 7 
 
Initial visit 1hr, 
following visits 





Daily dose ranged 
from 10-30 mg/day 
Mean daily 
prescription dose 
for entire tx period 
IG: 18mg (SD 
6.8mg), CG: 19.2 
(SD 6.9mg). 
 
Median length of 
prescription was: 
IG: 105 days (IQR 
35-175), CG: 70 
(IQR 35-175) 
 









participants at 1016 




women in the 
nicotine patch 
group and 143/199 
(72%) in the 
placebo patch 





56-99%) in the 
nicotine patch 
group and 83% 














patches 15 mg 
per 16 hours  
(4wk supply, 
additional 4wk 
supply if needed) 
Behavioral counseling (1 face-to-face 
and 3 telephone sessions). 
 
At enrollment, research midwives 
provided behavioral support lasting up to 
1 hour. In addition to behavioral support 
at enrollment, research midwives 
Total #: 4 (1 











Gum usage ranged 
from about 90% 
usage at visit 1 to 
30% usage at visit 
5.  
 
Number of days of 
At delivery, only 
7.2% (35/485) of IG 
and 2.8% (14/496) 
CG reported using 
trial medications for 
over 1 month. 
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provided three sessions of behavioral 
support by telephone to participants: one 
session on the quit date, one session 3 
days afterward, and one at 4 weeks. The 
women who collected a second month’s 
supply of NRT or placebo also received 
face-to-face support from the research 
midwife at the time of collection.  
Women were offered additional support 
from local National Health Service 
smoking cessation services and were 
encouraged to ask for support from the 
research midwives or smoking cessation 
service staff; support was provided 
according to the manual. 
1mo. 
 
Initial visit up 
to 1hr; phone 
visits NR 





Average number of 
pieces of gum 
used per day 
[placebo: 3.22 
(SD=2.27); NRT: 
3.04 (SD=2.43)]  
Rates of use of 
nonstudy nicotine-
replacement 




had no additional 
contact, either face 





Median number of 
extra phone 






2mg; 6 weeks of 
treatment with 
the gum followed 
by a 6-week 
taper period. 
Behavioral counseling (8 face-to-face 
sessions). 
 
At BL and Visit 1, women received 
individualized smoking cessation 
counseling.  
Subjects received two 35-minute 
counseling sessions (in English or 
Spanish) delivered by a research 
assistant trained to deliver smoking 
cessation counseling using a 
motivational interviewing approach. In 
addition to the counseling sessions, 
subjects received printed educational 
materials that were tailored for use in 
pregnancy and twice-monthly telephone 
calls to monitor progress until delivery. 
Total #: 8 
 
35 min (2 
visits); NR for 













lasted an average 
64.7 minutes 
(SD15.8): CBT-
only, 61.7, (16.7); 
and CBT+NRT, 
66.1, (15.7).  
Sessions two 
through six lasted 





M27.0 min, (13.9). 
CBT+NRT 
(n=122): 72 
selected the patch, 
32 selected the 
Overall, the IG was 
more likely to 
attend study visits 
than the placebo 
group (71% vs. 
60%; t(10)= 3.67, 
p=.004).  
 
The nicotine group 
participated at a 
significantly higher 
rate at visits 3 
(χ2(1)= 5.26, 
p=.022) and 5 
(χ2(1)= 4.74, 
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gum, 12 selected 
the lozenge, and 6 
opted to use no 
NRT.  
 




reported using a 
mean of only 23.4 
patches  
 
Gum dispensed to 
last the women 18 
days; they reported 




dispensed to last 
19 days; the 
women reported 
using lozenges for 
a mean of 4 days 
 
Overall, 76% of the 
women in the 
CBT+NRT arm 
reported using 
some form of NRT 
 
Only four women in 
the CBT-only arm 
reported using 
NRT 
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(4mg of nicotine 
from a porous 
plug containing 
10mg of nicotine) 
Planned for 6 
wks; inhaler 
available for 






inhalers used per 
day based on 
level of smoking. 
Protocol consisted of nine in-person 
visits and a phone call one month after 
delivery.  
After randomization, at the next two visits 
(baseline and one week after the quit 
date) participants received 35 minutes of 
individual smoking cessation counseling 
by a study nurse who was trained to 
deliver the counseling using a 
motivational interviewing approach. At 
the baseline visit we asked participants 
to pick a quit date (a date that they would 
completely stop smoking beginning at 12 
am) sometime within the next week and 
to start using the inhaler on that date. We 
also provided written educational 
materials on smoking cessation during 
pregnancy and the package insert for the 
nicotine inhaler. 









NR Compliance with 
the inhaler during 
treatment was 69% 
in the placebo 
group and 70% in 
the nicotine group, 





NRT, patch (15 
mg/ 16 hrs for 8 
weeks, 10 mg/16 
hrs for 3 weeks) 
planned for 11 
weeks. 
Behavioral counseling (4 visits). 
 
Prenatal smoking cessation counseling 
with a midwife four times during 
pregnancy. Visits were independent of 
routine antenatal care visits.  
At first visits, which lasted 45–60 
minutes, participants were interviewed 
about their smoking habits and previous 
attempts to stop smoking. Women were 
informed about pharmacologic and 
psychologic aspects of smoking and the 
consequences of smoking during 
pregnancy. Methods to stop smoking 
were carefully explained and the day of 
stopping was planned. A pamphlet on 
smoking and pregnancy also was 
distributed; pamphlets contained 









NR In the nicotine 
group 17% used all 
15-mg patches and 
11% used all 10-
mg patches. In the 
placebo group 8% 
and 7% used all 
patches. 
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information about the harmful effects of 












Behavioral counseling (5 face-to-face 
and 1 telephone session) 
 
Delivery of an evidenced-based 
intervention: the Smoking Cessation or 
Reduction in Pregnancy Treatment 
(SCRIPT) Program. In addition to 
counseling, women were given A 
Pregnant Woman’s Guide to Quit 
Smoking, a manual to assist patients 
with problem-solving and coping skills, 
written at a 6th grade reading level. 
Women who continued after visit 1 
received reinforcement and behavioral 
methods at Visits 2–5. 
























completed the NRT 
protocol.  
 
CG patients were 
adherent to the 
scheduled 
counseling and 
assessment visits.  
Although 
adherence levels in 
the IG and CG 
were comparable 
for Visit 1 to 4, the 
NRT 
Implementation 
Index was much 






Choice of NRT 
from patch (7-21 
mg/ 16 hrs 
depending on 
cpd), gum (2 mg 
per each cpd), or 
lozenge (2 mg 
per each cpd) 
Each woman’s 
NRT dose was 
based on current 
smoking level:  
 
Overall 
All women received six one-on-one 
counseling sessions (five face-to-face at 
prenatal visits and one via telephone) 
designed to enhance motivation and 
develop skills needed to quit smoking.  
“Quit kit” given: a smoking cessation 
booklet designed for pregnant smokers 
(Make Yours a Fresh Start Family), water 
bottle, straws, hard candy, an exercise 
band, and a stress management tape. 
Support specialists helped the women 
devise an action plan. After the first 
session, each woman was mailed a card 
containing details of her action plan. In 











number of patches 
used was 14 
(range 0–77) in the 
nicotine group and 
7 (range 0–77) in 
the placebo group 
 
Women who did 
not attend visits 
were given another 
appointment within 
the subsequent 2 
weeks. If they did 
A greater 
proportion of the 
women in the 
CBT+NRT arm 
completed four or 
more sessions 
(four was median 
number of 
sessions) than did 
women in the CBT-
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use NRT for 
6wks. 
all sessions, support specialists 
attempted to increase the women’s 
motivation, self-efficacy, and skills. In 
addition to the smoking-specific content, 
support specialists covered a relevant 
content area (stress, rewards, social 
support, and relapse prevention). 
The counseling protocol was based on 
motivational interviewing, the 
transtheoretical model of behavior 
change, and social cognitive theory. 




second, third, and 
fourth visits, 76 
(31%), 106 (44%), 




Abbreviations: BL = baseline; CBT = cognitive behavioral therapy; CG = control group; CI = confidence interval; CPD = cigarettes per day; IG = intervention group; mg = 
milligram; min = minute(s); NR = not reported; NRT = nicotine replacement therapy; OBGYN = obstetrics and gynecology; RCT = randomized controlled trial; RD = risk 
difference; SES = socioeconomic status; Tx = treatment; wks = weeks; yrs = years 
 
Appendix H Table 1. Intervention Details of Behavioral Interventions Among Adults 
Tobacco Cessation in Adults 255 Kaiser Permanente EPC 
Intervention 
Type 




Adult smokers who were typically motivated to quit, including generally healthy smokers as well as those with specific health needs such as those with 




Smoking cessation at the longest followup (at 6 months or more) using the strictest definition of abstinence, preferring sustained over point prevalence 
abstinence and using biochemically validated rates where available. 
Study findings Physician and nurse advice can increase the rate 
of smoking cessation at 6 or more months 
followup (RR for physician advice 1.76 [95% CI, 
1.58 to 1.96]; 26 trials; n=22,239 and for nurse 
advice 1.29 [95% CI, 1.21 to 1.38]; k=44; 
n=20,881). 
Individual counseling from a smoking cessation 
specialist increases the rate of cessation among 
smokers at 6 or more months followup versus no 
advice, brief advice, or self-help materials (RR 
1.48 [95% CI, 1.34 to 1.64]; k=33; n=13,762) and 
moderate quality evidence that compared with 
non-group self-help programs, group-based 
therapy interventions can increase quitting 
smoking (RR 1.88 [95% CI, 1.52 to 2.33]; k=13; 
n=4395).  
Providing proactive telephone counselors after 
smokers have called a Quitline improves rates of 
smoking cessation (RR 1.38 [95% CI, 1.19 to 1.61]; 
k=14; n=32,484), and moderate quality evidence 
that proactive telephone counseling increases quit 
rates in smoking in other settings (RR 1.25 [95% 
CI, 1.15 to 1.35]; k=65; n=41,233).  
Mobile phone-based interventions were less 
commonly studied but showed a positive benefit on 
smoking cessation at 6 months’ followup compared 
with usual care or a minimal intervention (RR 1.54 
[95% CI, 1.19 to 2.00]; k=13; n=14,133) and no 





Advice was defined as verbal instructions from the 
provider with a “stop smoking” message 
irrespective of whether information was provided 
about the harm effects of smoking; however, the 
included interventions were highly variable. In 
most cases, advice was given verbally and was 
supplemented with print materials, additional 
advice from additional healthcare staff, or referral 
to a cessation clinic.  
Typically included: review of smoking history and 
motivation to quit, help in the identification of high-
risk situations, and the generation for problem-
solving strategies to deal with such situations as 
well as non-specific support and encouragement. 
Many group-based sessions included cognitive 
behavioral therapy. Additional components such 
as written materials, video or audiotapes were 
also sometimes provided.  
Telephone counseling and mobile phone-based 
interventions were generally tailored according to 
participants’ smoking history, readiness to quit and 
focused on increasing motivation and strategies to 
increase likelihood of quitting. 
Duration of 
interventions 
Most interventions took place during 1 session 
with followup between 1 week and 3 months. 
Most interventions took place during one face-to-
face session with followup consultations over 1 
week to 4 months followup.  
Highly variable ranging from 2 weeks to 1 year with 
most taking place over 3 to 4 months. 
Settings of 
studies 
Most took place in primary care or hospital 
settings.  
Most took place in hospital or smoking cessation 
clinic settings. 
Most interventions were delivered entirely remotely 
via telephone or mobile phone, with few providing 
any face-to-face support.  
To whom is 
intervention 
targeted? 
Adult smokers motivated to quit. Adult smokers, regardless of motivation to quit. Generally adult smokers motivated to quit. Most 
mobile phone-based interventions targeted 
younger- (mean age 18-27 years) or middle-aged 




Most advice was given during a single 
consultation lasting less than 20 minutes (with or 
without print materials) plus up to one followup 
visits; although several studies compared more 
intense interventions (more than one session) with 
minimal interventions. 
Most individual-based advice was given during 
one face-to-face session with multiple followup 
sessions in-person or via the telephone. Group-
based sessions included smokers meeting for 
scheduled meetings delivered over 6 to 8 
sessions, with the first few sessions devoted to 
Telephone counseling was typically delivered in 
scheduled phone calls that began after smokers 
had proactively called a smoking Quitline. The 
number of calls ranged from a single call to 12 
calls. The duration of the calls was typically 10 to 
20 minutes, although the first calls were often 
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Intervention 
Type 
Physician or nurse advice Individual or group-based counseling Telephone and mobile phone-based 
interventions 
discussion of motivation for quitting, health 
benefits, and strategies for planning a quit 
attempt.  
longer.  
Almost all the included trials of mobile phone-
based interventions used text messaging (SMS) as 
a central component of the intervention. The 
number of text messages varied considerably but 
often was 0 to 2 messages per day every day over 
the course of the intervention. 
Example 
interventions* † 















Treatment guide: Orleans CT, Rimer BK, Fleisher 
L. Clear horizons: a quit smoking guide especially 
for those 50 and over. Philadelphia: FoxChase 
Cancer Center, 1989. (Morgan 19961) 
 
Intervention based on protocols established in 
How to Help Your Patients Stop Smoking: A 
National Cancer Institute Manual for Physicians13 
and followed the orientation of the Mayo Nicotine 
Dependence Center14 (Canga 20002) 
Office of Cancer Communications. Clearing the 
Air: How to Quit Smoking and Quit for Keeps. 
Bethesda, Md: National Cancer Institute; 1987. 
(Weissfeld 19915) 
American Lung Association guide (Bock 20138) 
 
Curry, S.J., Gordon, J. R., & Marlatt, G. A. (1987). 
Breaking Away: A guide to becoming a nonsmoker; 
unable to find original materials. (Curry 19959) 
 
https://www.cancer.gov/publications/patient-
education/clearing-the-air (McBride 199910) 
 
American Lung Association maintenance manual 
(American Lung Association. (1980). A lifetime of 
freedom from smoking. New York: Author) (Orelans 
199111) 
 
Solomon L, Quinn V. Spontaneous quitting: self-
initiated smoking cessation in early pregnancy. 





There was insufficient evidence to establish 
differences according to the intensity of the 
intervention. There was some evidence that 
physician advice interventions that provided 
further followup to a minimal intervention vs. those 
delivered in one single session were more 
effective, but this effect was not seen related to 
nurse advice. There was no evidence that the 
effects differed by patient group or setting. 
No evidence of effect modification based on 
whether pharmacotherapy was offered nor on 
population (hospital inpatients or outpatients vs. 
not). Evidence was too limited to determine 
whether there was a dose-response effect 
according to number of contacts or type (face-to-
face vs. remote) of followup consultations. 
Some evidence that participants who were selected 
based on their motivation to quit may be more likely 
to quit smoking versus those who were not 
selected on their motivation in response to 
proactive telephone counseling. There was not 
enough evidence to suggest that a higher number 
of calls would result in a larger effect. There were 
minimal differences in the effectiveness of mobile 
phone-based interventions according to different 
population and intervention characteristics. 
Comparison 
group 
No advice or usual care. No advice, brief advice, self-help materials, or 
usual care; non-group-based interventions. 
No intervention, self-help materials, or other 
nontailored and noninteractive remote support. 
Interventionist Physicians (e.g., general practitioners, family Smoking cessation specialists often with Telephone counseling was most often provided by 
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Intervention 
Type 




practice) or nursing staff with or without smoking-
related duties as part of their core clinical duties. 
Information about training provided to staff was 
not synthesized and was rarely reported. In those 
reporting, training ranged from “brief tutorial” to a 
4-hour training. 
backgrounds in social work, psychology, 
psychiatry, health education, and nursing. 
Training was otherwise not described. 
professional counselors or trained health care 
professionals. Many text message-based 
interventions were developed and administered 




Adherence to intervention not synthesized or abstracted by reviews. 
* Example interventions are those that demonstrated a positive direction of effect on smoking cessation, were at low risk-of-bias, and took place in the United States in primary 
care or a primary care-applicable setting among an unselected sample of adults (i.e., those not selected based on having smoking-related disease or other co-morbid conditions)  
† Inclusion of studies and materials are for example purposes only and does not indicate endorsement by the USPSTF.  
** Materials provided for practice include materials or protocols that were noted within the source study and that we were able to locate.  
§ Statistically significantly effect of intervention versus control on smoking cessation at 6 months or more followup. 
 
1Morgan GD, Noll EL, Orleans CT, et al. Reaching midlife and older smokers: tailored interventions for routine medical care. Prev Med. 1996;25(3):346-54. 
10.1006/pmed.1996.0065 
2Canga N, De Irala J, Vara E, et al. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes 
care. 2000;23(10):1455-60. 10.2337/diacare.23.10.1455 
3Fiore MC, McCarthy DE, Jackson TC, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev Med. 2004;38(4):412-20. 
10.1016/j.ypmed.2003.11.002 
4Glasgow RE, Whitlock EP, Eakin EG, et al. A brief smoking cessation intervention for women in low-income planned parenthood clinics. Am J Public Health. 2000;90(5):786-9. 
10.2105/ajph.90.5.786 
5Weissfeld JL, Holloway JL. Treatment for cigarette smoking in a Department of Veterans Affairs outpatient clinic. Arch Intern Med. 1991;151(5):973-7.  
6Ellerbeck EF, Mahnken JD, Cupertino AP, et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann Intern Med. 2009;150(7):437-46.  
7McClure JB, Westbrook E, Curry SJ, et al. Proactive, motivationally enhanced smoking cessation counseling among women with elevated cervical cancer risk. Nicotine Tob Res. 
2005;7(6):881-9. 10.1080/14622200500266080 
8Bock B, Heron K, Jennings E, et al. A Text Message Delivered Smoking Cessation Intervention: The Initial Trial of TXT-2-Quit: Randomized Controlled Trial. JMIR Mhealth 
Uhealth. 2013;1(2):e17. 10.2196/mhealth.2522 
9Curry SJ, McBride C, Grothaus LC, et al. A randomized trial of self-help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. J Consult Clin 
Psychol. 1995;63(6):1005-14.  
10McBride CM, Scholes D, Grothaus LC, et al. Evaluation of a minimal self-help smoking cessation intervention following cervical cancer screening. Prev Med. 1999;29(2):133-8. 
10.1006/pmed.1999.0514 
11Orleans CT, Schoenbach VJ, Wagner EH, et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. J 
Consult Clin Psychol. 1991;59(3):439-48.  
12Rigotti NA, Park ER, Regan S, et al. Efficacy of telephone counseling for pregnant smokers: a randomized controlled trial. Obstet Gynecol. 2006;108(1):83-92. 
10.1097/01.AOG.0000218100.05601.f8 
13Glynn TJ, Manley MW: How to Help Your Patients Stop Smoking: A National Cancer Institute Manual for Physicians. Washington, DC, U.S. Govt. Printing Office, 1998 
(DHHS publ. no. 98-3064) 
14Hurt RD, Dale LC, McClain FL, Eberman KM, Offord KP, Bruce BK, Lauger GG: A comprehensive model for the treatment of nicotine dependence in a medical setting. Med 
Clin North Am 76:495–514, 1992
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Intervention Type Individual psychosocial interventions 
Primary population Generally healthy pregnant adult women over 16 years of age, but including those with specific health 
needs. About half of the included trials explicitly recruited women categorized as having low 
socioeconomic status.  
Primary outcomes measured Smoking cessation in late pregnancy and continued abstinence post-partum. Using the strictest 
definition of abstinence, preferring sustained over point prevalence abstinence and using 
biochemically validated rates where available. 
Study findings Psychosocial interventions among pregnant women increased the rate of smoking cessation in late 
pregnancy compared with control (RR 1.35 [95% CI, 1.23 to 1.48]; 97 trials; n=26,637). 
Behavior change goals and 
techniques 
Psychosocial interventions were defined as non-pharmacological strategies that use cognitive 
behavioral, motivational and supportive therapies to help women to quit. This included counselling, 
health education, feedback, financial incentives, social support from peers and/or partners, and 
exercise, as well as dissemination trials. 
Duration of interventions Most interventions recruited women during their first antenatal visit or second trimester of pregnancy; 
the duration of the intervention typically took place from this time until late pregnancy.  
Settings of studies Most interventions took place in women’s clinics or tobacco cessation clinics. 
To whom is intervention targeting? Pregnant women who are currently smoking or have recently quit smoking. 
Mode and intensity of delivery Smoking cessation interventions implemented during pregnancy differed substantially in their intensity, 
their duration, and the people involved in their implementation. 





Materials provided for practice†** All patients (both control and experimental groups) received (Ask-Advise-Assess-Arrange) SCRIPT 
Procedures 1, 2, 3, 9, and 10.6, 7, 8, 9 and experimental group patients also received Assist SCRIPT 
Procedures 4 through 8, which included a video,10 guide to quit smoking,11 and a 10 minute or less 
counseling session12 
Evidence of effect modification Meta regression analyses found no differences in the effects of behavioral interventions according to 
the specific intervention strategies, comparator, intensity (categorized according to frequency of 
contact), intervention duration, the provision of self-help manuals, including telephone support, the 
SES of the sample, newly added studies, or study design (cluster versus individually randomized 
trials). 
Comparison group Any control 
Interventionist and training 
required 
Varied 
Reported adherence to 
intervention 
Adherence to intervention not synthesized by review. 
* Example interventions are those that demonstrated a positive direction of effect on smoking cessation, took place in the United States in primary care or a primary care-applicable 
setting, and were published in the past 10 years 
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† Inclusion of studies and materials are for example purposes only and does not indicate endorsement by the USPSTF.  
** Materials provided for practice include materials or protocols that were noted within the source study and that we were able to locate.  
 
1Bullock L, Everett KD, Mullen PD, et al. Baby BEEP: A randomized controlled trial of nurses' individualized social support for poor rural pregnant smokers. Matern Child Health 
J. 2009;13(3):395-406. 10.1007/s10995-008-0363-z 
2Lee M, Miller SM, Wen KY, et al. Cognitive-behavioral intervention to promote smoking cessation for pregnant and postpartum inner city women. J Behav Med. 2015;38(6):932-
43. 10.1007/s10865-015-9669-7 
3Pollak KI, Lyna P, Bilheimer A, et al. A pilot study testing SMS text delivered scheduled gradual reduction to pregnant smokers. Nicotine Tob Res. 2013;15(10):1773-6. 
10.1093/ntr/ntt045 
4Stotts AL, Groff JY, Velasquez MM, et al. Ultrasound feedback and motivational interviewing targeting smoking cessation in the second and third trimesters of pregnancy. 
Nicotine Tob Res. 2009;11(8):961-8. 10.1093/ntr/ntp095 
5Windsor R, Woodby L, Miller T, et al. Effectiveness of Smoking Cessation and Reduction in Pregnancy Treatment (SCRIPT) methods in Medicaid-supported prenatal care: Trial 
III. Health Educ Behav. 2011;38(4):412-22. 10.1177/1090198110382503 
6Fiore, M.; Bailey, W.; Cohen, S., et al. Smoking cessation: clinical practice guideline. Rockville, MD: AHCPR; 1996. 
7Fiore, M.; Bailey, W.; Cohen, S., et al. Treating tobacco use and dependence: a clinical practice guideline. Rockville, MD: AHRQ; 2008.  
8Windsor R, Cutter G, Morris J, Reese Y, Manzella B, et al. The effectiveness of smoking cessation methods for smokers in public health maternity clinics: A randomized trial. 
American Journal of Public Health. 1985; 75:1389–1392. 
9Windsor R, Lowe J, Perkins L, et al. Health education for pregnant smokers: Its behavioral impact and cost benefit. American Journal of Public Health. 1993; 83:201–206. 
10Windsor, R.; Crawford, M.; Woodby, L. Commit to quit smoking during and after pregnancy. Washington, DC: 1998. [Video]. UAB Medical Television. Edited 2004, Society 
for Public Health Education, www.sophe.org. 
11Windsor, R. A Pregnant Woman’s Guide to Quit Smoking. ISBN 0-935105-01-08. Washington, DC: Society for Public Health Education; 1985 &2005. www.sophe.org. 
12Laine C, Davidoff F. The patient-physician relationship: Patient-centered medicine, a professional evolution. Journal of the American Medical Association. 1996; 275:152–156. 
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Study reference/ trial 
identifier 
 
Primary Investigator Study name Location 
Estimated 








Clinical Outcomes of a 
Nationwide, Naturalistic E-
Cig Trial (CONNECT) 
USA 660 2-arm smoking cessation trial 
for 6 months comparing (1) e-
cigarettes (2) continued 
smoking with conventional 
cigarettes 








Effects Among Smokers 
Who Use and Do Not Use 
E-Cigarettes 
USA 187 2-arm smoking cessation trial 
comparing (1) 6 weeks of 
JUUL e-cigarettes vs. (2) 6 
















World Impact of the Use of 
Three Alternate Nicotine-
Delivery Products on 
Combustible Cigarette Use 
USA 200 3-arm smoking cessation trial 
comparing: 1) Very low 
nicotine cigarettes (VLNCs); 2) 
Juul e-cigarettes; or 3) no 
alternative product. During two 
different weeks, participants 
will be asked to switch from 
their usual cigarettes and use 
only study products. They will 
also be asked to use either an 
active nicotine or placebo 
patch (the within-subjects 
factor), provided in double-








Number of VLNCs 
or JUUL pods 
used during each 
Switch Week 
Not yet recruiting: 
Est. completion 





Preliminary Evaluation of 




USA 60 3-arm smoking cessation trial 
among low SES persons 
comparing 1) incentives for 
quitting smoking in addition to 
combination nicotine 
replacement therapy (patches 
+ lozenges), 2) the provision of 
JUUL(device and pods) along 
with directions to switch over 
from combustible cigarettes to 
CO-verified 7-day 
PPA at 1 month 
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Study reference/ trial 
identifier 
 
Primary Investigator Study name Location 
Estimated 





e-cigarettes exclusively, or 3) 
the combination of JUULand 





Can using nicotine as a 
long-term substitute 
enhance smoking cessation 
over using it only as a 
cessation aid? 
Australia 1600 Combination of varying levels 
of self-help materials, NRT, 
advice, or e-cigarettes 
Continuous 
abstinence at 6 
months 
 








Mark Eisenberg and 
Andréa Hébert-Losier 
Evaluating the Efficacy of E-
Cigarette Use for 
Smoking Cessation  
(E3) Trial 
Canada 486 3-arm smoking cessation trial 
with 12 weeks intervention and 
observation up to 12 months 
comparing (1) Nicotine e-
cigarettes plus minimal 
behavioral counseling with (2) 
placebo e-cigarettes plus 
minimal behavioral counseling 





CO<11ppm at 6 
and 12 months 
 
7-day PPA verified 
by exhaled-
CO<11ppm at 6 





adverse events at 









Presented by Dr. 
Mark J. Eisenberg 














Inner City RCT 
Canada 200 2-arm smoking cessation trial 
for 12 months comparing (1) 
NRT plus behavioral 
counseling with (2) e-cigarettes 
plus behavioral counseling 
7-day PPA 
(validated) at 6 
and 12 months 
 
Quality of life at 6 
months 
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Study reference/ trial 
identifier 
 
Primary Investigator Study name Location 
Estimated 








Efficacy and Safety of E-
cigarettes for 
Smoking Cessation in 
Middle-aged Heavy 
Smokers (EFFECT) 
Finland 450 3-arm smoking cessation trial 
with 12 weeks intervention and 
observation up to 12 months 
comparing (1) Nicotine e-
cigarettes + placebo-pills + 
Motivational Interview (MI) with 
(2) Placebo e-cigarettes + 
varenicline + MI and (3) 
Placebo varenicline + placebo 















of Electronic Cigarettes with 
or Without Nicotine in 
Smoking Cessation 
(ECSMOKE) 
France 650 3-arm smoking cessation trial 
for 6 months comparing (1) use 
of nicotine e-cigarettes plus 
placebo varenicline tablets with 
(2) placebo e-cigarettes plus 
active varenicline and (3) 
placebo e-cigarettes plus 
placebo varenicline 












Antismoking Effects of 
Electronic Cigarettes in 
Subjects with Schizophrenia 
and Their Potential 
Influence on Cognitive 
Functioning (SCARIS) 
Italy 153 3-arm smoking cessation trial 
among persons with 
schizophrenia for 3 months (1) 
nicotine e-cigarettes with (2) 
Placebo e-cigarettes and (3) 




CO≤7ppm at 12 
months 












Italy  129 3-arm smoking cessation trial 
among persons with 
depression for 3 months 
comparing (1) nicotine e-
cigarettes with (2) Placebo e-





CO≤7ppm at 12 
months 
Not yet recruiting: 
Est completion 
date June, 2022 
NCT03589989 
 
Reto Auer and Anna 
Schöni 
Electronic Nicotine Delivery 
Systems 
(ENDS/Vaporizer/E-
cigarette) as an Aid for 
Smoking Cessation 
(ESTxENDS) 
Switzerland 1,172 2-arm smoking cessation trial 
for 6 months comparing (1) e-
cigarettes plus behavioral 




by urinalysis and 
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Study reference/ trial 
identifier 
 
Primary Investigator Study name Location 
Estimated 




























Reto Auer and Anna 
Schöni 
The ESTxENDS Trial- 
Electronic Nicotine Delivery 
Systems as an Aid for 
Smoking Cessation-
extension of Follow-up 
(ESTxENDS) 
Switzerland 1,172 2-arm smoking cessation trial 
for 24 months comparing (1) e-
cigarettes plus behavioral 




by urinalysis or 
exhaled-CO at 12, 
24 months 
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Study reference/ trial 
identifier 
 
Primary Investigator Study name Location 
Estimated 







Use of any other 
smoking cessation 


















England 249 3-arm smoking cessation trial 
for 3 months comparing (1) 
nicotine-inclusive e-cigarettes 
(2) nicotine-free e-cigarettes 













Amanda L Graham 
Text Message Quit Vaping 
Intervention for Young 
Adults 
USA 2900 2-arm vaping cessation trial for 
6 months comparing (1) text 
message-based intervention 
for quit vaping support and (2) 
assessment only 
30-day self-
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Nicotine Replacement for 
Smoking Cessation During 
Pregnancy 
US 154 Pregnant smokers who smoke at least 5 cigarettes/ day 
will receive nurse-delivered behavioral counseling and 
be randomized to receive a 6-week course of treatment 
with either a nicotine inhaler or placebo, followed by a 6-












Placebo-controlled Trial of 
Bupropion for Smoking 
Cessation in Pregnant 
Women (BIBS) 
US 360 A randomized, parallel-group, double-blinded, placebo-
controlled, 10 week trial of Bupropion in 









Mindfulness Training Plus 
Oxytocin (MOXY) 
US 180 Clinical trial aimed to examine the effects of mindfulness 
training and a single 40 IU dose of Pitocin (oxytocin, 
USP; concentration = 10 IU/1 mL; PAR 







Electronic Cigarette Use 
During Pregnancy 
US 375 Observational study aimed to compare overall toxicant 
exposure in pregnant women who use e-cigs with 
women who smoke conventional cigarettes. Will also 
compare toxicant exposure and birth outcomes among 
infants born to pregnant women who use e-cigs 















A prospective population-based cohort study to examine 
whether varenicline use during pregnancy is associated 
with an increased risk of major congenital malformations 











Targeted antenatal smoking 
cessation intervention in 
high-risk substance 
dependent pregnancy: a 
feasibility study 
Australia 100 This study aims to assess the feasibility and 
acceptability of the addition of current evidence-based 
smoking cessation care to routine prenatal care of 
women attending a substance use in pregnancy clinic. 
Recruiting: 
Anticipated date 
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Assessment of the 
acceptability, feasibility and 
impact on smoking 
cessation, of an intensive 
smoking cessation 
intervention, including 
financial incentives, among 
pregnant Indigenous women 
reporting daily smoking and 
receiving maternity care 
through the Birthing in Our 
Community program. 
Australia 140 This study will assess how effective the program is, what 
women think about it, and how easy it is to provide “Stop 
Smoking in its Tracks”. The study will involve collecting 
information on the care provided, whether women quit 
smoking and what other factors might be influencing quit 
attempts and successful quitting. 
Recruiting: 
Anticipated date 
of last data 
collection Jun 
2019; no results 
published.  
Abbreviations: EST = estimated; mg = milligram(s); UK = United Kingdom; US = United States 
